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Abstract
Widespread metastases are characteristic of the most aggressive form of lung
cancer, small cell lung cancer (SCLC). Although initially sensitive to treatment by
radio- and chemotherapy, SCLC develops chemoresistance so the 2-year survival
rate remains less than 5%. The aberrant proliferation of SCLC is sustained by
multiple autocrine and paracrine growth loops involving calcium mobilising
neuropeptides such as vasopressin (AVP) and gastrin releasing peptide (GRP). The
expression of these neuropeptides and their receptors are a hallmark of the disease
and present an important target for therapeutic intervention. Analogues of
substance-P, including [D-ArgI,D-Phe5,D-Trp7-9,Leu11]-substance-P (SP-D) and
[Arg6,D-Trp7-9,NmePhe8]-substance-P (6-11) (SP-G), are novel anti-cancer agents
which inhibit the growth of SCLC cells. Investigations into the mechanism of action
of substance- P analogues on bombesin receptors revealed that in addition to
blocking bombesin-induced mitogenesis and signal transduction they also have
agonist activity. This unique pharmacological activity of 'biased agonism' may be
centred to the growth inhibitory effects of these agents.
The aim of this study was to determine whether these agents exhibit 'biased agonist'
activity at receptors other than the bombesin/GRP receptor and investigate factors
influencing their ability to modulate neuropeptide signalling. Model cell systems
consisting of CHO-K1 cell-lines stably expressing GRP or Via receptors were
therefore established and the effect of SP-D and SP-G tested. Expression of GRP and
Via receptors led to the development of a transformed phenotype as cells showed
increased cloning efficiency and survival in soft-agar and suspension growth
respectively. GRP and Via receptor expressing cells were less adherent, more
migratory and not contact inhibited. Neuropeptide receptor stimulation provided
some protection from the cytotoxic effects of etoposide suggesting a role in
chemoresistance. Substance-P analogues inhibited normal and anchorage-
independent growth of receptor expressing cells. In receptor binding studies on
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GRP and Via receptor expressing cells, analogue inhibited radioligand binding non-
competitively. Transfected GRP and Via receptors effectively coupled to Ga.q to
increase intracellular calcium and the analogues were effective antagonists of this
response. Neuropeptide and analogues stimulated ERK activity in GRP and Via
receptor expressing cells. Activation of ERK by neuropeptide was rapid and
transient while analogue induced activation was delayed and sustained. Analogue-
stimulated ERK activity was pertussis toxin sensitive whereas neuropeptide-
stimulated ERK activation was not. In addition, analogue induced ERK activity was
blocked by inhibition of EGF receptor kinase. This indicates that SP-D and SP-G
facilitate receptor coupling to G-protein Gj/Gq subunits for subsequent calcium-
independent ERK activation via EGFR transactivation. Stable cell-lines expressing
different levels of Via receptor were used to examine the effect of altering the ratio
of receptor to G-protein on the ability of the analogues to direct receptor signalling.
There appeared to be little receptor reserve for calcium and ERK responses
stimulated by neuropeptide as the efficacy of the response increased with increasing
receptor numbers. In contrast, analogue-induced ERK activation occurred with a
higher receptor reserve for activated Gj as the magnitude of the response did not
increase between medium and high expressing cells. Chimeric Via receptors
containing the second (Vjj2) or third intracellular (Vii3) loop of the V2 receptor were
used to investigate the influence of substance-P analogues on G-protein selectivity.
Both receptors were still capable of binding AVP and SP-G but had altered ability to
activate PLC and ERK. The second intracellular loop of VIAR was essential for
AVP-stimulated PLC and ERK activation but not for SP-G-induced ERK activation.
This confirms that the effects of the agents cause an alteration in the receptor-G-
protein coupling domains of receptors. These findings demonstrate that substance-P
analogues are biased agonists of receptors other than GRP receptors, activating
downstream signals which differ from those stimulated by the natural agonist
through promoting an alternative agonist state of the receptor. This pathway
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selectivity combined with the receptor specificity of different substance-P analogues













Numerous physiological processes, such as cell growth, selective cell death,
embryogenesis, tissue repair and immune responses, involve tight regulation of cell
proliferation. In fully developed organisms, the differentiated cells of many tissues
and organs are generally maintained in a non-proliferating condition. When the
need arises, a milieu of growth factors and extracellular matrix proteins interact
with the cell in a regulated manner to resume proliferation. In contrast, the
proliferation of cancerous cells is unrestrained due to the acquisition of partial or
complete independence from mitogenic signals present in the extracellular
environment (Cross & Dexter, 1991; Westermark & Heldin, 1991). Studies of human
tumours and animal models suggest that this is a consequence of a multistage
process involving genetic alterations which drive the progressive transformation of
normal cells into malignant ones (Hanahan & Weinberg, 2000). Such genetic
alterations in tumour cell genomes are demonstrated across multiple sites and over
a spectrum which ranges from subtle point mutations to severe changes in
chromosome complement (Blume-Jensen & Hunter, 2001).
Generally, a minimum of six successive genetic changes are believed to collectively
dictate malignant growth and are manifest in the accepted hallmarks of cancer: self-
sufficiency in growth signals, insensitivity to growth-inhibitory (anti-growth)
signals, evasion of programmed cell death (apoptosis), limitless replicative
potential, sustained angiogenesis, and tissue invasion and metastasis (Hanahan &
Weinberg, 2000). Cancer cells can secrete growth factors which stimulate
proliferation through activating receptors present in the cell membrane in an
autocrine or paracrine manner. Alterations in the number or structure of receptors
and changes in the activity of intracellular signalling pathways can therefore
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contribute to the escape from normal regulatory controls (Sager, 1989). An
increasing number of oncogenes are being found to represent growth factors, their
receptors and post-receptor signalling molecules. This has fuelled intense
investigation into growth factors and their associated signal transduction
mechanisms in an effort to understand their role in mediating cancer cell growth
and provide novel targets for controlling this devastating disease.
It has emerged that cell proliferation can be stimulated through the activity of two
major types of growth factors; one involves polypeptide growth factors binding to
receptors with intrinsic tyrosine kinase activity (Aaronson, 2005) while the other
involves hormones binding to receptors coupled to guanine nucleotide binding
regulatory proteins (G-proteins) (Gutkind, 1998b). The intracellular signalling
cascades activated by the growth factors form an extensive network and
considerable cross-talk can occur between pathways. Multiple, independent
pathways can therefore act in a synergistic manner to stimulate cell growth
(Rozengurt, 1986; Lowes et al, 2002).
Neuropeptides, such as bombesin, gastrin and substance-P, are found in the neural
and neuroendocrine cells of the gastrointestinal tract and nervous system (Walsh,
1987). These small regulatory peptides are more commonly known for their role as
fast-acting neurotransmitters in the central nervous system where they are
synthesised and stored in pre-synaptic neurones. They also function both
systemically and locally in the peripheral neuroendocrine system as autocrine and
paracrine regulators. This group of structurally diverse signalling molecules play a
crucial role in the regulation of exocrine and endocrine secretion, smooth muscle
contraction, pain transmission, fluid homeostasis, blood pressure and inflammation
as well as food intake, body temperature and behavioural response (Rozengurt,
2002). Over the last two decades, the discovery that these peptides are also potent
cellular growth factors for both normal and cancerous cells (Table 1.1)
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Table 1.1. Neuropeptides mitogenic for normal and cancerous cells
Neuropeptide Normal cells Cancer cells
Angiotensin Cardiac and lung fibroblasts;
hepatic stellate cells; intestinal




Bombesin 3T3 fibroblasts; airway
epithelium
SCLC; prostate; glioblastoma;
renal cell carcinoma; colon
Bradykinin 3T3 fibroblasts; mesangial cells SCLC; prostate
Cholecystokinin Pancreas SCLC; pancreatic; colon
Endothelin 3T3 and cardiac fibroblasts;
endothelial; keratinocytes;
astrocytes; smooth muscle
Ovarian and cervical carcinoma;
Kaposi's sarcoma; prostate;
melanoma
Galanin Sensory neurons SCLC
Gastrin Enterochrommafin cells; gastric
mucosa; colon epithelium
SCLC; colon




Neuropeptide Y Olfactory neurons; smooth
muscle
Breast cancer
Substance-P Fibroblasts; smooth muscle;
endothelial cells; corneal
epithelial cells; astrocytes; T
lymphocytes
Astrogliomas








Breast; SCLC; prostate; colon;
urinary bladder; neuroblastoma
(Table from Rozengurt, 2002)
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has made them the subject of further interest. Hence it has become apparent that
the mitogenic effects of neuropeptides are central to a variety of normal and
abnormal processes which include development, inflammation, and malignant
transformation (Woll & Rozengurt, 1990). Neuropeptides have been demonstrated
to function as autocrine growth factors for a number of cancers including lung,
breast, prostate and pancreas (Wang et al, 1996c; Moody et al, 2003). In addition,
neuropeptides and their receptors have been found to be the principal driving force
behind the clinically aggressive small cell lung cancer (SCLC), providing a
paradigm for neuropeptide-driven tumourigenesis (Cuttitta et al, 1985; Moody &
Cuttitta, 1993).
1.1 Lung Cancer
Each year, more than a quarter of a million people in the UK are diagnosed with
cancer. The most common fatal malignancy is lung cancer, which causes over 40,000
deaths each year in the UK (World Health Organisation mortality statistics 2000).
Whilst the incidence of lung cancer in men has begun to fall, the incidence in
women is continuing to increase (Osann, 1998; Peto et al, 2000). Lung cancer has
been the commonest cause of cancer death in British men for many years and it has
now overtaken breast cancer as the commonest cause of cancer death in British
women. Despite medical and surgical intervention, there has been little change in
the survival rate for cancer with approximately 90% of affected patients dying
within one year of diagnosis. Cigarette smoke carcinogens are the major cause of
most lung cancers (Hecht, 1999). However, it is anticipated that an increasing
number of future cases will be unrelated to smoking and presumably due to
environmental pollution instead (Sethi, 1997).
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Molecular studies have shown that genetic damage to the smoking exposed
respiratory epithelium persists for decades after smoking cessation (Fong et al,
2003). The cells are thought to begin to harbour genetic damage after prolonged
exposure to cigarette smoke since changes have been detected in morphologically
normal cells from smokers. Consistent with a multi-step model of carcinogenesis, it
is believed that 10-20 genetic mutations are required to produce a lung cancer cell
from a normal one (Sethi, 1997).
1.1.1. Classification of Lung Cancer
Lung carcinomas, which originate from the respiratory epithelium, are classified
into two groups according to histological type. Approximately 75% of all cases are
non-small cell lung cancer (NSCLC) and include squamous cell carcinomas,
adenocarcinomas and large-cell carcinomas while the remaining 25% are small-cell
lung cancers (SCLCs).
Around thirty percent of lung cancers are squamous cell carcinomas (SQCC), which
arise from metaplastic squamous epithelial cells. SQCCs, adenosquamous and
mucoepidermoid carcinomas display features of squamous differentiation to
varying degrees, ranging from well to poorly differentiated (Maggiore et al, 2004).
The markers of squamous differentiation which characterise these cell-lines include
involucrin, transglutaminase activity, higher molecular weight keratins and
cornified envelope formation. In addition, all of these tumour types demonstrate
EGF receptor (EGFR) upregulation (Ullmann et al, 2004).
Thirty percent of lung tumours are adenocarcinomas; previously considered to arise
from a number of cell types such as surface epithelium (ciliated and mucus
producing cells) which generate mucin-containing or mucin-secreting tumours, and
the progenitor cells of the peripheral airways (Clara cells and Type II pneumocytes)
which result in peripheral airway cell tumours (Gazdar & McDowell, 1988).
Peripheral airway tumours include the adenocarcinoma subtypes,
bronchioloalveolar and papillary, and often display the morphological features of
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lepidic and papillary growth. The recent development of a mouse model of lung
tumourigenesis by Kim et al (2005) has led to the isolation of a population of stem
cells from which adenocarcinomas are likely to arise. This invaluable model will
allow the detailed study of non-small cell lung cancer development and, through a
better understanding of the role of stem cells in this process, should aid the design
of better intervention strategies for treating human lung cancer (Berns, 2005).
Ten percent of lung tumours are classified as large cell, and usually diagnosed by
exclusion of the other 3 types of lung cancer. Like adenocarcinomas, large cell
tumours are preferentially located in the periphery of the lung.
SCLCs were commonly thought to arise from pulmonary neuroendocrine cells and
some evidence suggested a stem cell origin (Gazdar & Carney, 1985). They are now
believed to be derived mainly from epithelial cells that line the larger airways
(Garber et al, 2001). SCLCs can be histologically classified into three sub-groups as
follows (Hirsch et al, 1988):
(1) Small cell carcinoma- includes most of the tumours previously included in the
oat cell/ intermediate subtypes and more than 90% of untreated SCLC fall into this
category.
(2) Mixed small cell/large cell carcinoma- contains a spectrum of cell types ranging
from typical SCLC to larger cells having prominent nucleoli and resembling large
cell carcinoma.
(3) Combined small cell carcinomas- typical SCLC elements mixed with areas of
differentiated squamous cell or adenocarcinoma.
Neuroendocrine carcinomas represent a spectrum of disease and SCLC, which is
associated with a poor prognosis, is at one extreme. Bronchial carcinoids are at the
other extreme and have a more favourable outlook following surgical resection
(Harpole et al, 1992). Between the two extremes is a sub-type called well-
differentiated neuroendocrine carcinoma of the lung. Like SCLC, it occurs primarily
in smokers but metastasises less frequently and has a 5 year survival rate greater
than 50%. However, the pathological diagnosis of well-differentiated
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neuroendocrine tumours from SCLC is difficult due to the extreme similarities
between the cell-types.
Patients with mixed tumours have been observed, with cells simultaneously
displaying features of both SCLC and NSCLC phenotypes. For example,
neuroendocrine features are displayed by 25% of NSCLC tumours and correlate
with greater initial sensitivity to radio- and chemo-therapy. However, such tumours
are also faster growing and have a worse prognosis than adenocarcinomas lacking
neuroendocrine features. Clinical evidence has also demonstrated that a potential
for transitions between tumour types also exists e.g. from SCLC to NSCLC
phenotype. Each of the four major types of lung cancer reflect the phenotypic
features of cells present in the normal bronchial epithelium. Therefore, it has been
considered that such transitions may mimic the normal cellular transitions which
take place in the bronchial epithelium and be mediated by persistent genetic
abnormalities. It has thus been proposed that a common differentiation pathway
present in the bronchial epithelium may give rise to the four types of lung
carcinoma (Mabry et al, 1991). The possibility has been demonstrated in vitro
through a model cell system of the transition from a SCLC to NSCLC phenotype
(Wang et al, 1996a). The oncogene-induced transition led to an undifferentiated
phenotype with the loss of neuroendocrine markers, reduction in GRP secretion,
increase in EGFR expression and the acquisition of drug resistance patterns
reminiscent of NSCLC.
1.1.2. Lung Cancer Treatment & Prognosis
1.1.2.1. Non-Small Cell Lung Cancers
Long term survival in NSCLC patients can be up to 70% depending on stage.
Localised carcinomas are potentially curable and therefore NSCLCs with no or few
metastases at the time of presentation are subject to surgical resection. Following
surgical resection alone, 5 year survival rates of 55-67% have been reported
(Mountain, 1997). Patients with un-operable disease of similar stage are treated with
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radiotherapy and this has resulted in 5 year survival rates of 13-39% (Rowell &
Williams, 2001). However, the majority of patients with NSCLC are not surgical
candidates at the time of diagnosis. For these patients, minimally invasive
interventional radiology procedures can improve survival, reduce pain, and
improve quality of life. In patients with extensive stage disease, a good performance
status, haemoglobin levels >11 g/dL and age >47 years confers a survival advantage
(Albain et al, 1991a).
Systemic chemotherapy can also be used and has provided short-term relief to
patients with advanced stage disease. However, a chemotherapeutic approach is not
routine at present and is viewed as being successful only in a small minority of
patients. Traditionally, NSCLC tumours have commonly been regarded as being
less sensitive to chemotherapy than untreated SCLC tumours. This could be
attributed to the previous lack of efficacy of agents such as cyclophosphamide,
methotrexate, and adriamycin in NSCLC compared with their effectiveness against
SCLC. Second generation cytotoxic drugs, such as cisplatin, ifosamide, mitomycin,
vinblastine and etoposide, have since demonstrated significant responses in NSCLC
(Rintoul & Sethi, 2002a). Nonetheless, uncertainty over the benefit of chemotherapy
in NSCLC has generated an apparent deadlock in survival rates which could
potentially be improved through more wide-spread use of these second generation
cytotoxic drugs. The NSCLC Collaborative Group carried out a meta-analysis to
evaluate the effect of cytotoxic therapy on survival in 1995 which indicated that
combination therapy containing cisplatin provided a significant survival advantage
in early stage disease when used in combination with either radio- or chemo¬
therapy (NSCLC Collaborative Group, 1995).
Adverse prognostic factors associated with NSCLC survival include large tumour
size, erb-2 oncoprotein expression levels, mutation of the K-ras gene, vascular
invasion and tumour angiogenesis (Albain et al, 1991a; Harpole et al, 1995). Overall,
the prognosis for NSCLC patients is unfavourable.
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1.1.2.2. Small-cell Lung Cancers
SCLCs are invariably associated with smoking. SCLC is considered to be a systemic
disease and is the most aggressive form of lung cancer. The majority of patients
present with extensive disease, characterised by thoracic disease involving more
than one hemithorax and/or widespread metastases. The occurrence of limited
disease involving only one hemithorax is less common. SCLC follows an aggressive
course and, although initially sensitive to radio- and chemotherapy, the 5-year
survival rate remains 3-8% (Rintoul & Sethi, 2002a). SCLC, once diagnosed, is not
normally operable as patients present with metastatic disease.
Most SCLC tumours are sensitive to the cytotoxic effects of chemotherapeutic drugs
and initially demonstrate high response rates. Around 15-20 cytotoxic agents have
been shown to have major activity against SCLC and various regimens produce
similar responses (Hong et al, 1989). However, it has been found that combinations
containing etoposide are well tolerated and highly active (Jett et al, 1990). At present,
a cisplatin/etoposide combination is the most commonly, but not exclusively, used
regimen in the UK (Rintoul & Sethi, 2002a).
Combination chemotherapy is more effective in limited SCLC than single agent
treatment, and intensive doses are more effective than those which only produce
mild toxic effects. The optimum duration of chemotherapy for limited disease
patients has not been defined, although no significant improvement in survival
occurs beyond 3-6 months of treatment (Murray et al, 1993; Johnson et al, 1996).
Combined chemotherapy with simultaneous chest irradiation provides a survival
advantage of 5.4% at 3 years (Pignon et al, 1992). The average survival of patients
with limited disease is 14-20 months (Osterlind et al, 1986).
Extensive stage SCLC is treated using multiple chemotherapeutic agents, usually in
combination with radiotherapy. For these patients however, radiotherapy does not
provide an additive survival advantage and is used primarily for symptomatic relief
from primary tumour and control of metastatic disease (Twelves et al, 1990). Many
extensive disease patients have a poor performance status compared with limited
stage patients and are less able to tolerate aggressive treatment regimens. Low-dose,
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single agent regimens have been developed for these patients which is not as
effective as normal treatment and thus associated with a poorer prognosis (James et
al, 1996; Souhami et al, 1997). The average survival of patients with extensive disease
is 8-13 months (Osterlind et al, 1986).
The main drawback with SCLC is that despite initial sensitivity to chemotherapy,
patients invariably relapse with chemoresistant disease and such patients have an
exceptionally poor prognosis with median survival 2-3 months. SCLC patients who
survive beyond 2 years from initial diagnosis are more likely to die from other
forms of lung cancer and this can retrospectively be attributed to an original mis¬
diagnosis. Limited success has been obtained through second-line chemotherapy
with oral etoposide, etoposide/ cisplatin, cyclophosphamide/ doxorubicin/
vincristin, lomustine/ methotrexate and topotecan (Evans et al, 1985; Johnson et al,
1990; Greco, 1993). Nonetheless, relapse and chemoresistance are an inevitable
outcome irrespective of treatment modality. With no significant improvements in
the treatments available for SCLC being obtained of late, the overall prognosis for
SCLC patients is dishearteningly poor. Consequently, there is a striking need for
new therapeutic approaches to the treatment of this disease and this could be
forthcoming through a greater understanding of the molecular and cellular biology
of SCLC.
1.1.3. Small Cell Lung Cancer
1.1.3.1. SCLCCharacteristics
SCLC 'oat' cells are classically characterised by indistinct or absent nucleoli and
sparse cytoplasm. The cells are 2-3 times the size of mature lymphocytes and their
nuclei are darkly stained. Small dense-core granules are visible in the cytoplasm and
are the manifestation of peptide secretion. This is a hallmark of the neuroendocrine
properties observed in SCLC and less frequently in other lung carcinomas.
13
When cultured, SCLC cell-lines grow as tightly clustered spheroids in suspension,
form colonies in soft agarose and can form tumours in nude mice. The cell
population doubling time ranges from 32-72 hours for various cell-lines.
SCLC cells clearly possess neuroendocrine biochemistry and have been found to
express numerous peptide hormones, which stimulate the aberrant growth of these
tumours and that are also responsible for many of the clinical symptoms associated
with SCLC (Sethi & Woll, 1995). The cells have also been shown to express a number
of bio-markers of neuroendocrine differentiation such as L-Dopa decarboxylase
(DCC), neuron specific enolase (NSE), creatine kinase BB isoenzyme and
chromogrannin A. The endocrine markers L-Dopa Decarboxylase and NSE are also
found expressed in approximately 25% of NSCLC adenocarcinomas. Although these
cells have chemosensitivity, they also grow faster and have a worse prognosis than
other adenocarcinomas (Gazdar & McDowell, 1988).
SCLC cell-lines have been sub-classified into two distinct groups according to
heterogeneity in neuroendocrine marker expression (Carney et al, 1985). Classic
SCLC cell-lines express high levels of all 4 bio-markers whereas variant SCLC cell-
lines express only some of these markers. For example, L-Dopa carboxylase is
absent in 10% of SCLC cell-lines. Morphological variants represent 20% of SCLC
cell-lines and grow as loose aggregates with increased growth rates and cloning
efficiencies.
Variant cell-lines grow more rapidly in culture, have higher cloning-efficiency in
soft agar and are more tumourigenic in nude mice than classic cell-lines. In addition,
variant cells are larger, less differentiated and relatively radio- and chemo-resistant.
These cell-lines are thought to be representative of mixed small cell/ large cell SCLC
tumours and are associated with a poor prognosis. In some cases, but not all, the
clinical development of chemoresistance can be associated with a conversion from
classic to variant SCLC phenotype. In other cases, since only 10% of SCLC patients
have tumours demonstrating large cell admixture histology, other mechanisms may
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underlie the transition from chemo-responsive to non-responsive SCLC. Overall, the
majority of SCLC cell-lines are of a classic phenotype and are thought to maintain
this phenotype during chemotherapy and the development of chemoresistance. In
the present study, the classical SCLC cell-line NCI-H345 is used which grows well in
culture and expresses neuropeptide receptors (Sethi et al,1992).
A number of longitudinal studies have identified a positive correlation between
extensive disease and the presence of endocrine markers (Carney, 1991). The levels
of NSE, which is a highly specific marker for neurons, are elevated in extensive
disease. Sequential determinations of NSE levels are of value in monitoring the
response to chemotherapy and detection of relapse. Similarly, Chromogrannin A,
BB isoenzyme of creatine kinase and carcinoma embryonic antigen have also
demonstrated a prognostic value and correlate significantly with tumour response
to cytotoxic therapy and subsequent relapse. Furthermore, a longitudinal study
involving cell-lines before and after the development of radio- and chemo-therapy
resistance demonstrated an increase in neurosecretory granules and differentiation
in SCLC cells after chemotherapy (Brambilla et al, 1991). In contrast, another study
of cell-lines and biopsies from treated patients, as well as long-term untreated SCLC
cultures, demonstrated large cells of de-differentiated phenotype and loss of
neuroendocrine markers (Bepler et al, 1987).
1.1.3.2. SCLCNeuroendocrinology
As mentioned previously, the neuroendocrine nature of SCLC is the most
prominent feature of this clinically aggressive cancer. The first neuropeptide
discovered to be produced by SCLCs was bombesin/GRP (Wood et al, 1981; Moody
et al, 1981), and since then the number of peptide hormones and growth factors
found to be secreted by SCLCs has been expanding (Table 1.2). Most SCLCs
produce only a subset of these products, although a minority of SCLCs tumours
appear capable of synthesising a variety of these hormones (Sethi & Woll, 1995).
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Many of these products are synthesised as pro-hormones, and specific post-
Lranslational modification is required for biological activity (Quinn et al, 1991). The
ectopic hormone production underlies some of the paraneoplastic syndromes which
SCLC patients present with. For example, adrenocorticophic factor (ACTH)
secretion causes ectopic Cushing's Syndrome, while the release of vasopressin and
atrial natriuretic protein (ANP) contribute to dilutional hyponatremia (Gross et al,
1993). A number of these products have also been detected in NSCLCs and normal
lung tissue (Wood et al, 1981; Becker, 1985).
A great deal of investigation has been undertaken into the role of ectopic hormone
secretion in SCLC tumour biology. It was postulated that SCLC cells may express
receptors for many of these peptides, enabling the peptides to function as autocrine
growth factors for SCLCs. The presence of functional receptors was demonstrated
through assessing the ability of some 32 neuropeptides and hormones to mobilise
intracellular calcium as a measure of receptor-ligand interaction (Table 1.3) (Woll &
Rozengurt, 1990). Heterogeneity in the expression of individual receptors was found
to exist amongst the cell-lines and each of the five cell-lines responded to at least
two different agents (Sethi & Woll, 1995). It was further demonstrated that
nanomolar concentrations of the calcium mobilising neuropeptides were able to
increase the cloning efficiency of SCLC cells under serum-free conditions. This
showed that SCLC growth could be sustained by a network of autocrine and
paracrine interactions involving multiple neuropeptides. Numerous studies have
focussed on elucidating the signal transduction mechanisms underlying the
mitogenic effects of neuropeptides, with a view to discovering prospective targets
for therapeutic intervention.
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Table 1.2. Peptides and hormones secreted by SCLC
Neuropeptides Growth Factors
Atrial natriuretic peptide Adrenocorticotrophic hormone
Calcitonin Chorionic gonadotrophin
Calcitonin gene-related peptide Estradiol
Cholecystokinin Follicle stimulating hormone
Endothelin Granulocyte colony-stimulating factor
Gastrin Growth hormone releasing hormone
GRP/bombesin Insulin-like growth factor-I
Neuromedin B Insulin-like growth factor-I binding protein
Neurotensin Parathyroid hormone









(Table and references for each individual hormone in Sethi & Woll (1995)
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Table 1.3. The effect of neuropeptide and peptide hormones on calcium






Bombesin Follicle stimulating hormone






(Adapted from Woll & Rozengurt (1990))
1.2. Neuropeptides
1.2.1. Neuropeptide receptors
Neuropeptides mediate their cellular effects through binding extracellularly to G-
protein coupled receptors (GPCRs). The human genome encodes more than 1000
members of this superfamily, making it the largest group of cell surface receptors.
Neuropeptides are ligands for about 20% of the GPCRs, 55% have classic
transmitters or compounds like prostaglandin E2 and anandamide as ligands, and
25% have no known ligands (Hokfelt et al, 2003). GPCRs associate with and activate
heterotrimeric G-proteins to stimulate or inhibit the formation of second messengers
and modulate ion channels (Gether, 2000). The receptors are also capable of directly
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interacting with other effector molecules, including receptor serine/threonine
kinases, tyrosine kinases, protein tyrosine phosphatases and adaptor proteins
(Pierce et al, 2002). As shown in Figure 1.1 all GPCRs are predicted to adopt a
structure comprising of seven transmembrane a-helical segments of 20-25 amino
acid residues with three extracellular loops, three intracellular loops, an
extracellular N terminus and cytoplasmic C terminus each of varying length (Ji &
Grossman, 1998). GPCR domains involved in ligand binding include
transmembrane (TM) regions, the N-terminus and the extracellular loops joining
transmembrane domains (Gether & Kolbika, 1998). Intracellularly, the second and
third cytoplasmic loops and the C-terminal region (which can form a 'pseudo-loop'
through membrane tethering at a conserved palmitoylation site) are thought to be
critical for interaction with G-proteins (Wess, 1997b; Erlenbach & Wess, 1998).
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Figure 1.1. GPCR secondary structure. The disulfide bond that links TM3 and ECL2 is
conserved in 91.8% of GPCRs but absent in 7.6% members of the rhodopsin family, 2% of the
secretin receptor family, 8% of the glutamate receptor family and 7.4% of the frizzled
receptor family. Abbreviations: CL, cytoplasmic loop; CT, cytoplasmic tail; ECL,
extracellular loop; GPCR, G-protein-coupled receptor; NT, N terminus; TM, transmembrane
helix. Numbers indicate the numbers of residues in each region (mean+S.D). (Karnik et al,
2003)
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Ligands are thought to be initially attracted towards the receptor through
electrostatic interactions with specific receptor residues, effectively increasing the
local concentration of ligand and subsequent binding probability. Further non-
covalent interactions with the receptor facilitate a conformational change in the
spatial organisation of receptors' transmembrane bundle. This subsequently affects
the conformation of the intracellular loops, uncovering previously masked G-
protein binding sites, and results in the formation of a high affinity ligand-receptor-
G-protein complex (Gutkind, 1998b). The ensuing G-protein activation leads to the
initiation of downstream signalling. The process of signal transfer by the receptor
from the cell exterior to the interior can thus be viewed as a three-step process: (1)
signal generation (ligand binding), (2) transmembrane signal transduction
(conformational change in receptor), (3) signal transfer to cytoplasmic signal
molecules (G-protein activation).
1.2.1.1. The GPCR superfamily
Members of the GPCR superfamily are grouped into subfamilies A, B and C
according to amino acid sequence homology (Gether, 2000). Sequences within each
family generally share over 25% sequence identity in the transmembrane core
region, and a distinctive set of highly conserved residues and motifs. The largest
subfamily, family A, comprises rhodopsin-like GPCRs (Figure 1.2) which are
activated by a wide range of structurally unrelated ligands binding within a pocket
formed by transmembrane (TM) regions 3, 5, 6 and 7 (e.g. rhodopsin, 02-
adrenoreceptor and many neuropeptides) or to extracellular regions of the receptor
(e.g. glycoprotein receptors for FSH, LH) (Jensen & Spalding, 2004). Gastrointestinal
peptides activate receptors of the smaller subfamily B through binding to both
extracellular and transmembrane regions of the receptor. Family C contains the
metabotropic-like receptors for glutamate, calcium and various taste molecules,
which bind exclusively to the extracellular amino-terminal domain. Thus, different
modes of ligand binding exist across the various sub-classes of GPCRs and this is a
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reflection of the configuration of the ligand binding pocket. Key residues present in
the transmembrane helices may contribute to the formation of the binding pocket
which is dictated by the spatial organisation of the receptor in the membrane.
1.2.1.2. HeterotrimericG-proteins
The heterotrimeric G-proteins, which associate with GPCRs, are important for
maintaining the specificity and temporal characteristics of the cellular responses to
signals (Rudolph et al, 1996). They are composed of a, (3 and y subunits and
demonstrate heterogeneity through the 17 a subunits, five P subunits and 14 y
subunits which have been cloned and identified to date. G-proteins are generally
referred to according to the function of the a subunits and are grouped into four
distinct classes according to the sequence similarity of these subunits: Gq proteins
activate phospholipase CP; Gs proteins stimulate adenylyl cyclase; G; proteins
inhibit adenylyl cyclase and activate G-protein-coupled inwardly rectifying
potassium (GIRK) channels; Gi2 and G13 regulate the activity of small GTPases
(Pierce et al, 2002).
The domain of the Got subunit which is involved in binding and hydrolysing GTP is
structurally identical to the superfamily of GTPases that includes small G-proteins
(e.g. Rho, Rac, Arf) and elongation factors (Kjeldgaard et al, 1996). The p and y
subunits form a functional dimer that is not dissociable except by denaturation.
Membrane attachment is proposed to occur via sites of lipid modification present in
the N-terminal region of the a-subunit and the C-terminal region of the y subunit
which are in close proximity in the heterotrimer (Resh, 1996). G-proteins are inactive
in the GDP-bound, heterotrimeric state and are activated by receptor catalysed
guanine nucleotide exchange resulting in GTP binding to the a subunit (Rudolph et
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Family A. Rhodopsin/R2 adrenergic receptor-like
Biogenic amine receptors (adrenergic, serotonin,
dopamine, muscarinic, histamine)
CCK, endothelin, tachykinin, neuropeptide V, TRH, neurotensin,
bombesin, and growth hormone secretagogues receptors
plus vertebrate opsins
Invertebrate opsins and bradykinin receptors
Adenosine, cannabinoid, melanocortin, and
olfactory receptors.
Chemokine. fMLP, C5A, GnRH. eicosanoid, leukotriene,
FSH. LH, TSH, fMLP, galanin, nucleotide, opioid, oxytocin,
vasopressin, somatostatin, and protease-activated
receptors plus others.
Melatonin receptors and other non-classified
Family B. Glucagon/VIP/Calcitonln receptor-like
Calcitonin, CGRP and CRF receptors
PTH and PTHrP receptors
Glucagon, glucagon-like peptide, GIP, GHRH, PACAP, VIP.
and secretin receptors
Latrotoxin







Figure 1.2. The GPCR superfamily. A snake diagram for a prototypical member of each
subfamily is shown with highly conserved residues (black letter in white circles) and
disulphide bonds between conserved cysteine residues (white letters in black circles) . Family
A receptors (upper panel) can phylogenetically be divided into six subgroups as indicated.
Family A receptors are characterized by a series of highly conserved key residues and a
majority of the receptors have a palmitoylated cysteine in the carboxy-terminal tail causing
formation of a putative fourth intracellular loop. Family B receptors (middle panel) are
characterized by a long amino terminus containing several cysteines presumably forming a
network of disulfide bridges. The conserved prolines are different from the conserved
prolines in the A receptors and the DRY motif at the bottom of TM 3 is absent. Family C
receptors (lower panel) are characterized by a very long amino terminus (-600 amino acids).
The amino-terminal domain is thought to contain the ligand-binding site. Except for two
cysteines forming a putative disulfide bridge, the C receptors do not have any of the key
features characterizing A and B receptors. A unique characteristic of the C receptors is a very
short and highly conserved third intracellular loop. (Gether, 2000)
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al, 1996). GTP binding reduces the affinity of Got for GPy which leads to dissociation
of the GTP-bound a subunit from Gpy subunits. In the GTP-bound, active
conformation, a new surface is formed on Ga-GTP subunits which enables them to
interact with effectors with 20-100 fold higher affinity than in their GDP-bound
state. The 'active' Ga-GTP and the free GPy subunits subsequently initiate cellular
responses by altering the activity of intracellular effector molecules (Dhanasekaran
et al, 1998). The cellular response is terminated when the intrinsic GTPase activity of
the a subunit hydrolyses GTP to GDP which facilitates the re-association of Ga-
GDP with GPy.
In general, the G-protein subunits Gaq, Gai and Gas preferentially couple to
different families of receptors (Birnbaumer, 1992). However, many GPCRs are able
to activate more than one sub-type of G-protein and thereby modulate multiple
intracellular signals. For example, the thryotropin receptor is able to activate all
three families of G-proteins (albeit each with differing efficacy) whereas the a2-
adrenergic receptor couples to both Gas and Gaj (Eason & Liggett, 1995). Since
homologous receptors display similar coupling specificity, a receptor's
conformation (particularly the intracellular regions which recognise G-proteins) is
thought to dictate the G-protein selectivity of distinct receptor sub-types (Albert &
Robillard, 2002).
1.2.1.3. GPCR activation and downstream signalling initiation
The diversity of GPCR binding modes for agonists suggests that there could be
multiple ways of propagating the activation of GPCRs. However, given the ability
of the receptors to activate the same intracellular signaling pathways through the
same classes of G proteins it is thought that the fundamental underlying
mechanisms of GPCR activation may have been conserved during evolution
(Gether, 2000).
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The most extensively investigated GPCRs are members of the largest subfamily of
GPCRs, the rhodopsin-family. This subfamily is also the most relevant to the study
here since the receptors for many neuropeptides, including bombesin and
vasopressin, are also members. The process of receptor activation is thus described
according to the molecular insights this subfamily provides. Bovine rhodopsin is the
only member of the GPCR superfamily for which a crystal structure has been
solved, and this confirms the existence of an anti-clockwise bundle of
transmembrane helices (viewed from extracellular side) that are connected by loops
of varying lengths (Palczewski et al, 2000). The transmembrane helices are tightly
packed in this arrangement through the formation of extensive hydrogen bonds
between residues of the same TM as well as others. Conserved cysteine residues in
extracellular loop 1 and TM3 form a disulphide bond, provide stability through
constraining the loops and the receptor. This effectively positions extracellular loop
2 in such a way that the transmembrane core is inaccessible for ligand-binding. In
addition, ionic interactions occur between conserved residues of the TM regions.
Overall, important conformational constraints imposed by intramolecular
interactions are believed to preferentially maintain the receptor in an inactive
conformation. The process by which the constraining intramolecular interactions are
released through ligand binding is not fully understood but thought to be
responsible for the conformational changes which result in receptor activation and
G-protein binding. Specific movements of the TM helices are believed to form an
essential part of the switch from the inactive to the active conformation. The bovine
rhodopsin structure has been used as a guide to structure-function analysis of other
GPCRs and has shown that the separation of the TM3 and TM6 in GPCR activation
is common (Karnik et al, 2003). It has also been postulated that a key element of
receptor activation involves the conserved Asp-Arg-Tyr (DRY) motif which is
located at the interface of TM3 and the second intracellular loop. The invariably
conserved arginine (ArgIII:26) located within this motif has been postulated to be
constrained in the hydrophilic binding pocket (formed by conserved polar residues
in TM1, TM2 and TM7) through ionic interaction with the adjacent residue
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(AspIII:25) (Gether, 2000). Protonation of AspIII:25 through agonist binding is
thought to disrupt this interaction and so enable AspIII:26 to shift out of the polar
pocket (Gether & Kolbika, 1998). This subsequently leads to the cytoplasmic
exposure of previously buried sequences in the second and third intracellular loops,
facilitating G-protein interaction and the induction of GDP release from the G-
protein. Site-directed mutagenesis studies have shown that altering key residues
leads to increased agonist-independent receptor activity, demonstrating their
importance in the receptor activation process (Bihoreau et al, 1993). Such studies of
constitutively active mutant (CAMR) receptors have been crucial to the
understanding of how receptor activation relates to downstream signalling.
1.2.1.4. Ligand-seiective receptor conformations
GPCRs with known native ligands have been successfully targeted for therapeutic
intervention, with >50% of drugs on the market acting as either surrogate activators
(agonists) or inhibitors (antagonists) of GPCR activity. Central to the drug discovery
process has been the development of various pharmacological models to describe
the efficacies of different GPCR ligands.
A simple model was initially used to describe the formation of the high affinity
agonist-receptor-G-protein complex which initiates downstream signalling. The
two-state model is based on the ability of a receptor to adopt an inactive and an
active conformation and to activate a single G-protein (De Lean et al, 1980).
According to this model, a receptor exists in equilibrium of functionally distinct
conformations: inactive R, which does not interact with G-proteins and active R*,
which activates G-proteins and initiates downstream signalling events. The level of
basal receptor activity, in the absence of ligands, is determined by the equilibrium
between R and R*. The intrinsic efficacy of a ligand (effectiveness in stimulating a
response) is determined by its ability to alter this equilibrium. Thus, agonists bind to
and stabilise the active R* form of the receptor, whereas antagonists bind to and
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stabilise the inactive conformation, thus reducing the formation of R*. The receptor
activity induced by various other types of GPCRs ligands, e.g. partial agonists and
inverse agonists, can also be accommodated by this model. For example, a partial
agonist stimulates a partial response because it less effectively stabilises the active
state (therefore less effectively stimulates GDP/GTP exchange) than does the native
(full) agonist.
Constitutive GPCR activity can also occur in the absence of agonist binding and is
due to spontaneous isomerisation of GPCRs from the inactive to the active state
(Seifert & Wenzel-Seifert, 2002). This increases the basal G-protein activity in
comparison to the absence of GPCR. The 'extended' ternary complex model
accommodates the ability of a receptor to spontaneously form active states, and the
'cubic' ternary complex model (Figure 1.3) builds upon this by allowing the inactive
state of the receptor to also interact with G-proteins (Kenakin, 2002b). These models
are used to describe the efficacies of different agonists for stabilising distinct
receptor states which can be influenced by an agonist's affinity for a particular
receptor state. Given that a single receptor can couple to more than one G-protein,
traditional receptor theory as proposed by Furchgott (1966) would predict that an
agonist would have similar efficacies for different downstream signalling pathways.
Flowever, there are a number of reports that show that differential effector
activation by agonists that cannot be explained by this mechanism (Berg et al, 1998).
For example cua receptor agonists show different efficacies for Gj-mediated
adenylate cyclase inhibition and Gs-mediated adenylyl cyclase stimulation in
transfected CHO cells (Brink et al, 2000), and the neurotensin receptor (NTS1)
agonists EISA-1 and neuromedin N show reverse potency orders for Gq- and Gs-







Figure 1.3. Models of GPCRs. (A) Extended Ternary Complex (ETC) model: The receptor
exists in an inactive (Ri) and active (Ra) state; G proteins (mediating physiological response)
bind only to the active-state Ra. The addition of a ligand [A] results in three corresponding
ligand-bound species with varying propensities to form the active state and different
affinities for G proteins. (B) Cubic Ternary Complex (CTC) model: as for the ETC model,
with the addition that the inactive state of the receptor can also form a complex with the G
protein (but does not signal). The rate constant K adds a description of the quality of the
ligand-receptor complex, in terms of what characteristics it imparts to the ability of the G
protein to exchange GDP and GTP. Figure adapted from Kenakin (2002b).
In addition, experimentally derived data can not be explained by the idea of a single
receptor active state underlying agonist efficacy. Studies of constitutively active
receptor mutants (CAMR) and the use of insurmountable antagonists have
suggested that intermediate receptor conformational states can exist (Vauquelin &
van Liefde, 2005). In addition, different agonists may trigger distinct effector
pathways through a single receptor by dictating its preference for certain G-
proteins. 'N-state receptor models', in which the receptor is assumed to adopt N
states that may be inactive (R) or active (R*, R**, R***,„) have been developed to
accommodate these findings (Brink et al, 2000). According to these, a ligand can
bind to a variety of receptor conformations according to the relative affinity of the
ligand for those conformations; enriching certain receptor conformations and
depleting others. Each ligand-selective conformation can potentially couple to a
different G-protein subtype as a consequence of differential ligand-specific affinity
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factors (ot,y,8 in Figure 1.3) influencing the efficacy of coupling to G-proteins. Such
factors can be incorporated into a three-state receptor model (Figure 1.4.)
representing the interaction of one receptor (two active, one inactive state) and two
G-proteins. The nature of the ligand determines the efficacy of the ligand, which
dictates the affinity of the ligand-bound receptor for G-protein. The affinity of an
activated receptor for G-protein is thus altered in the presence of ligand according
to the efficacy of the ligand. Therefore, the efficacy with which one such ligand-
selective receptor conformation couples to a particular G-protein species can differ
from that of a different ligand-selective receptor state. This would account for the
ability of a ligand to produce multiple stimuli (have multiple intrinsic efficacies)
upon interaction with a receptor and reveals a potential for differential regulation of
each signalling pathway coupled to the receptor (Clarke, 2005).
The concept of agonist-directed trafficking of receptor signalling ('ADTRS' which is
also known as 'agonist trafficking' or 'biased agonism') is based upon this idea of
distinct receptor states differentially activating G-proteins (Kenakin, 1995). The
hypothesis of ADTRS proposes that when a receptor signals though two or more
independent signal transduction pathways, the relative efficacies of a series of
agonists may differ for the pathways (Kenakin, 1995). Central to ADTRS is a
requirement for the independent pathways activated by a receptor to diverge at the
receptor/G-protein level (e.g. receptor activates two G-proteins independently,
leading to the transduction of the stimulus through two separate effector pathways)
(Leff et al, 1997). Thus, based upon the capacity of ligands to promote unique,
ligand selective receptor conformations, a ligand could theoretically activate each
different pathway with varying efficacy. Evidence in support of this notion has
started to accumulate (Watson et al, 2000; Cussac et al, 2002; Newman-Tancredi et al,
2002; Martin et al, 2002; Skrzydelski et al, 2003), which suggests that ligand-directed
signalling to different cellular effector pathways using biased agonists may be a real
possibility. This could provide the next effective level of agonist selectivity for drug
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development strategies beyond agonist affinity for selective receptor subtypes
(Kenakin, 1997b).
Figure 1.4. Extended ternary complex model for the interaction between a single
receptor and two different G-proteins. The receptor undergoes transition from an
inactive (Rj) to an active (Ra) state and the activated receptor (Ra) can interact with two
separate G-proteins according to a scheme where A is the ligand and G is the G-protein.
Transition between states is governed by Ka (the affinity of the ligand for Rj); aKa (affinity
of ligand for Ra); Kg (affinity of Rj for G in absence of A); yKg (affinity of Ra for G in
presence of A); L (natural constitutive activity of receptor). In general, the response in such a
system will be controlled by the relative concentrations of the two G-protein types, the
capability (efficacy) of the ligand to induce receptor coupling to each G-protein (yl and y2),
the ability of ligand to induce the receptor active state (a) and the natural constitutive
activity of the receptor (L). (Kenakin, 2003a)
As mentioned previously, site directed mutagenesis of GPCRs can produce
constitutively active receptors. However, the first GPCR isolated through a screen
for fibroblast transforming potential was not found to contain any activating
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mutations, indicating that some other mechanism may underlie its growth
promoting ability (Young et al, 1986). Cellular transformation simply through
ectopic expression of 5-HT2C and muscarinic acetylcholine M„ M3 and M5 receptors
demonstrated that wild-type GPCRs could be tumourigenic in an agonist-
dependent manner (Julius et al, 1989; Gutkind et al, 1991). Agonist-dependent
transformation by a1B-adrenoceptors was rendered agonist-independent through
mutation, indicating that analogous mutations occurring spontaneously in this class
of receptor proteins could play a key role in the induction or progression of
neoplastic transformation (Allen et al, 1991). Such naturally occurring, constitutively
activating mutations have been identified in thyroid-stimulating hormone receptors
in 30% of hyperfunctioning human thyroid adenomas and in a minority of
differentiated thyroid carcinomas (Arvanitakis et al, 1997). This suggests a direct
link between GPCRs and human cancer and, although not common, activating
mutations have also been detected in a few other GPCRs (Table 1.2). It is interesting
to note that the naturally occurring mutations identified so far have been found in
GPCRs which all belong to the rhodopsin-like GPCR subfamily (subfamily A).
Activating mutations of GPCRs in human neoplasias have been identified relatively
rarely but more commonly the persistent stimulation of GPCRs by tumour-secreted
agonists has been implicated. A prime example of this is the autocrine and/or
paracrine mechanism of action of the neuropeptides secreted by small-cell lung
cancer (SCLC) cells which also express the cognate receptors (Sethi & Woll, 1995). A
number of the same neuropeptide/GPCR combinations have also been implicated in
colon adenomas and carcinomas and gastric hyperplasia and carcinomas (Gutkind,
1998b). In particular, GRP receptors have been implicated in prostate cancer and
CCKi and CCK2 receptors in pancreatic hyperplasia and carcinoma (Marinissen &
Gutkind, 2001). Several anti-cancer strategies are thus aimed at targeting these
autocrine and paracrine growth loops.
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Functional GPCRs are also encoded by the genome of several DNA viruses. Kaposi's
sarcoma-associated herpes virus (KSHV) encodes a constitutively active GPCR that
has transforming potential (Sodhi et al, 2000) and has recently been shown to
contribute to the angiogenic response characteristic of Kaposi's sarcoma lesions by
up-regulating expression of vascular endothelial growth factor (VEGF) (Xu et al,
1993). A number of other GPCRs (e.g. for LPA, interleukin 8, thrombin, sphingosine-
1-phosphate) have similarly been found to play a key role in tumour angiogenesis
(Marinissen & Gutkind, 2001). This has made GPCRs attractive targets for affecting
tumour growth through inhibition of new blood vessel formation.
At least ten of the 17 Ga-subunits cloned so far have demonstrated oncogenic
potential (Dhanasekaran et al, 1998) and mutations that affect the intrinsic GTPase
activity of Gas (gsp oncogene) and Gcq2 (gip2 oncogene) have been identified in
various tumours (Table 1.4). The gep oncogene isolated from Ewing's sarcoma has
potent fibroblast transforming ability in NEH 3T3 cells and encodes a wild-type form
of Gai2- Although activating mutations of the G12/13 or Gq family have not been
identified in human cancers, breast, colon and prostate adenocarcinoma cell-lines
have been found to express high levels of wild-type Gai2/i3 •
G-protein a-subunits and GPCRs are thus implicated in aberrant cell growth and
provide novel targets for the therapeutic treatment of cancer.
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Table 1.4. G-proteins and GPCRs in tumourigenesis
Activating Mutations Type of Tumour




Gai2 Ovarian sex cord tumours; adrenal
cortical tumours
GPCRs TSH receptor Thyroid adenoma; thyroid carcinoma
FSH receptor Ovarian sex cord tumours; ovarian
small cell carcinoma
LH receptor Leydig cell hyperplasia; male
precocious puberty
CCK2 receptor Colorectal cancer
Ca2+-sensing receptor Autosomal dominant hypocalcaemia;
neoplasms
Autocrine and paracrine activation
Neuromedin B receptor Small-cell lung carcinoma (SCLC)
Neurotensin receptor SCLC; prostate cancer
Gastrin receptor SCLC; gastric cancer




(Adapted from Marinissen & Gutkind, 2001)
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1.3 Neuropeptide Growth Factor Signalling
Much of the early work of screening neuropeptides for growth promoting activity
was carried out using Swiss 3T3 mouse embryonic fibroblasts, establishing that the
cells expressed numerous mitogenic GPCRs. Therefore, the intracellular signalling
pathways which neuropeptides use to stimulate cellular growth have been
extensively investigated using this cell-line (Rozengurt & Mendoza, 1985a;
Rozengurt et al, 1985b; Rozengurt, 1986). Bombesin has been an attractive model
peptide for elucidating the signal transduction mechanism of neuropeptides for a
number of reasons. In serum-free medium, DNA synthesis can be initiated by
bombesin in the absence of other growth promoting agents (Rozengurt & Sinnett-
Smith, 1983). In contrast with other neuropeptide growth factors which are
mitogenic only in synergistic combinations, this shows that bombesin has the ability
to act as a sole mitogen (Rozengurt, 1986). In addition, the receptors for bombesin-
like peptides have been well characterised at the molecular level (Cardona et al,
1992; Moody & Cuttitta, 1993; Akeson et al, 1997; Donohue et al, 1999; Jian et al,
1999). A number of the GPCRs for mitogenic neuropeptides (Table 1.1), including
those for bombesin and vasopressin, predominantly couple to the Gq/n sub-class of
heterotrimeric G-proteins for the transduction of neuropeptide signals (Offermanns,
2003). The early signals and molecular events induced by bombesin have thus
provided a paradigm for the study of other mitogenic neuropeptides and illustrate
the activation and interaction of a variety of signalling pathways (Seckl &
Rozengurt, 1995).
1.3.1. Bombesin
Bombesin is a 14 amino acid peptide and was first isolated from the skin of the frog
Bombina bombina. Numerous bombesin-like peptides have since been identified from
various species and are classified into the three sub-families: bombesin-related
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peptides, GRP and neuromedin B (Figure 1.5). The 27 amino acid gastrin releasing
peptide (GRP), first isolated from porcine stomach, was originally thought to be the
mammalian homologue of bombesin. However, an amphibian GRP was later
isolated and suggests that a mammalian bombesin may yet exist (Nagalla et al,
1992). It has been demonstrated that a minimum of 7 C-terminal amino acids are
required for the biological effects of bombesin-like peptides (Heimbrook et al, 1988).
Bombesin-Related Peptide (BRP) family
Bombesin pGlu-Gln-Arg -Leu-Gly-Asn-Gln- Trp-Ala -Val -Gly- His-Leu- •MetNH2
Ranatensin pGlu-Val-Pro-Gln- Trp-Ala -Val ■Gly- His-Phe ■MetNH2
Leu-8 phyllolitorin pGlu-Leu- Trp-Ala -Val •Gly- Ser-Leu ■MetNH2
GRP family
Human GRP-10 Gly-Asn-His- Trp-Ala -Val •Gly- His-Leu •MetNH2
Rat GRP-10 Gly-Asn-His- Trp-Ala -Val ■Gly- His-Leu -MetNH2
Frog GRP-10 Gly-Asn-Ser- Trp-Ala -Val ■Gly- His-Leu -MetNH2
NMB family
Human NMB Gly-Asn-Leu- Trp-Ala -Thr- •Gly- His-Phe- ■MetNH2
Rat NMB Gly-Asn-Leu- Trp-Ala -Thr- Gly- His-Phe ■MetNH2
Figure 1.5. The three subfamilies of bombesin-like peptides. Representative
members of each subfamily are shown. Bombesin, ranatensin, and phyllolitorin are
amphibian, GRP and NMB are from the species shown. GRP-10 is the COOH-terminal
decapeptide of GRP and contains full biological activity of GRP. (Nagalla et al, 1996).
The human GRP gene is located on chromosome 18 (18q21) (Naylor et al, 1987),
whereas the human neuromedin B lies on the long arm of chromosome 15 (Krane et
al, 1988). Bombesin-like immunoreactivity (BLI) has been demonstrated in
mammalian gastrointestinal tract tissues, brain, spinal cord and lung. Bombesin-like
peptides are most commonly known for their functions as neurotransmitters in the
central nervous system and as secretory agents in the gut (Panula et al, 1984).
Infused GRP, with a plasma half-life of 2.8 minutes, can stimulate the secretion of
gastrin, pancreatic polypeptide, insulin, glucagon, cholecystokinin and gastric
inhibitory peptide which results in amylase and gastric acid secretion (Knigge et al,
1984).
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The GRP receptor isolated from Swiss 3T3 membranes was found to be a
glycosylated transmembrane protein with an apparent molecular weight of MW
75,000-85,000 (Sinnett-Smith et al, 1990) and later cloned and proven to belong to the
GPCR family (Battey et al, 1991). Four subtypes of receptors for bombesin-like
peptides have been cloned and characterized to date: a GRP-preferring subtype
(GRPR or BB1), a neuromedin B receptor (NMBR or BB2), and a third subtype
whose ligand is still unknown (BRS-3R or BB3) (Wada et al, 1991; Fathi et al, 1996). A
fourth class of bombesin receptors (designated BB4) appears to constitute the
receptors for the bombesin-related peptides as they have higher affinity for
bombesin than GRP (Cutz et al, 1981). Receptors cloned from various sources show
similar pharmacological properties; GRPR has high affinity for GRP and bombesin
but low affinity for NMB whereas NMBR has high affinity for NMB, moderate
affinity for bombesin but low affinity for GRP.
The human GRP-R and NMB-R genes are localised on chromosome X (Xp22) and
chromosome 6 (6q21-ter) respectively (Iwabuchi et al, 2003). Overlapping
distribution of GRPR and NMBR has been observed in the gastrointestinal tract and
in many parts of the brain. The GRPR is particularly abundantly expressed in the
hypothalamus, suggesting roles in regulating pituitary hormone secretion and food
intake. GRP infusion has been shown to stimulate the secretion of ACTH,
corticotropin and endorphin in human subjects (Knigge et al, 1987).
1.3.1.1. Signal Transduction Pathways activatedbyBombesin
Bombesin stimulates the growth of Swiss 3T3 cells in a concentration and time-
dependent manner (Rozengurt & Sinnett-Smith, 1983). The cascades of intracellular
signalling events which follow BN/GRP binding to the GRPR to stimulate DNA
synthesis are described (illustrated in Figure 1.6).
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Inositol phosphatidyl turnover, Ca2+ mobilisation and PKC activation
BN/GRP binding to the GRP receptor chiefly promotes the activation of Gq proteins
(Jian et al, 1999). One of the earliest events following Gq-protein activation is the
mobilisation of calcium from intracellular stores which results in a transient increase
in cytosolic calcium and calcium efflux (Rozengurt & Mendoza, 1985a). This is due
to the interaction of active Gaq with its cellular effector phospholipase C (3 (PLC-P).
PLC-p becomes activated and catalyses the hydrolysis of phosphatidyl inositol 4,5-
bisphosphate (PIP2), resulting in the formation of second messengers inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG) (Berridge, 1993). IP3 binds to its
receptor present in the endoplasmic reticulum and stimulates the rapid release of
calcium from intracellular stores. The change in intracellular calcium levels is one of
the synergistic signals promoting DNA synthesis (Charlesworth & Rozengurt, 1994).
The activation of protein kinase C (PKC) by DAG also contributes to the growth
promoting ability of bombesin (Nishizuka, 1995). There are eleven known PKC
isoforms which are differentially expressed in cells and tissues and each has distinct
functions at different subcellular locations (Dekker et al, 1995). One of the major
PKC substrates is myristoylated alanine-rich C kinase substrate (80K/MARCKS) and
bombesin increases phosphorylation of this substrate (Zachary et al, 1986a).
Calcium-dependent calmodulin binding to 80K/MARCKS sequesters this substrate
from the membrane. The effective downregulation of 80K/MARCKS causes a
reversal of high level 80K/MARCKS expression which is induced when cells cease
proliferation and is thus implicated in the control of cell proliferation (Blackshear,
1993). It has also become apparent that PKC has a central role in transducing
neuropeptide signals into the activation of serine/threonine (Ser/Thr) protein
kinases such as mitogen-activated protein kinase (MAPK/ERK), p70S6K and protein
kinase D, although the pathways leading to such activation remain incompletely
understood.
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Figure 1.6. A paradigm of mitogenic GPCR signalling: signal transduction
pathways activated by engagement of the bombesin/GRP receptor. The binding of
the ligand (e.g. bombesin) to the cognate GPCR (e.g. the bombesin/GRP preferring receptor)
induces activation of the heterotrimeric G proteins of the Gq and G12 subfamilies. Signalling
through Gq/Gn leads to PLC activation, hydrolysis of PIP2, generation of IP3 and DAG and
activation of subsequent phosphorylation cascades leading to the activation of ERKs, p70S6K
and PKD. These pathways are representative of studies in Swiss 3T3 fibroblasts, SCLC cell
lines and pancreatic cancer cells. In other cell types, activation of tyrosine phosphorylation
pathways including Src, EGFR and/or Pyk-2 promote Ras-mediated ERK activation via the
SOS-Grb2 complex. Signalling through the G12 subfamily (comprising Gem and Gem)
transduces GPCR signals into Rho activation, actin remodelling, assembly of focal adhesions
and tyrosine phosphorylation of the focal adhesion-associated proteins FAK, CAS and
paxillin, and complex formation between FAK and Src. These pathways are implicated in
both cell proliferation and cell migration. (Rozengurt, 2002).
Bombesin stimulated ERK activation
Extracellular regulated kinases (ERKs) are activated through protein
phosphorylation cascades to relay mitogenic signals to the nucleus and this can be
mediated by PKC in some cell types (Seufferlein et al, 1996a). ERK activation leads
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to increased expression of the immediate early response genes (e.g. FOS, JUN and
MYC) and subsequent regulation of cell cycle events (Treisman, 1996). The dual
specificity ERK kinase (MEK), which directly phosphorylates ERK1 (p44) and ERK2
(p42) on specific serine and threonine residues, can be activated in a number of
ways (Rozengurt, 1998a). MEK can be activated through tyrosine kinase receptor
signalling as well as through the activation of Gi and Gq coupled GPCRs, but
different mechanisms have been described. Tyrosine kinase receptors (RTKs)
activate ERK1/2 through the adaptor complex, SOS-Grb2, which activates the small
GTPase Ras (p21ras) (Marshall, 1995). ERK1/2 activation by Gi-coupled GPCRs has
been shown to be mediated by GPy subunits and involves the Src-kinase dependent
tyrosine phosphorylation of She, which recruits the SOS-Grb2 complex for Ras
activation (Gutkind, 1998a). In both cases, activated Ras recruits Raf-1 (p74raf_1) to
the plasma membrane and activates a kinase cascade which involves Raf-1, MEK
and ERK1/2.
In Swiss 3T3 cells, bombesin stimulates ERK1/2 activation via Gq in a PKC-
dependent but Ras-independent manner (Seufferlein et al, 1996a). The precise
mechanisms by which PKC isoforms are able to activate ERK1/2 have not been
defined. However, studies using recombinant cell systems have revealed that the
same GPCR can activate ERK through different pathways according to cell type
(Delia Rocca et al, 1997). Thus, bombesin has been shown to stimulate ERK1/2 via a
PKC-independent and Ras-dependent manner in Rat-1 fibroblasts expressing
GRPRs (Charlesworth & Rozengurt, 1997). This highlights the importance of cell
context in studies of GPCR signalling pathways.
Importantly, GPCRs have been shown to be able to transactivate RTKs such as the
EGFR and this is thought to lead to Ras-dependent ERK activation (see Wetzker &
Bohmer (2003) for a review on mechanisms underlying such activity). It has recently
been demonstrated that bombesin-stimulated EGFR transactivation does not
mediate synergistic cell proliferation induced by bombesin and insulin, and that
insulin compensates for the requirement for EGFR transactivation in bombesin-
induced DNA synthesis (Santiskulvong et al, 2004).
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Bombesin stimulated p70 S6 kinase activation
Activation of p70 ribosomal S6 kinase (p70S6K) is a common cellular response to
mitogenic stimulation and requires phosphorylation of the kinase at multiple sites
by several kinases. This leads to increased translation of essential components of the
protein synthetic apparatus (Pullen et al, 1998). The activation of p70S6K by RTKs is
dependent on phosphatidylinositol 3-kinase (P13-K) activity (Pullen & Thomas,
1997). Bombesin stimulated p70S6K activation is PKC dependent but the mechanism
is not fully understood (Withers et al, 1997). The drug Rapamycin inhibits p70S6K
activation in response to all mitogenic stimuli, including bombesin. Rapamycin
blocks the activity of the RAFTl/FRAP/mTOR kinase, which shares homology with
the catalytic domain of PI3-K and is able to phosphorylate p70S6K at the rapamycin
sensitive-site (Burnett et al, 1998). This suggests that RAFT1 and p70S6K activity are
involved in the mitogenic effects of bombesin. The effect of rapamycin on
mitogenesis is reduced when Swiss 3T3 cells are stimulated with both bombesin and
insulin. This suggests that p70S6 is a signalling intermediate of one of the parallel
pathways leading to DNA synthesis rather than an obligatory point of convergence
in mitogenic signalling (Withers et al, 1997).
Bombesin stimulated Protein Kinase D activation
As shown, PKC is central to the transduction of neuropeptide signals into protein
kinase cascades but the precise downstream targets of specific PKC isoforms remain
undefined. Protein kinase D (PKD) is a Ser/Thr kinase with distinct structural and
enzymological properties (Valverde et al, 1994). Activation of PKD requires
phosphorylation at multiple sites and is stimulated by bombesin through a PKC
dependent pathway (Yuan et al, 2000). PKD activation has been shown to potentiate
neuropeptide-stimulated DNA synthesis by increasing the duration of ERK
39
signalling (Sinnett-Smith et al, 2004). In addition, it has been demonstrated that Gai3
contributes to PKD activation through a Rho- and protein kinase C-dependent
signalling pathway (Yuan et al, 2001) showing that PKD activation is mediated by
both Gaq and Ga.13 in response to bombesin receptor stimulation.
Bombesin stimulated Tyrosine Kinase Activation
Unlike the RTKS, GPCRs lack intrinsic tyrosine kinase activity. Nonetheless,
bombesin stimulates the rapid tyrosine phosphorylation of a number of substrates
(Zachary et al, 1991b; Tallett et al, 1996). Other neuropeptides, including vasopressin,
also have similar effects (Zachary et al, 1991b; Sinnett-Smith et al, 1993).
The non-receptor protein tyrosine kinase Focal Adhesion Kinase (FAK/pl25FAK) is
one of the most prominent of neuropeptide-stimulated tyrosine phosphorylation
substrates (Zachary et al, 1992). FAK localises to focal adhesions and FAK-mediated
signal transduction is implicated in embryonic development, cell migration,
proliferation, apoptosis and metastasis (Seckl & Rozengurt, 1993). FAK
phosphorylation facilitates the binding of Src family kinases which leads to further
FAK phosphorylation (Parsons & Parsons, 1997). This induces the formation of a
FAK signalling complex that activates multiple effector pathways. Neuropeptide-
induced phosphorylation of the focal adhesion proteins paxillin and pl30cas (CAS)
promotes assembly of a FAK signalling complex (Zachary et al, 1993).
Phosphorylated CAS forms a complex with the proto-oncogene c-Crk, which has Src
homology binding domains SH2 and SH3, and this is thought to regulate c-Crk
activity (Rosen et al, 1995). The kinase is able to regulate the activity of the small
GTPase Rapl, which has been shown to stimulate mitogenesis in Swiss 3T3 cells,
through binding to the guanine nucleotide exchange factor C3G (Cassamassima &
Rozengurt, 1997). The importance of tyrosine phosphorylation in neuropeptide-
stimulated mitogenesis is demonstrated through the inhibition of bombesin induced
DNA synthesis by tyrosine kinase inhibitors (Seckl & Rozengurt, 1993).
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Bombesin-stimulated tyrosine phosphorylation occurs via a pathway which is
independent of the Gq-mediated PLC pathway. It has been demonstrated that FAK
phosphorylation does not require calcium mobilisation and is largely independent
of PKC (Sinnett-Smith et al, 1993). Bombesin stimulates focal adhesion assembly and
stress fiber formation in Swiss 3T3 cells (Buhl et al, 1995). FAK tyrosine
phosphorylation is thought to occur downstream of focal adhesion assembly and
actin re-organisation since disruption of the actin cytoskeleton prevents bombesin-
mediated FAK phosphosphorylation (Rozengurt, 1995). Activation of the small
GTPase Rho induces focal adhesion assembly, stress fiber formation and nuclear
signalling and also leads to FAK phosphorylation (Tapon & Hall, 1997). Inhibition
of Rho activity using C3 exoenzyme from C. botulinum inhibits bombesin-induced
FAK, paxillin and CAS phosphorylation suggesting that neuropeptide-stimulated
FAK phosphorylation is downstream of Rho activation (Rankin et al, 1994).
Members of the G12 G-protein subfamily, Ga12 and Ga13, induce Rho activation and
constitutively active subunits have been shown to stimulate Rho-dependent
cytoskeletal responses as well as FAK, paxillin and CAS phosphorylation (Buhl et al,
1995; Needham & Rozengurt, 1998). Thus, neuropeptide receptors such as the
bombesin receptor are thought to also be able to couple to G12 proteins to mediate
their effects.
Bombesin stimulated Arachidonic Acid release and Prostaglandin svthesis
Although bombesin stimulates DNA synthesis in the absence of other factors,
vasopressin is mitogenic for Swiss 3T3 cells only in synergistic combination with
other factors, e.g. insulin (Rozengurt & Sinnett-Smith, 1983). Since independent
neuropeptide-stimulated pathways apparently act synergistically to promote DNA
synthesis, it is considered that the ability of bombesin to act as a sole mitogen may
be due to the activation of a unique pathway not stimulated by vasopressin. Along
this line, bombesin induces the release of arachidonic acid into the extracellular
medium whereas vasopressin does not (Millar & Rozengurt, 1990). Arachidonic acid
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release has been shown to occur through ERK-mediated Phospholipase A2 (PLA2)
activation in many cell types (Clark et al, 1995). A role for arachidonic acid in
mitogenesis is demonstrated through the potentiation of vasopressin-induced
mitogenesis by externally applied arachidonic acid (Millar & Rozengurt, 1990). In
addition, it has been found that arachidonic acid released by bombesin-stimulated
cells is converted to E-type prostaglandins, leading to an increase in intracellular
cAMP levels (Millar & Rozengurt, 1988). cAMP has been shown to be a mitogenic
signal for Swiss 3T3 cells, and neuropeptides which bind to receptors coupled to Gs
(G-protein subtype that stimulates cAMP synthesis) are mitogenic for these cells
(Rozengurt, 1986; Withers et al, 1996).
1.3.2. Vasopressin
Arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), belongs to
the neurohypophysial family of hormones which includes oxytocin. AVP is more
traditionally known for its role as a vasoconstrictor hormone acting on vascular
smooth muscle cells and its antidiuretic effect via the renal collecting system. In
addition to its function in the regulation of body fluid, vascular tone and blood
pressure, AVP has mitogenic effects on a number of cell types and has also been
shown to possess immunomodulatory properties (Chikanza et al, 2000). The human
AVP gene is located on chromosome 20 (20pl3). The cyclic nonapeptide is
synthesised in the hypothalamus as part of a larger pre-cursor protein which is
cleaved in the secretory granules to produce vasopressin, vasopressin-associated
neurophysin (VP-NP) and vasopressin-associated glycopeptide (VAG) (North,
1997a). Expression of the neuropeptide is largely restricted to the brain but also
detected in peripheral organs as a result of systemic secretion.
AVP exerts its biological effects through binding to three vasopressin receptor
subtypes: Vj vascular (ViR/ViaR)/ V2 renal (V2R) and V3 pituitary membrane
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(V3R/VibR) receptors which are coupled to distinct G proteins and second
messengers (Thibonnier et al, 1998). Vj and V3 receptors predominantly couple to
Gq proteins to modify phospholipase activity whereas V2 receptors couple to Gs
proteins to regulate adenylate cyclases. AVP receptors are expressed in vascular
smooth muscle cells, hepatocytes, blood platelets, adrenal cortex, kidneys, the
reproductive organs, spleen, adipocytes, brain and various cell-lines (3T3, A10,
WRK-1 and A7r5) (Thibonnier et al, 1994). The receptors show tissue-specific
distribution and each has a predominant biological role: Vq receptors mediate the
vascular effects of AVP; V2 receptors mediate renal effects, while V3 receptors
are involved in the regulation of ACTH secretion (Chikanza et al, 2000). The
human ViaR gene is located on chromosome 12 (12ql4-ql5) and expressed in the
liver, platelets, smooth muscle vascular cells and the central nervous system
(Birnbaumer, 2000). Stimulation of the Via receptor promotes cell contraction and
proliferation, platelet aggregation, coagulation factor release, and glycogenolysis
(Thibonnier et al, 1994). ViaR activation also leads to a mitogenic response in
vascular smooth muscle cells, 3T3 cells, renal mesangial cells, hepatocytes and
adrenal glomerulosa cells (Thibonnier et al, 2000).
As mentioned previously, vasopressin is a mitogen for Swiss 3T3 cells in synergistic
combination with insulin, serum, EGF and PDGF (Rozengurt & Sinnett-Smith,
1983). The pathways activated by vasopressin have many signalling intermediates
in common with those stimulated by bombesin (Rozengurt, 1991). Stimulation of
Via receptors leads to the activation of phospholipases A2, C and D; generation of
IP3 and DAG; mobilisation of intracellular calcium; PKC activation; PKD activation;
ERK activation; tyrosine phosphorylation of Src family kinases and FAK (Zachary et
al, 1991b; Thibonnier, 1992; Thibonnier et al, 2000; Chiu et al, 2002). The mediators of
the mitogenic action of ViaR were also found to include the simultaneous and
parallel activation of calcium/calmodulin kinase II and phosphatidylinositol 3
kinase (PI3-K) (Thibonnier et al, 2000). Thus, the pathways discussed for bombesin-
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mediated mitogenesis should also be applicable for vasopressin-mediated
mitogenesis.
The importance of the neuropeptides GRP and AVP in mitogenesis in model cell
systems has therefore led to the proposal that these neuropeptides may have a
regulatory role in the transformation of tumour cells.
1.4 Neuropeptide Growth Factors & Lung Cancer
SCLC tumour growth is sustained in part by multiple autocrine and paracrine loops
involving calcium mobilising neuropeptides, including bombesin/GRP, bradykinin,
cholecystokinin, gastrin, neurotensin and vasopressin (Sethi & Woll, 1995). It
appears that SCLC cells can express autocrine growth loops for an overlapping
subset of these neuropeptides. Although SCLC cells in culture secrete a variety of
these neuropeptides, they only respond mitogenically to those for which the cognate
receptor is co-expressed. GRP and vasopressin, the two neuropeptides most
relevant to the study here, are discussed below.
1.4.1. Bombesin/Gastrin releasing peptide
As mentioned previously, GRP was the first neuropeptide to be detected in SCLC
(Wood et al, 1981; Moody et al, 1981). GRP is found abundantly expressed in the
foetal lung but barely detectable, in contrast, in the neuroendocrine cells lining the
bronchi of human adult lung (Moody, 1984). These and other studies have
suggested that GRP has an important role in normal lung development (Ghatei et al,
1983; Wang et al, 1996a; Spindel et al, 1987; Cuttitta et al, 1988; Li et al, 1994).
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The demonstration that Bombesin/GRP could stimulate the growth of explants of
normal human bronchial epithelial cells suggested that GRP could function as a
growth factor in the human lung (Willey et al, 1984). A study investigating the effect
of GRP on the cloning efficiency of human bronchial epithelial (HBE) cells taken
from 13 donors showed that the neuropeptide stimulated colony formation in 8/13
cell-lines (Siegfried et al, 1997). The elevated expression of GRP receptor subtypes
and increased proliferative response found in some of the HBE cell-lines correlated
with a history of smoking (al Moustafa et al, 1995). The role of GRP as a lung
mitogen was further supported through the ability of bombesin to stimulate growth
of a HBE cell-line transfected with GRP receptors (Olincy et al, 1999). Expression of
the three subtypes of bombesin receptor (GRPR, NMBR and BRS-3E) has been
demonstrated in HBE cells (DeMichele, 1994). Interestingly, one study found that
transformed HBE cells expressed only the GRPR, indicating a possible role for
altered regulation of bombesin receptors in lung transformation (Kane et al, 1996).
The normal lung responds to changes in pulmonary oxygenation, such as those
associated with birth (increased oxygenation) or with chronic obstructive airways
disease (decreased oxygenation), by stimulating pulmonary neuroendocrine cells to
secrete bombesin/GRP. Increased GRP secretion has been found to be accompanied
by pulmonary neuroendocrine hyperplasia (Schuller, 1991). Further to this, it has
been suggested that GRP and abnormal oxygenation may play a role in the
initiation of smoking-related tumours (Sethi & Woll, 1995). Accordingly, a high
incidence of SCLC has been found in smokers with a history of chronic obstructive
disease and also the bronchoaleveolar lavages of normal smokers have been found
to have elevated levels of GRP compared with non-smokers (Aguayo et al, 1990).
The serum bombesin levels in schizophrenic smokers, who are often heavy smokers
but have a lower incidence of lung cancer, have been found to be reduced (Olincy et
al, 1999). In a comparison of GRPR expression in the airway cells and tissues of
males and females, GRPR expression was found to be significantly higher in women
(who have two expressed copies of the X-linked gene) than in men in the absence of
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smoking (Shriver et al, 2000). GRPR expression was also found to be activated earlier
in women in response to tobacco exposure, and could be a contributing factor in the
increased incidence of smoking-related lung cancer in women.
Cloning of human GRP mRNA from pulmonary carcinoid tissue showed that the
protein is synthesised as a 148 amino acid precursor; a pre-pro-GRP translation
product composed of a signal sequence (amino acids 1-27) and a GRP-gene
associated peptide (amino acids 31-125) (Spindel et al, 1984). Two types of pre-pro-
GRP cDNA clones were isolated, indicating the potential existence of at least two
forms of pro-GRP differing in the carboxy-terminal GRP-associated peptide.
A marked correlation between pre-pro-GRP expression and the occurrence of
bombesin-like immunoreactivity (BLI) has been found in SCLC cells, confirming
that the peptides originate in those cells (Sausville et al, 1986). Alternative splicing is
thought to give rise to the different forms of pre-pro-GRP mRNA which are found
in the SCLC cells and suggests that different forms of pro-GRP may be synthesised.
In addition to pre-pro-GRP mRNA, pro-bombesin C-terminal peptide and multiple
GRP gene associated peptides have also been demonstrated to be present in SCLC
tumours (Cuttitta et al, 1988; Sunday et al, 1991; Sausville et al, 1986).
Although plasma GRP is elevated in patients with extensive metastatic SCLC, it was
found that GRP itself was not useful as a tumour marker because of low serum
levels and its rapid metabolism in the blood (Bork et al, 1988). More recently
however, it has been proposed that pro-GRP may be useful in this respect. One
study showed that pro-GRP levels were elevated in neuroendocrine tumours
(Molina et al, 2004). High levels of pro-GRP were found in SCLC patients with local
and extensive disease in contrast with only 4% of NSCLC cases. Another study
indicated that pro-GRP would not be useful in early detection of SCLC since levels
were found to be high at an early stage, whereas levels of the more commonly used
marker, NSE, tended to increase with disease progression (Sunaga et al, 1999). A
correlation was found to exist between a positive response to treatment and a
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reduction in serum pro-GRP levels, and patients who relapsed had serum pro-GRP
levels which were again elevated. In addition, patients whose pro-GRP levels
dropped by more than 50% following treatment survived significantly longer than
those patients whose pro-GRP levels decreased by less than that. Thus, serum pro-
GRP may be useful as a highly specific SCLC marker for treatment monitoring and
prognosis. Scintigraphy using a labelled bombesin ligand (99mtc-bombesin) has
been used to detect prostate cancer, including pelvic lymph node metastases, and
could be applicable to the detection of other endocrine tumours such as SCLC (De
Vincentis et al, 2004).
To date, deletion of chromosome 18 (the site of the GRP gene) has not been observed
in SCLC which suggests that chromosomal abnormalities do not affect the GRP
structural gene in this tumour (Virmani et al, 1998). Similarly, re-arrangement or
amplification of the GRP structural gene has also not been detected. The most
consistent and specific chromosomal abnormality found in SCLC cells is deletion of
the short arm of chromosome 3, and this has been associated with poor prognosis in
limited stage SCLC patients with no pre-operative chemotherapy.
The specific binding of [^I-Tyr4] bombesin showed that SCLC cells express
bombesin receptors, and therefore that GRP could act as an autocrine growth factor
for SCLCs (Moody et al, 1985; Layton et al, 1988). It was demonstrated that the main
bombesin receptor subtypes (GRPR, NMBR and BRS-3R) are expressed in an
overlapping subset of human lung carcinoma cell-lines (Fathi et al, 1996). In one
study using RT-PCR, the GRPR, NMBR and BRS-3R were shown to be expressed in
17/20, 11/20 and 5/20 SCLC cell-lines respectively, and could also be detected in
NSCLC cell-lines (Toi-Scott et al, 1996). In another study using an RNAase
protection assay to detect receptor mRNAs, GRPR and NMBR were detected in 3/7
and 7/7 SCLC cell-lines respectively (Yang et al, 1998). Analysis of GRPR and NMBR
cDNAs from SCLC cell-lines showed there was no structural change in receptor
protein or genomic rearrangement associated with expression of these receptors
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(Giladi et al, 1993). Recently, glucocorticoids have been implicated in the regulation
of GRPR expression in SCLC cells. Dexamethasone treatment of a SCLC cell-line led
to increased proliferation, which could be blocked by a GRPR antagonist, and was
accompanied by significant up-regulation of GRPR expression (Novak et al, 2004). It
has been shown that SCLC cell-lines, but not NSCLC cell-lines, co-express GRP and
GRP receptors and this suggests that autocrine growth loops are likely only to exist
in SCLCs (Ocejo-Garcia et al, 2001). Pro-GRP mRNA expression has been shown to
correlate with elevated serum pro-GRP levels but not with GRPR expression in
tumours from SCLC patients (Uchida et al, 2002). Thus, it should be noted that not
all SCLCs express an autocrine system for GRP.
GRP has been demonstrated to function as a growth factor in SCLC both in vitro and
in vivo. In one study, GRP was shown to enhance DNA synthesis in SCLC cell-lines
and in another study, the cloning efficiency of 9/10 SCLC cell-lines was increased
150-fold by GRP (Weber et al, 1985; Carney et al, 1987). In vivo, growth of SCLC
xenografts (NCI-H69) increased 77% above control in nude mice given three daily
intra-peritoneal injections of bombesin (Alexander et al, 1988). The monoclonal
antibody to circulating bombesin (2A11) inhibited the cloning efficiency of 2 SCLC
cell-lines in serum-free medium and the growth of a SCLC xenograft in nude mice
(Cuttitta et al, 1985). The same antibody was shown to inhibit the cloning efficiency
of SCLC cells in a GRPR-expression dependent manner (Yang et al, 1998). Inhibition
of SCLC cloning efficiency has also been demonstrated using the specific bombesin
antagonist [Leu13-psi-(CH2NH)-Leu14] bombesin (Trepel et al, 1988a).
In terms of mitogenic signalling in SCLC, GRP has been shown to stimulate PLC
activity and elevate intracellular calcium levels in SCLC cells (Trepel et al, 1988b;
Heikkila et al, 1987). The modulation of PLC activity by non-hydrolysable GTP
analogues showed that the GRP receptor expressed in SCLC coupled to a G-protein
for intracellular signalling (Sharoni et al, 1990). Inositol phosphate production and
calcium mobilisation could be inhibited with a specific bombesin antagonist and a
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monoclonal antibody against bombesin (Trepel et al, 1988b; Heikkila et al, 1987).
Downregulation of PKC led to inhibition of IP3 production and intracellular calcium
release, demonstrating that these GRP-stimulated events occurred in a PKC
dependent manner in SCLC cells (Trepel et al, 1988a). A role for the kinases ERK and
p70s6k jn bombesin-stimulated proliferation and colony formation of SCLC cells has
also been demonstrated (Seufferlein & Rozengurt, 1996b; Seufferlein & Rozengurt,
1996c). SCLC cell stimulation with bombesin induced expression of the immediate
early response genes c-fos and c-jun, demonstrating that the neuropeptide is able to
regulate nuclear expression in SCLC cells (Draoui et al, 1995). Tyrosine
phosphorylation, including phosphorylation of FAK, is also observed in SCLC in
response to bombesin stimulation (Tallett et al, 1996b). The calcium mobilising
neuropeptides bradykinin, gastrin and neurotensin also stimulated tyrosine kinase
activity, indicating that common signalling events could be induced by various
neuropeptides. It therefore appears that SCLC growth may be stimulated by the
normal intracellular signals evoked by ligand-dependent activation of bombesin
receptors. However, to date, therapeutic strategies aimed at specifically
antagonising the GRP receptor have not proved fruitful in clinical studies
(Chaudhry et al, 1999).
1.4.2. Vasopressin
Vasopressin growth loops in SCLC have been less intensively studied than the
bombesin autocrine system. However, it has become apparent that expression of
vasopressin is a very common feature of SCLC cells (Verbeeck et al, 1992; North et al,
1980; Sorenson et al, 1981; Friedmann et al, 1994). Immunohistochemical analysis of
24 SCLC cell-lines (using antibodies directed against vasopressin (VP), vasopressin-
associated human neurophysin (VP-NP), the bridging region between the hormone
and the neurophysin, and vasopressin-associated human glycopeptide (VAG)),
showed that all of the cell-lines expressed at least some part of the vasopressin
precursor (Friedmann et al, 1994). Positive immunoreactivity for all four regions of
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the precursor was detected in 67% of cell-lines while in the remaining 33%, only VP-
NP and/or VAG was present. Further investigation has revealed that in some SCLC
tumours and cultured cells, intact pro-VP can become localised at the cell surface
(North et al, 1993). This pro-vasopressin product that aberrantly remains attached to
the cell membrane may conceivably contribute to autocrine-driven mitogenesis in
SCLCs (Friedmann et al, 1994). Antibodies recognising this cell surface antigen have
been developed as a potential diagnostic and therapeutic tool that targets SCLC
tumours in vivo (Keegan et al, 2002).
Expression of the pre-pro-vasopressin cleavage products, VP and VP-NP, has also
been evaluated in non-neuroendocrine tumours. Vasopressin immunoreactivity was
not present in any of the tumours examined, although VP-NP immunoreactivity
was detected in 1/12 adenocarcinomas and 1/10 squamous cell carcinomas
(Friedmann et al, 1993). This demonstrated that vasopressin gene expression is
restricted to neuroendocrine tumours and this could potentially be exploited in
distinguishing SCLC from NSCLC. Another study also demonstrated that
vasopressin is expressed in SCLC cell-lines but not in NSCLC cell-lines, F1BE cells or
transformed FFBE cells (Coulson et al, 1999c). As mentioned previously, vasopressin
is physiologically expressed largely in the hypothalamus and therefore the
mechanisms which facilitate de-regulated expression of vasopressin in SCLC are
being investigated. Vasopressin expression can be stimulated in SCLC cells through
the modulation of VP gene promoter activity by high osmolality as well as non-
osmotic factors such as endothelin-3, angiotensin-II and acetylcholine (Kim et al,
1996). Studies of the VP promoter have shown that a short region of the promoter
drives expression in SCLC but not NSCLC cell-lines (Coulson et al, 1999c). It has also
been demonstrated that the transcription factor, USF-2 (upstream stimulatory
factor) binds within this promoter region to initiate transcription of the vasopressin
gene (Coulson et al, 2003b). The study showed that in NSCLC cells, USF-2 is
endogenously expressed at levels which are insufficient for transcriptional
activation of vasopressin expression. SCLC cells have also been found to over-
express a novel splice variant of the transcriptional silencer neuron-restrictive
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silencer factor (NRSF) which may prevent normal NRSF repressing vasopressin
gene expression (Coulson et al, 2000).
V1A receptor expression has been detected in 4/4 SCLC cell-lines (Waters et al, 2003).
In another study, it was demonstrated that 5/5 SCLC cell-lines expressed V1A
receptors whereas NSCLC, HBE and transformed HBE cells did not express the
receptors (Coulson et al, 1999c). It was shown that vasopressin and V1A receptors
were co-expressed in all SCLC cell-lines examined, while no such co-expression was
observed for NSCLC (Ocejo-Garcia et al, 2001). This demonstrates that SCLC cells
express an autocrine system for vasopressin. In general, co-expression of
neuropeptides and their receptors was found to be restricted to SCLC cells and it
was suggested that particular neuropeptide/receptor pairs would be useful as early
markers for the detection of lung cancer (Coulson et al, 2003a). Both classic and
variant SCLC cell-lines have also been shown to co-express vasopressin and ViA
receptors (Fay et al, 1994). These SCLC cell-lines were also found to express other
vasopressin receptor subtypes, which implies that vasopressin may play a more
complex role in SCLC growth than has previously been considered (North et al,
1998).
Consistent with a role as a growth factor, vasopressin is able to increase the cloning
efficiency of SCLC cells (Sethi & Rozengurt, 1991; Bunn et al, 1992; Seufferlein &
Rozengurt, 1996b). A role for vasopressin in SCLC metastasis has also been
suggested since vasopressin is a chemoattractant for SCLC cells (Ruff et al, 1985).
Vasopressin is able to stimulate calcium mobilisation in SCLC cells and this can be
blocked by vasopressin antagonists (Woll & Rozengurt, 1989a; Woll & Rozengurt,
1990; Bunn et al, 1992; Hong et al, 1991; Bunn et al, 1994). Interestingly, variant SCLC
cell-lines do not mobilise intracellular calcium or proliferate in response to
vasopressin although functional, structurally normal ViA receptors have been
detected on both classical and variant cell lines (Fay et al, 1994; North et al, 1998).
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Whereas vasopressin stimulates calcium mobilisation in classic SCLC cells, Via
receptor activation in variant SCLC results in an increase in inositol phosphate
levels without a corresponding rise in intracellular calcium (North et al, 1997b). This
indicates that discordant vasopressin signalling occurs at a post-receptor level in
variant SCLC cells.
In addition to calcium mobilisation, mitogenic vasopressin signalling in SCLC cells
has been shown to involve the activation of ERK in a PKC-dependent manner
(Seufferlein, 1996b; Pequeux et al, 2004). The downstream target of ERK activation is
p90rsk, which is phosphorylated in response to vasopressin stimulation of SCLC
(Pequeux et al, 2004). Through the use of a specific vasopressin antagonist as well as
inhibitors of various signalling intermediates, the same study showed that
vasopressin stimulated ERK activation and p90rsk phosphorylation was dependent
upon PLC, PKC, MEK1/2 and calcium signalling. An absolute requirement for PLC,
calcium, PKC and ERK1/2 for vasopressin-stimulated DNA synthesis in SCLC cells
was also demonstrated. This indicates that the growth of classic SCLCs may be
stimulated by the normal intracellular signals evoked by ligand-dependent
activation of Via receptors. Thus, vasopressin receptors provide an attractive target
for SCLC therapy.
1.4.3. Strategies for Blocking Neuropeptide Growth Factor
Action
Since the growth of SCLC can be sustained by autocrine and paracrine growth loops
involving calcium mobilising neuropeptides, interruption of these growth loops
provides an opportunity for controlling the growth of this cancer. The mitogenic
effect of the neuropeptides are elicited through binding to their receptors, therefore
preventing the ligand-receptor interaction is the most immediate way of blocking
mitogenesis. The majority of work along these lines has been in the development of
bombesin antagonists to disrupt bombesin growth loops.
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The monoclonal antibody against circulating bombesin (2A11), which had
previously been shown to inhibit SCLC growth in vitro and in vivo, showed no dose-
limiting toxicity in a phase I clinical trial (Chaudhry et al, 1999). In the phase II trial,
one relapsed SCLC patient went into clinical remission (Kelley et al, 1997). More
recently, a bi-specific molecule targeting cell surface BN/GRPR on SCLC cells and an
immune trigger molecule on host immune effector cells has been developed to
direct immune effector cells to SCLC cells (Zhou et al, 2003). The bispecific molecule
consisted of a synthetic BN/GRP antagonist (Antag 2) and a humanized monoclonal
antibody for FcgammaRI (H22). In an animal model of human SCLC xenografts, the
study showed that targeted immunotherapy in combination with chemotherapy led
to greater SCLC killing. However, the cost-effectiveness of antibody therapeutics
coupled with relatively low tissue penetration present potential drawbacks for
antibody-mediated therapy of SCLC.
A novel approach has been to use antisense (AS) oligodeoxynucleotides (ODNs)
directed against gastrin releasing peptide (GRP) receptor mRNA (Langer et al, 2002).
AS ODNs significantly inhibited the growth of NCI-H345 SCLC cells in vitro, but not
the growth of cells that lacked an autocrine system for GRP. The AS ODNs down-
regulated GRP receptor expression and also caused a reduction in the number of
cells mobilising intracellular calcium in response to GRP. It is hoped that AS ODN
specificity and effectiveness in human SCLC cell can be increased through further
development of this type of strategy.
A more conventional approach has been the development of peptide antagonists of
bombesin. A pseudo-peptide analogue of bombesin [Leu13-psi(CH2NH)Leu14]
inhibited the growth of SCLC cells both in vitro and in vivo (Mahmoud et al, 1991).
Using similar pseudo-nonapeptides, the Schally group introduced D-Trp or Trp
analogue (Tpi) substitutions at position 6 to produce a series of more potent
bombesin antagonists (Radulovic et al, 1991a). Of these, RC-3095 QD-Tpi6,Leu13
psi(CH2NH)Leu14-bombesin (6-14)]) has been shown to inhibit the growth of GRPR
expressing SCLC cells in vitro and in vivo, but not the growth of non-GRPR
expressing NSCLC cells (Pinski et al, 1994b). The mechanism of in vivo growth
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inhibition involves the down-regulation of GRPR and EGFR expression (Koppan et
al, 1998; Halmos et al, 1997). More recently, the antagonist has also been found to
have anti-angiogenic effects in various tumour models (Bajo et al, 2004; Heuser et al,
2005; Stangelberger et al, 2005a). RC-3095 delayed the progression of pre-malignant
lesions to invasive cancer in a hamster model (Liebow et al, 1993). RC-3095 has also
demonstrated anti-tumour activity against an extensive range of tumour types
which express bombesin receptors (Table 1.5), which highlights the significance of
GRP as a cancer growth factor. RC-3095 has recently completed a phase-I trial in
patients with advanced solid malignant disease of various types, which
demonstrated that the agent was well-tolerated without clinically relevant side
effects and that there were signs of anti-tumour effects even at low doses
(Schwartsmann G and colleagues, unpublished data). A bombesin antagonist (RC-
3094) conjugated to a doxorubicin derivative (AN-201) has recently been developed
for targeted chemotherapy. In vivo studies indicated that the conjugate inhibited
SCLC and prostate cancer growth in vivo more effectively and with less toxicity than
the cytotoxic agent alone (Kiaris et al, 1999a; Stangelberger et al, 2005b).
Bradykinin is also an important growth factor for SCLC. The bradykinin receptor is
expressed in most of the human lung cancer cell-lines, and bradykinin is one of the
most potent neuropeptides that causes intracellular calcium flux in these SCLC and
NSCLC cell-lines (Bunn et al, 1992). Peptide and non-peptide bradykinin antagonists
have been developed which demonstrate anti-cancer activity (Stewart, 2003). In
particular, a non-peptide bradykinin antagonist dimer inhibited the growth of SCLC
and prostate cancer xenografts in nude mice more potently than standard anti¬
cancer drugs (Stewart et al, 2005). In the same study, it was demonstrated that anti-
angiogenesis and anti-matrix metalloprotease activities are components of the anti¬
cancer effect.
54
Table 1.5. Tumour types sensitive to growth inhibition in xenograft
models by bombesin antagonist (RC-3095)
Tumour Type









Combination chemotherapy forms the basis of many cancer treatment regimes.
Thus, while a single agent may not fully eliminate cancer, a more potent effect can
be obtained when used in combination with other drugs, particularly those which
target a different aspect of cancer growth. For example, through the combined use
of a cytotoxic drug to inhibit growth, an angiogenesis inhibitor to block
neovascularisation and a matrix-metalloprotease inhibitor to prevent invasion. The
finding that some of these single neuropeptide antagonists also have anti-
angiogenic and anti-matrix metalloprotease properties suggests that the combined
chemotherapy effect may be attainable through the use of a single compound.
However, the heterogeneity of neuropeptide receptor expression and
responsiveness in SCLC is a potential hindrance to the therapeutic usefulness of
single neuropeptide antagonists. Targeting a single neuropeptide growth loop
would therefore be unlikely to inhibit SCLC growth fully and instead,
simultaneously blocking the action of multiple neuropeptide growth factors would
55
be required. For treatment to be fully effective using single neuropeptide
antagonists, a cocktail of neuropeptide antagonists would need to be administered
according to the neuropeptide receptor profile of the tumour. The ideal alternative
would be the development of antagonists which inhibit the action of a broad range
of neuropeptide growth factors. Substance-P analogues were the first compounds
found to possess broad-spectrum antagonist activity against multiple neuropeptide
growth factors.
1.4.3.1. Substance-P analogues as novel anti-canceragents
Substance-P (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met) is a member of the
tachykinin family of neuropeptides. A series of substance-P analogues were
developed, with various D-amino acid substitutions, as antagonists of substance-P
activities. Remarkably, substance-P antagonist A (SP-A: [D-Arg1, D-Pro2,D-Trp7-9,
Leu11]) was found to also antagonise the cellular effects of structurally unrelated
bombesin (Jensen et al, 1984). In swiss 3T3 cells, SP-A inhibited 125I-GRP binding and
early signalling events and mitogenesis stimulated by bombesin (Zachary &
Rozengurt, 1985; Woll & Rozengurt, 1988b). The first indication that substance-P
analogues may have broad-spectrum activity came from the finding that SP-A was
also able to block the specific binding of 3H-vasopressin and vasopressin stimulated
calcium mobilisation and DNA synthesis (Zachary & Rozengurt, 1986b). This
showed that SP-A could interact with receptors for three structurally unrelated
neuropeptides, and so further substance-P analogues were investigated.
Antagonist G (SP-G: [Arg6,D-Trp7-9,MePhe8]-substance-P (6-11); a truncated
substance-P analogue) and antagonist D (SP-D: [D-Arg1, D-Phe5,D-Trp7<9, Leu11])
inhibited signal transduction and DNA synthesis stimulated by bombesin, GRP,
bradykinin and vasopressin (Woll & Rozengurt, 1988c; Woll & Rozengurt, 1990).
The analogues were also able to inhibit the binding of these ligands to their
receptors. As well as inhibiting neuropeptide binding and calcium mobilisation,
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substance-P analogues have been shown to inhibit PLCp, PKC, ERK and FAK
activation by bombesin and vasopressin (Seckl et al, 1996a).
In SCLC cells, SP-G inhibited calcium mobilisation induced by bombesin,
bradykinin, gastrin, galanin, vasopressin, cholecsytokinin and neurotensin (Woll &
Rozengurt, 1990). Various substance-P analogues inhibit SCLC cell growth in vitro in
liquid and semi-solid media (Bepler et al, 1988; Layton et al, 1988; Woll & Rozengurt,
1988c; Woll & Rozengurt, 1990; Sethi et al, 1992; Bunn et al, 1994). SP-D and SP-G are
equipotent in their growth inhibitory effects, with half-maximal effect at around
20pM, whereas SP-A is five-fold less potent (Woll & Rozengurt, 1988c). Table 1.6
illustrates the range of potencies with which substance-P analogues inhibit H69
SCLC cell growth. A more potent inhibitor of SCLC cell growth, [D-ArgbD-Trp
5-7'9,Leun] Substance-P (ICRT5), was identified out of a panel of novel substance-P
analogues (Seckl et al, 1997). This analogue inhibited proliferation in liquid culture
and semisolid media, and also vasopressin- or bradykinin-induced calcium
mobilisation and ERK activation.
SP-D inhibited DNA synthesis and cloning efficiency of 6/6 SCLC, 1/1 NSCLC
(squamous), 2/2 ovarian and 1/1 squamous cervical carcinoma cell-lines,
demonstrating that the growth inhibitory effects were not restricted to effects on
SCLC cells alone (Everard et al, 1992). Another study assessed the effects of a panel
of substance-P analogues and showed that the compounds inhibited the growth of
peptide-sensitive SCLC cell lines more efficiently than their inhibition of peptide-
insensitive NSCLC or breast cancer cell lines (Bunn et al, 1994). Growth inhibition of
a range of tumour types (SCLC, NSCLC, ovarian, pancreatic and colorectal
carcinoma cell-lines) by SP-G correlated with GRPR expression (Waters et al, 2003).
Of particular interest was the finding that SP-G was able to inhibit the growth of
SCLC, NSCLC and ovarian cell-lines which were resistant to standard
chemotherapeutic agents such as etoposide. A comparison of specific bombesin,
cholecystokinin or AVP antagonists with a number of broad specificity substance-P
analogues showed that the substance-P analogues were more effective at inhibiting
SCLC growth in vitro (Bunn et al, 1994).
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Table 1.6. Substance-P analogue structures and inhibition of H69 SCLC
cell growth in liquid culture on day 12 (adapted from Seckl and Rozengurt,
1998)








Arg6-D-Trp7-MePhe8 -D-Trp9-D-Leu10-Metn -NH2 27
Arg6-D-Trp7-MePhe8 -D-Trp^D-Leu^-Val11 -NH2 19
Arg6-D-Trp7-MePhe8 -D-Trp9-D-Leu10-Glyn-NH2 16














In mouse xenograft model studies, SP-D and SP-G inhibited the growth of WX332
SCLC tumours and the inhibitory effects were maintained beyond the duration of
administration (Langdon et al, 1992). SP-D and ICRT5 also inhibited H69 SCLC
xenografts, and analysis of the biodistribution of SP-D in the mice showed that
although there was poor uptake into the tumour xenograft, there was good uptake
into the lungs indicating that it may be possible to attain therapeutic concentrations
in primary lung tumours (Seckl et al, 1997; Jones et al, 1997). A phase I clinical trial
using SP-G has been completed which evaluated the effects of dose-escalation up to
400mg/m2. Volunteer cancer patients received a 6hr infusion every three weeks for
up to 12 cycles. No dose-limiting toxicity was found and plasma concentrations up
to 40pM were achieved (Clive et al, 2001). This concentration is within the range of
IC50 values for SCLC growth inhibition derived from in vitro studies.
More recently, studies of the most potent substance-P analogue [D-Arg^D-
Trp5'7'9,LeuM] have been carried out using a well-differentiated pancreatic cancer
cell-line which expresses multiple GPCRs for mitogenic agonists and produces pro-
angiogenic chemokines (Guha et al, 2005). The analogue inhibited multiple
neuropeptide-induced calcium mobilisation, DNA synthesis, and anchorage-
independent growth in vitro and significantly blocked the growth of HPAF-II
tumour xenografts in nude mice beyond the treatment period. The novel finding of
this study was that the analogue markedly reduced tumour-associated angiogenesis
in the HPAF-II xenografts and was also shown to specifically inhibit IL-8/CXCL8-
induced angiogenesis in a rat corneal micropocket assay in vivo. This demonstrates
that substance-P analogues can inhibit tumour growth through a dual mechanism
which involves both anti-proliferative and anti-angiogenic properties.
The mechanisms underlying substance-P analogue induced growth inhibition
Due to the clinical requirement for compounds with broad-spectrum specificity
against multiple neuropeptide receptors for the treatment of neuroendocrine
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tumours such as SCLC, it has been of great importance to elucidate the mechanisms
underlying substance-P analogue induced growth inhibition. The substance-P
analogues have broad-spectrum specificity against mitogenic neuropeptides whose
receptors couple to Gq proteins to activate a common set of signal transduction
pathways (Sethi & Woll, 1995). In accordance with this, substance-P analogues do
not inhibit the mitogenic signalling of platelet-derived growth factor (which binds
to a RTK to mobilise intracellular calcium), or vasoactive intestinal peptide (which
induces cAMP accumulation without calcium mobilisation through a Gs-coupled
receptor) (Mitchell et al, 1995; Seckl et al, 1996a). Given the ability of these analogues
to inhibit binding and subsequent signalling of multiple, structurally unrelated
neuropeptides it was originally believed that the compounds were acting as
competitive antagonists of ligand binding. However, several lines of evidence
suggested the mechanism was more complex than simple competitive antagonism.
The growth inhibitory effects of the analogues were found to be at least partly
mediated through the active induction of apoptosis. SP-G induced apoptosis in
SCLC cell-lines at similar concentrations to which it caused growth inhibition
(Tallett et al, 1996a; MacKinnon et al, 1999). The pro-apoptotic and growth inhibitory
effects of the analogues could not be reversed by exogenously added neuropeptides
(Mitchell et al, 1995; MacKinnon et al, 1999). In terms of intracellular signalling, SP-D
prevented ERK activation at low concentrations of bombesin (1-lOnM) whereas at
higher concentrations of bombesin (>10nM) the analogue enhanced bombesin-
stimulated ERK activation (Mitchell et al, 1995). This suggested that the GRP
receptor could still be capable of signalling even when bombesin-induced PLC
activation was fully blocked by analogue. It was subsequently found that SP-G was
able to induce the sustained activation of c-Jun-N-terminal kinase (JNK) in SCLC
cells and this activation could not be reversed by high concentrations of
neuropeptides (MacKinnon et al, 1999). Thus, SP-G was demonstrated to possess
neuropeptide independent agonist activity in addition to its previously known
antagonist properties. It had previously been demonstrated that JNK activation by
GPCRs could be mediated through receptor coupling to G12 proteins (Prasad et al,
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1995). SP-D was also shown to be able to activate JNK and it was found that this
JNK activation was dependent on the expression of GRP receptors (Jarpe et al, 1998).
Jarpe et al (1998) suggested that SP-D activated G-proteins of the G12 family whilst
simultaneously blocking signal transduction via Gq-proteins, and proposed the
novel pharmacological term 'biased agonism' to describe this behaviour.
Direct evidence for biased agonism was provided through studies of SP-D agonist
activity in cells expressing bombesin receptors (Mackinnon et al, 2001). SP-D
inhibited bombesin binding and bombesin-stimulated calcium mobilisation within
the same concentration range which caused sustained JNK and ERK activation. SP-
D stimulated JNK activation was blocked by dominant negative inhibition of Gai2
and ERK activation inhibited by pertussis toxin. In contrast, bombesin stimulated
ERK activity was not sensitive to pertussis toxin showing that SP-D facilitated
bombesin receptor coupling with Gai2 and G; proteins whilst blocking receptor
activation of Gq proteins. Thus it was demonstrated that SP-D was capable of
differentially modulating the activation of the G-proteins Gai2, Gj and Gq compared
with bombesin. It has been proposed that the biased agonist activity of SP-D, which
results in the inhibition of intracellular calcium mobilisation and the prolonged
stimulation of ERK and JNK, is central to the growth inhibitory effects of this agent
(MacKinnon et al, 2001; Waters et al, 2003).
1.5 Plan of study
As discussed above, substance-P analogues represent a novel therapeutic strategy
for the treatment of neuroendocrine tumours such as SCLC. The demonstration that
SP-D acts as a biased agonist at bombesin receptors is of great importance as it
shows that a ligand can selectively direct intracellular signalling pathways to alter
the normal biological outcome of receptor signalling. Targeting multiple mitogenic
neuropeptide receptors with a novel pharmacological agent which acts as a
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molecular switch converting a normally growth promoting signal into a death
signal offers a novel opportunity to inhibit cancer progression. It would therefore be
of consequence to the clinical use of substance-P analogues as anti-cancer agents to
establish whether their biased agonist activity is restricted to effects at GRP
receptors alone. The aim of this study is to determine whether substance-P
analogues exhibit biased agonist activity at receptors other than the GRP receptor.
The factors which may influence the ability of substance-P analogues to modulate
neuropeptide signalling will also be investigated as this could aid in the future
development of novel biased agonists. The following specific questions will be
addressed:
1) Are substance-P analogues biased agonists of vasopressin receptors as
well as GRP receptors? Model cell systems expressing vasopressin or
GRP receptors will be established for this purpose. Substance-P analogue
activity will be investigated at the levels of receptor binding, calcium
mobilisation and ERK activation in order to further investigate the
mechanism underlying biased agonism.
2) Does specific expression of GRP and Via receptors lead to cellular
transformation in a model CHO-K1 cell system? Cell growth, migration
and adhesion will be assessed in order to evaluate the oncogenic
potential of neuropeptide receptors expressed in CHO-K1 epithelial cells.
In addition, the chemosensitivity of the model cell systems will be
investigated to ascertain whether neuropeptide growth factor signalling
could play a role in the acquisition of chemoresistance.
3) Does neuropeptide receptor expression alter the ability of substance-P
analogues to signal and inhibit growth? Substance-P analogue-induced
growth inhibition will be assessed under both anchorage dependent and
independent conditions. This may indicate whether a correlation
between biased agonist activity and analogue induced growth inhibition
exists. The effect of substance-P analogues on migration will also be
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investigated to determine whether they can function as chemoattractants
for neuropeptide receptor expressing cells.
4) Does modulation of the stoichiometry of receptor to G-protein alter
substance-P analogue directed signalling?
5) What regions of the V^a receptor are necessary for substance-P-analogue
induced signalling? Using the Via receptor as a model, chimeric
receptors comprising substitutions from the V2 receptor will be used in
an attempt to elucidate whether any particular receptor regions are






The epithelial CHO-K1 cell-line was purchased from the European Collection of
Animal Cell Cultures (ECACC, Porton Down, UK). The small cell lung cancer cell-
line, NCI-E1345 SCLC, was purchased from the American Type Culture Collection
(ATCC, Rockville, USA). All tissue culture flasks and plates were from Costar
unless otherwise stated.
Table 2.1. List of materials used and sources
Product Description Source
Dulbecco's modified eagles medium
(DMEM)
Cell culture reagent Sigma, Poole
Foetal Calf Serum (FCS) Cell culture reagent
Phosphate Buffered Saline (PBS) Cell culture reagent Sigma, Poole
Hanks Balanced Salt Solution (HBSS)
with calcium
Cell culture reagent Sigma, Poole (H-8264)
Hanks Balanced Salt Solution (HBSS)
without calcium
Cell culture reagent Sigma, Poole (H-6648)
GIBCO" Non-essential amino acids
(NEAA)
Cell culture reagent Invitrogen, Paisley
GIBCO® L-glutamine Cell culture reagent Invitrogen, Paisley
GIBCO® Penicillin Antibiotic Invitrogen, Paisley
GIBCO" Streptomycin Antibiotic Invitrogen, Paisley
GIBCO" G418-sulphate Antibiotic Invitrogen, Paisley
GIBCO® Trypsin-EDTA Cell culture reagent Invitrogen, Paisley
Soybean Trypsin Inhibitor Trypsin Inhibitor Sigma, Poole
LipofectAMINE PLUS Transfection reagent Invitrogen, Paisley
Bombesin (Bn) Neuropeptide Sigma, Poole (B-4272)
Arginine8-vasopressin (AVP) Neuropeptide Sigma, Poole (V-9879)
Substance P Neuropeptide Sigma, Poole (S-6883)











Substance P analogue Cancer Research UK,
London
Spantide [D-Argl, D-Trp7,9, Leull]-
Substance P
Substance P analogue BACHEM,
Switzerland
Monoclonal antibody against
diphosphorylated ERK 1 and 2
Antibody Sigma, Poole (M-8579)




















Wortmannin P13K inhibitor Sigma, Poole

















Pertussis Toxin Endotoxin inhibiting



















[3H]-arginine vasopressin (73Ci/mmol) Tritiated radioligand New England
Nuclear, PerkinElmer,
USA
Agarose, Low melting point Sigma, Poole
Seakem® GTG® Agarose BioWhittaker
Molecular
Applications, USA
Fibronectin (human plasma) Plasma glycoprotein Sigma, Poole (F-0895)
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2.2. Cell Culture
CHO-Kl cells were maintained in DMEM supplemented with 10% (v/v) foetal calf
serum (FCS, heat-inactivated at 57°C for 1 h), 1% (v/v) non-essential amino acids, 50
U ml"1 penicillin, 50 pg ml-1 streptomycin and 5 pg ml-1 L-glutamine in a humidified
atmosphere of 5% CC>2:95% air at 37°C. CHO-Kl cells stably transfected with GRPr
or VIAr were maintained in the same DMEM growth media with the addition of
400 pg ml1 G418-sulphate (Promega, WI, USA). For routine passage, cells were
detached from the culture flask with trypsin-EDTA, quenched with serum
containing media and pelleted at 300g for 4 minutes. Cells were divided into ten
new flasks in fresh media. Cells were quiesced in DMEM supplemented with 0.1%
(v/v) foetal bovine serum (heat-inactivated at 57°C for 1 hour), 1% (v/v) non¬
essential amino acids, 50 U ml"1 penicillin, 50 pg ml"1 streptomycin and 5 pg ml"1 L-
glutamine when necessary. For experimental purposes, cell-lines were continually
cultured only up to ten passages before being replaced with cells of earlier passage
number from liquid nitrogen stocks.
Stock NCI-H345 SCLC cells were cultured in RPMI-1640 medium with 25mM
HEPES supplemented with 10% (v/v) FCS, 50U ml"1 penicillin, 50pg ml1
streptomycin and 5pg ml"1 L-glutamine. Cell cultures were allowed to grow to a
density of 106 cells ml"1 in a humidified atmosphere of 5% carbon dioxide/95% air at
37°C. For experimental purposes, the cells were grown in SITA medium consisting
of RPMI-1640 medium containing SIT supplement (30nM selenium, 5pg ml"1 insulin,
lOpg ml-1 transferrin from Sigma) and 0.25% (w/v) bovine serum albumin (BSA).
2.3. Plasmid DNA preparation
2.3.1 Transformation
A frozen aliquot of transformation competent Escherichia coli DH5a (Invitrogen,
Paisley) was thawed on ice. Plasmid cDNA (pcDNA) [l-10ng] was added to cells
and incubated on ice for 30 minutes. Cells were then heat-shocked at 42°C for 60
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seconds and put back on ice for two minutes. Transformed cells were then grown in
SOC media (Invitrogen, Paisley) at 37°C with agitation (500rpm) for 60 minutes.
The culture was then spread onto agar plates containing lOpg ml 1 ampicillin and
incubated overnight at 37°C. Individual colonies were picked into LB broth
containing ampicillin and grown overnight at 37°C with agitation.
2.3.2 DNA purification
Plasmid cDNA was prepared from bacterial cultures using the Endofree® Plasmid
Maxi Prep kit (Qiagen, Crawley, UK) according to the manufacturers' instructions.
Purified pcDNA was quantified using a Pharmacia Biotech Ultraspec2000 UV
spectrophotometer.
Diagnostic restriction digests of purified pcDNA were carried out using appropriate
restriction enzymes (Promega). Restriction products were visualised by UV
exposure after being resolved on 1-2% agarose gels containing 0.3)u.g ml1 ethidium
bromide.
2.4. Transfection
CHO-Kl cells were transfected using LipofectAMINE-PLUS reagents from
Invitrogen (MD, USA). 10cm tissue culture dishes or 6 well plates were seeded with
2xl06 or 0.5xl06 cells respectively and incubated until 60-70% confluent (overnight).
Cells were transfected by pre-complexing pcDNA (Table 2.2) with PLUS™ reagent
in serum-free DMEM. The pre-complexed pcDNA was combined with
LipofectAMINE™ reagent (diluted in serum-free DMEM) and incubated for 15
minutes at room temperature. Meanwhile, the cell monolayers were washed and
media replaced with serum-free DMEM before gently adding the LipofectAMINE-
pcDNA-PLUS complexes and incubating for 5 hours at 37°C. At the end of this
period, serum-levels were increased by the addition of complete medium (10%
FCS).
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For transient expression, cells were washed the following morning and incubated
with fresh complete media. 24 hours post-transfection, cells were washed again and
incubated overnight with quiescence media. Quiescent, transiently-transfected cells
were then used in experiments the following day (48 hours post-transfection).
For stable clones, the day after transfection the cells were split 1:2 and incubated
overnight in fresh complete medium. 24 hours later, 800pg ml"1 G418 was added
and the media changed every three days until isolated colonies were visible. Cells
were trypsinised and diluted in complete medium containing 800pg ml"1 G418 to a
density of 5 cells ml"1 and 200pl was added to each well of a 96 well plate (2 plates
per transfection). Cell growth was monitored for two weeks until single colonies
were visible in the wells. Individual wells were trypsinised and 12 clones from
each transfection were expanded. The clones were screened for the presence of
transfected receptors by testing their ability to mobilise intracellular calcium in
response to receptor ligands. Positive clones were further expanded and stocks
frozen. Stable cell cultures were maintained in the presence of 400 pg ml"1 G418.
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Table 2.2. Plasmid cDNA transfected into CHO-K1 cells






GRP receptor Full-length human
GRP receptor






VlA receptor Full-length human
Via receptor




























Cccj-3 G protein alpha j.3
subunit
6pg per 10cm dish







Gaq G protein alpha q
subunit
6pg per 10cm dish












6pg per 10cm dish









2.5.1 Whole cell binding assay
Receptor binding was carried out on confluent and quiescent cultures of vector or
neuropeptide receptor transfected CHO-K1 cells grown in 24 well plates. Cell
monolayers were washed twice with DMEM containing lmg ml-1 BSA and 225pl of a
binding medium containing DMEM, lmg mb1 BSA and radioligand (1.0 nM GRP
containing 2nCi [12T]-GRP for GRPR transfected cells or 0.6 nM AVP containing
45nCi [12SI]-AVP for ViaR transfected cells). 25pl control diluent or increasing
concentrations of inhibitors (neuropeptide, Sp-D or Sp-G) were added and plates
incubated for 30 minutes at 37°C. Non-specific binding was defined in the presence
of 1 pM bombesin or AVP respectively. The reaction was stopped by transferring
plates to ice and unbound ligand was removed by washing three times (twice for
[125I]-AVP) with ice-cold phosphate buffered saline. Plates were left to dry before
adding 250pl solubilisation buffer (0.1 M NaOH, 2% Na2C03, 1% SDS). Samples
were transferred to scintillation vials, scintillation fluid added and left to stand for 1
hour or overnight. Bound ligand was estimated by liquid scintillation counting
using a PACKARD scintillation counter. Specific binding in the transfected cells
was 60-90% of the total binding. Nonlinear regression analysis of the binding data
was used to determine the IC50 (concentration of drug displacing 50% specific
binding). The binding parameters Kd (dissociation constant) and Bmax (number of
binding sites) were then calculated from competition binding isotherms with
unlabelled ligand according to the following equations derived by DeBlasi et al.
(1989):
Kd = IC50- [ligand]
Bmax= Specific Binding X IC50 / [ligand]
Cells grown in a separate 24 well plate were trypsinised and counted using a coulter
counter to enable maximum binding (Bmax) t° be adjusted for cell numbers.
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The inhibitory constant (Ki), of unlabelled analogues was calculated based on the
assumption that the labelled and unlabelled ligands have equal affinities for the
receptor. The Kq is therefore equal to the inhibitory constant Ki, enabling Ki to be
derived from the IC50 and Kq according to the Cheng-Prusoff equation (Cheng &
Prusoff, 1973):
Ki = IC50 / (1 + ([ligand] / Kd))
2.5.2 Membrane binding assay
2.5.2.1. Membrane preparation
Membranes were prepared from confluent cell cultures grown in 500cm2 tissue
culture plates. Cell monolayers were washed twice with PBS (without calcium)
containing 5mM EDTA and cells removed by scraping in 25mls PBS/EDTA solution
using a plastic cell lifter. The cell suspension was transferred to a 50ml falcon tube
on ice and plates washed twice with 12.5ml PBS/EDTA to harvest remaining cells.
Cells were pelleted by centrifugation at lOOOg for 10 minutes (0°C) followed by a
further wash in 20mls PBS/EDTA solution. Pelleted cells were resuspended in 4ml
Hypotonic lysis buffer (lOmM Tris (pH 7.4), 5mM EDTA, 5mM EGTA and protease
inhibitors) and left to swell for 15 minutes on ice. Cells were homogenised on ice
by 3x5sec bursts of a Polytron homogeniser followed by centrifugation at 1700rpm
for 10 minutes (4°C) to pellet cell debris and unhomogenised cells. The supernatant
(SN1, containing membranes) was retained and the pellet resuspended in 4ml
hypotonic lysis buffer was subject to further 3x5sec bursts of homogenisation. Cell
debris was pelleted again and the resulting supernatant (SN2) combined with SN1.
Membranes were collected from the supernatants by centrifugation at 49000g for 20
minutes at 4°C (Beckman JA20 rotor). The membrane pellet was resuspended in 2ml
of 50mM Tris-HCl (pH 7.4) by homogenisation, adjusted to lmg mb1 following
protein assay and aliquots stored at -70°C.
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2.5.2.2. BindingAssay
Receptor binding assays were carried out using a 96 well glass fibre filter plate
(MultiScreen-FB plates from Millipore) coupled to a vacuum manifold. Filters were
pre-wet by adding lOOpl wash buffer (50mM Tris (pH 7.4), 3mM MgCl2) to each
well and applying vacuum to draw buffer through. Homogenised membranes
(lOOpg) were added to wells containing assay buffer (50mM Tris (pH 7.4), 0.5% BSA,
3mM MgCl2)/ InM [3H]-vasopressin and increasing concentrations of unlabelled
vasopressin in a total volume of 200pl. Non-specific binding was determined by
the addition of excess unlabelled vasopressin. Plates were incubated at 37°C for 30
minutes and then transferred to the vacuum manifold to filter through binding
media. Wells were washed six times with 200pl cold wash buffer. Filters were
removed from wells using forceps, transferred to scintillation vials and scintillation
fluid added. Vials were vortexed and bound ligand estimated by liquid
scintillation counting in a PACKARD scintillation counter. Nonlinear regression
analysis of the binding data was used to determine the binding parameters as
previously described (section 2.4.1).
2+
2.6. Intracellular [Ca L flux assay
CHO-Kl cells expressing the GRP or ViaR receptor were grown to confluence on
10cm plates and quiesced overnight. Cells were washed with PBS and detached
from plates using trypsin, which was then neutralised by the addition of 1 mg ml"1
soybean trypsin inhibitor (STI). The cell suspension was washed and 5xl05 cells
loaded with 2pM of the calcium indicator Fura-2-tetraacetoxymethylester AME
(from ImM FURA-2/AM stock in DMSO) in calcium-free Hank's balanced salt
solution (HBSS) in the dark for 30 minutes at 37°C. The cells were pelleted by
centrifugation at 300g for four minutes and resuspended in 2ml of HBSS containing
1.26mM CaCl2- After a short recovery period on ice, the FURA-2 loaded cells were
transferred to a plastic fluorimeter cuvette (Sigma, C-0793) containing a Teflon-
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coated magnetic bar for continuous stirring and placed in the thermostat-regulated
sample chamber of a fluorescence spectrophotometer (PerkinElmer LS50B).
Fluorescence was monitored in real-time at 37°C following alternate dual
wavelength excitation at 340nm and 380nm and FURA-2 fluorescence emission
measurement at 510 nm (measured in arbitrary fluorescence units). Test agents
were added at 100x[final] followed by the addition of 1% FCS (v/v) as a positive
control response. Before terminating each measurement, cells were lysed with 1%
(v/v) Triton X-100 in order to saturate all of the calcium indicator (FURA-2 in
completely bound state giving maximum fluorescence intensity measurement) and
then 20mM EGTA added to chelate all calcium (FURA-2 in unbound form giving
minimum fluorescence intensity measurement).
The intracellular [Ca2+]i was calculated by ratiometric analysis of bound and
unbound FURA-2 using 'FFWinFab' software which relates the calcium
concentration to the measured fluorescence intensity according to the equation
[Ca2+]i = P x K (R-Rmin)/(Rmax-R): where R is the ratio of the induced sample, Rmax is
the ratio after the addition of 1% triton X-100 and Rmin is the ratio after [Ca2+]i
chelation with 10 mM EGTA and P is the ratio of the denominator (380nm)
fluorescence intensities. K is the dissociation constant of Fura-2 for [Ca2+]j, which
was 224 nM as determined previously by Grynkiewicz et al. (1985). Data points
from the intracellular calcium measurements represent the total peak area of the
[Ca2+]j transients elicited.
Antagonist potency (the concentration of antagonist which produces a 2-fold shift in
the agonist response curve) was determined from a Schild plot of the (DR-l)log for a
series of antagonist concentrations against the [antagonist]log, where the dose ratio
(DR)
= ICso in the presence of antagonist
ECso of control response
The antagonist potency was obtained from the x-intercept of the line.
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2.7. ERK activation
2.7.1. ERK stimulation and preparation of cell lysates
Quiescent cell cultures in 6 well plates were washed twice with warm HBSS and
pre-incubated in a 37°C waterbath with HBSS. Test agents were added (as described
in figure legends) at 100x[final] into a final volume of lml. At the end of the
incubation period, the 6 well-plate was placed on ice and the media aspirated. 0.25
ml ice-cold lysis buffer (20mM Tris (pH 7.5), 150mM NaCl, ImM EDTA, ImM
EGTA, 2.5mM sodium pyrophosphate, 1% triton X-100, ImM p-glycerphosphate,
0.5mM dithiothreitol, ImM sodium orthovanadate, protease inhibitors (Roche,
Germany; from 25X stock solution prepared according to manufacturers
instructions) and ImM PMSF was added to each well and cells removed from the
plate by scraping with a plastic cell scraper. Cell suspensions were transferred to
chilled eppendorfs and then vortexed for 15 minutes at 4°C to lyse cells. Lysates
were clarified by centrifugation at 13000rpm for 10 minutes and the protein
concentration of retained supernatants determined using Pierce BCA protein assay
reagent (Pierce).
Pertussis toxin was activated by adding an equal volume of activation buffer (1%
CHAPS, lOmM DTT, ImM ATP) for 15 minutes at 37°C (Kaslow & Burns, 1992).
Cells were pre-treated with Pertussis toxin by overnight incubation with lOOng ml 1
toxin in quiescence media. All other inhibitors (e.g. FTS, PP2) were added shortly
before ERK stimulation for pre-incubation periods as indicated.
2.7.2. Determination of protein concentration in cell lysates
A series of BSA protein standards [0.1-0.5 mg ml1] was prepared in lysis buffer to
generate a standard curve from which the protein concentrations of test samples
could be derived. Test samples were diluted 1:5 then 200pl of BCA reagent
(prepared from 1:50 dilution of reagent B with reagent A) was added to 10pl of
standard or test sample in a 96 well plate and incubated at 37°C for 30 minutes.
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Absorbance was read at 560nm using a 96 well-plate reader (MRXII, Dynex
Technologies). Samples for SDS-PAGE analysis were equilibrated for protein and
denatured by heating (5 minutes at 95°C) in 4X SDS-PAGE loading buffer (50mM
Tris, 10% glycerol, 2% SDS, 0.1% bromophenol blue and 10% P-mercaptoethanol
(pH 7.4)).
2.7.3. SDS-PAGE and Western Blotting
Molecular weight markers (Benchmark™ pre-stained protein ladder, Invitrogen)
and 15pg lysate/lane were resolved on a 12% SDS-PAGE gel as described by
Laemmli (1970). Gels comprised of a stacking gel (0.125M Tris-HCl (pH6.8), 0.1%
SDS and 12% acrylamide/bisacrylamide polymerised with ammonium persulphate
(APS) solution (50ju.l of a 25% solution per 10ml gel) and TEMED (10pl per 10ml gel))
and a separating gel (0.375M Tris-HCl (pH 8.8), 0.1% SDS solution and 4.5%
acrylamide/bisacrylamide, 25% APS (50pl per 10ml gel) and TEMED (lOpl per 10ml
gel)). Gels were run at 170V for 80 minutes then transferred to nitrocellulose
membrane at 110V for 60 minutes in transfer buffer (210mM Glycine, 24.7mM Tris
base and 20% methanol). Nitrocellulose membranes were stained with Ponceau S
solution (Sigma) to confirm transfer then blocked for 1 hour at room temperature
with 3% BSA in TBS containing 0.05% Tween-20 (TBST). Bands were detected by
incubation of blots with primary antibody (Table 2.3) diluted in 3% BSA-TBST for 1
hour at room temperature (or overnight at 4°C). Blots were washed three times with
TBST then incubated with a HRP-labelled secondary antibody (Table 2.3) for 1 hour
at room temperature (or overnight at 4°C). After washing blots with TBST again,
bands were visualized and quantified using enhanced chemifluorescence (ECL
Plus™, Amersham Biosciences) and a phosphor imager (Storm™, Molecular
Dynamics™, Amersham Biosciences) equipped with ImageQuant software.
75
Absorbance was read at 560nm using a 96 well-plate reader (MRXII, Dynex
Technologies). Samples for SDS-PAGE analysis were equilibrated for protein and
denatured by heating (5 min at 95°C) in 4X SDS-PAGE loading buffer (50mM Tris,
10% glycerol, 2% SDS, 0.1% bromophenol blue and 10% P-mercaptoethanol (pH
7.4)).
2.7.3. SDS-PAGE and Western Blotting
Molecular weight markers (Benchmark™ pre-stained protein ladder,. Invitrogen)
and 15pg lysate/lane were resolved on a 12% SDS-PAGE gel as described by
Laemmli (1970). Gels comprised of a stacking gel (0.125M Tris-HCl (pH6.8), 0.1%
SDS and 12% acrylamide/bisacrylamide polymerised with ammonium persulphate
(APS) solution (50jul of a 25% solution per 10ml gel) and TEMED (lOpl per 10ml gel))
and a separating gel (0.375M Tris-HCl (pH 8.8), 0.1% SDS solution and 4.5%
acrylamide/bisacrylamide, 25% APS (50pl per 10ml gel) and TEMED (lOpl per 10ml
gel)). Gels were run at 170V for 80 minutes then transferred to nitrocellulose
membrane at 110V for 60 minutes in transfer buffer (210mM Glycine, 24.7mM Tris
base and 20% methanol). Nitrocellulose membranes were stained with Ponceau S
solution (Sigma) to confirm transfer then blocked for 1 hour at room temperature
with 3% BSA in TBS containing 0.05% Tween-20 (TBST). Bands were detected by
incubation of blots with primary antibody (Table 2.3) diluted in 3% BSA-TBST for 1
hour at room temperature (or overnight at 4°C). Blots were washed three times with
TBST then incubated with a HRP-labelled secondary antibody (Table 2.3) for 1 hour
at room temperature (or overnight at 4°C). After washing blots with TBST again,
bands were visualized and quantified using enhanced chemiluminescence (ECL
Plus™, Amersham Biosciences) and a phosphor imager (Storm™, Molecular
Dynamics™, Amersham Biosciences) equipped with ImageQuant software.
75
Table 2.3. Antibodies used for western blotting










ERK 1/2 Rabbit polyclonal antibody
against ERK 1 (Santa Cruz)
Rabbit polyclonal antibody
against ERK 2 (Santa Cruz)


















Exponentially growing cells were trypsinised and 10cm plates seeded with 5x10^
cells in DMEM containing 5% or 1% FCS in the presence or absence of mediators in
triplicate. Cells were grown for 1-9 days and cell number determined at various
time-points using a Coulter Counter (model Zl, Coulter Electronics).
2.8.2. Clonogenic assay
Molten 5% agarose (2.5% (w/v) Seakem® GTG® agarose and 2.5% (w/v) Low melting
point agarose) was diluted ten-fold with DMEM containing 1% or 5% FCS to
provide a solid base of 0.5% agarose in Ultra Low Attachment 6 well tissue culture
plates (Corning® Life Sciences, USA). Viable vector or neuropeptide receptor
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transfected CHO-K1 cells suspended in DMEM containing 1% or 5% FCS in the
presence or absence of mediators were used to dilute 3% agarose (1.5% (w/v)
Seakem® GTG® agarose and 1.5% (w/v) low melting point agarose) with a final cell
density of lxlO4 cells ml1. 2ml of the 0.3% agarose containing cells was layered over
the 0.5% solid base and allowed to set. Plates were wrapped in foil to prevent
drying out and incubated at 37°C for 1-10 days. Viable colonies were stained by
incubating plates with 4mg mb1 MTT (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl
tetrazolium bromide) for four hours. Colonies from 10 randomly-selected fields
were counted using a microscope with a X4 objective. Cloning efficiency was
calculated as the % of original number of seeded cells forming colonies of > 6 cells.
2.8.3. Suspension growth
Wild-type and transfected CHO-K1 cells suspended in DMEM containing 1% or 5%
FCS in the presence or absence of mediators were seeded at a density of 2x104 cells
per well into Ultra low attachment tissue culture plates over a solid base of 0.5%
agar. Under these conditions the cells did not adhere. Cells were maintained in
culture for up to 9 days and viable cell number determined at various time-points as
follows. Cell suspensions were washed twice with PBS and briefly trypsinised to
disaggregate cell clusters. Cells were washed and resuspended in 500pl PBS and
kept on ice. Cells were counted by FACS after the addition of lOpM TO-PR03
(Molecular Probes, USA) to distinguish live cells from dead cells.
2.8.4. Chemosensitivity assay
Exponentially growing cells were trypsinised and 96 well-plates seeded with lxl 0^
cells in DMEM containing 10% FCS. After incubation overnight at 37°C, cells were
washed and incubated with serum-free media containing increasing concentrations
of etoposide with or without 50nM neuropeptide for 48 hours. Cell viability was
then determined by incubation with 4mg mb1 MTT at 37°C. After four hours, all
media was aspirated and the blue formazan crystals solubilised with 200pl DMSO.
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Absorbance was read at 560nm using a 96 well-plate reader (MRXII, Dynex
Technologies). Results are expressed as % viability in the absence of neuropeptide.
2.8.5. SCLC growth studies
H345 SCLC cells were cultured in SITA medium for 2-3 days then disaggregated
into a single cell suspension by two passes through a 19 gauge needle followed by
one pass through a 23 gauge needle. Cells were re-suspended in SITA medium at a
density of 1x10s cells ml1. Cells were cultured in 24 well plates in the presence of
increasing concentrations of test agents in duplicate and total cell number
determined after 0, 3, 5, 7, 10, 12 and 14 days. At each time-point, cell clusters were
disaggregated as before and the total cell number determined using a Coulter
counter.
2.9. Adhesion assay
Wells of a 96 well plate were coated with lOpg ml 1 human plasma fibronectin in
PBS for 1 hour at room temperature (or overnight at 4°C). After coating, the
fibronectin solution was aspirated and wells washed twice with PBS. Plates were
blocked with lmg ml1 BSA for 1 hour at room temperature followed by washing
twice with PBS. Vector and neuropeptide receptor-transfected CHO-K1 cells
(quiesced in DMEM containing 0.1% BSA) were detached from sub-confluent flasks
using trypsin and lmg ml1 soybean trypsin inhibitor (STI) added to the cell
suspension. Cells were washed twice then resuspended at a density of 2xl05 cells
mb1 in DMEM containing 0.1% (w/v) BSA and the appropriate test agent. In the cold
room, media only (negative control), 2x104 cells in DMEM-BSA (positive control) or
2xl04 cells per treatment were added to wells. Plates were incubated at 37°C for 20
minutes. Each plate was vortexed (3x10s at 800rpm) using a thermomixer and
media aspirated from all wells except positive control wells. Wells were washed
with PBS, vortexed and washed again before adding 100% methanol to fix cells (2
minutes at room temperature). Cells in the positive control wells were allowed to
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adhere fully by incubating the plate for a further hour. The media was then
removed, cells washed with PBS and fixed with methanol. Cells were stained at
room temperature by adding Diff-Quik® Solution I for 2 minutes. The stain was
removed using a multichannel pipette and the plate inverted on a pad of absorbent
paper to remove any remaining solution. Diff-Quik® Solution II was then added for
2 minutes and removed as before. Wells were washed by repeatedly flooding the
plate in a container of tap water. Plates were allowed to dry before the stain was
eluted with 0.5M HC1 and absorbance read at 630nm using a 96 well plate reader
(MRXII, Dynex Technologies). % Adhesion was calculated relative to the positive
control where all cells adhered. Experiments were performed in quadruplicate and
repeated five times.
2.10. Migration assay
Transwell migration was evaluated using 96 well MultiScreen™-MIC plates
(Millipore, USA) composed of a 96 well filter plate (8pm pore size) and a 96 tear¬
drop well plastic receiver plate housed in a single well tray with lid. Filters were
coated overnight (4°C) by placing the filter plate in the plastic receiver plate
containing lOpg ml 1 fibronectin. The filter plate was washed twice with PBS and
allowed to dry. Meanwhile, vector and neuropeptide receptor-transfected CHO-K1
cells (quiesced in DMEM containing 0.1% BSA) were detached from sub-confluent
flasks using trypsin and lmg mb1 STI added to the cell suspension. Cells were
washed twice then resuspended at a density of lxlO6 cells ml-1 in DMEM containing
0.1% (w/v) BSA. DMEM containing 10% FCS (positive control response) or
chemotactic agents (neuropeptides or Substance P analogues) diluted in DMEM-
BSA were added to the receiver plate (150pl) and the filter plate carefully placed on
top. The cell suspension (7.5xl04 cells) was pipetted slowly into the centre of the
filter plate wells and the plate incubated for 4 hours at 37°C in a humidified
atmosphere. In IGF-stimulated migration experiments, cells were resuspended in
DMEM-BSA containing neuropeptide or analogue and lOOng ml"1 IGF-1
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(Calbiochem) was added to the receiver plate. At the end of the assay, the filter
plate was removed from the receiver plate and media aspirated from negative
control (no cell input) and positive control (total cell input) wells. Non-migrated
cells from all other wells were removed by wiping inside the wells with a cotton
bud. Cells remaining on the underside of the filter were then fixed and stained as
for the adhesion assay to quantify the number of cells that had migrated. Stain was
eluted by placing the filter plate in a receiver plate containing 150|al 0.5M HC1 per
well. Eluted stain (lOOpl) was transferred to a 96 well plate and absorbance read
colorimetrically at 630nm. The control used to determine unstimulated random
migration was DMEM containing 0.1% BSA in lower wells. Experiments were
performed in quadruplicate and repeated three times or more.
Data is expressed as a Migration Index:
OD of cells that migrated in response to agonist
OD of cells that migrated randomly (DMEM-BSA only)
2.11. Phospholipase C activation
Cells were grown in 6 well-plates until near-confluent and then labelled with myo-
l,2-[3H]-inositol at a concentration of 1 pCi ml1 overnight in serum- and inositol-free
medium. Labelled cells were washed twice with PBS and incubated in HBSS
containing 20 mM HEPES, 1.8% glucose, 0.2% BSA and 20 mM LiCl, for 30 minutes
at 37°C. Cells were then treated with agonists for 30 minutes at 37°C. Reactions
were terminated by removal of assay buffer and addition of ice cold 10 mM formic
acid for 60 minutes on ice. Samples were applied to Dowex columns (200-400 mesh,
formate form, 0.5g per column) and washed through with 10ml 60mM ammonium
formate: 5mM sodium tetraborate. Inositol phosphates were eluted with 5ml 1.2M
ammonium formate: 0.1M formic acid. Radioactively labelled IP fractions were
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measured by liquid scintillation counting. Columns were regenerated with 2M
ammonium formate and washed with distilled H2O.
2.12. Statistical analysis
Combined data was analysed by one way ANOVA (with Dunnetts post t-test to
compare all columns vs. control column where overall P<0.05) using Prism®
(GraphPad Software Inc, USA).
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Chapter 3
Effects of Substance-P Analogues on Neuropeptide
Signalling
Since SCLC growth can be driven by multiple neuropeptides, there is a need for
broad spectrum neuropeptide antagonists to treat this and other neuropeptide-
dependent cancers. Substance-P analogues have been previously characterised as
such due to their ability to block binding of neuropeptides and calcium mobilisation
induced by multiple neuropeptides (Woll & Rozengurt, 1990; Bunn et al, 1994; Sethi
et al, 1992). Rather than just being simple antagonists which inhibit SCLC growth,
substance-P analogues were also found to activate JNK and thus proposed to be
biased agonists (Jarpe et al, 1998). This concept was first verified using a GRP-
receptor expressing model cell system (Mackinnon et al, 2001). Binding of SP-D to
the GRP receptor was shown to induce receptor coupling to selective G-proteins
compared to the natural ligand GRP. However it is not known whether the biased
agonist properties of the analogues can be similarly regarded as broad spectrum or
specific only to its effects on the GRP receptor. The work presented in this chapter
was thus initiated to determine whether Substance-P analogues exhibit biased
agonist activity at receptors other than GRP receptors.
While 60% of SCLC cells express the GRP receptor, receptor expression has
been detected in all SCLC cell-lines tested to date (Ocejo-Garcia et al, 2001; Waters et
al, 2003). It was therefore decided to investigate the effects of the substance-P
analogues on the Vja receptor and the GRP receptor. Model cell systems consisting
of Chinese Hamster Ovary (CHO-K1) cells (a non-cancerous, non-neuroendocrine
epithelial cell-line) stably expressing GRP or receptors were established for this
purpose. In order to better understand the substance-P analogues' mechanism of
action, the effects of SP-D and SP-G were then studied at distinct steps of the V^R
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and GRPR signalling process: neuropeptide growth factor binding, calcium
mobilisation and ERK1/2 activation.
3.1 Production of model cell systems
3.1.1 Stable transfection of CHO-K1 cells with GRPR or ViaR
CHO-Kl cells were transfected with cDNA encoding the Via receptor as described
in materials and methods. These cells were cultured in the presence of 800pg ml1
G418 for one week, after which time the cells were trypsinised and transferred into 2
96 well plates at a density of one cell per well. After a further two week period of
growth in the presence of 800pg ml"1 G418, the resulting clones were trypsinised and
transferred to individual wells of a 6 well plate. Once confluent, each sub-clone was
then split equally between a 75cm2 tissue culture flask and a 100mm tissue culture
dish. The ability of neuropeptide agonist to stimulate intracellular calcium
mobilisation was then measured using the Ca2+-sensitive dye Fura-2AM, as
described in materials and methods, in order to confirm the presence of functional
receptors. Confluent, quiescent cultures grown in 100mm tissue culture dishes were
screened for the ability of InM, lOnM and lOOnM vasopressin to induce
mobilisation of intracellular calcium. Out of 24 clones screened in this manner, six
clones were found to respond with varying levels of calcium release. The six cell-
lines were expanded and stocks frozen in liquid nitrogen. Clones V3B and V4I were
selected for further characterisation and use in experiments.
The same procedure was followed in order to create a cell-line expressing the GRP
receptor. 24 clones were screened for the ability of InM, lOnM and lOOnM
bombesin to induce a calcium response. Of these clones, seven responded to
stimulation and these cell-lines were expanded and stocks frozen in liquid nitrogen.
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Of the seven positive clones, clones G6H and G6A were selected for further
characterisation and use in experiments.
At the same time, CHO-K1 cells were transfected with empty vector and a G418-
resistant clone isolated for use in control experiments (CHO-vector cell-line).
3.1.2 Characterisation of ceii-iines expressing GRPR or ViaR
3.1.2.1 Intracellular calciummobilisation
The mobilisation of calcium from intracellular stores leading to a rapid and transient
increase in [Ca2+]i is one of the earliest events stimulated by neuropeptide binding to
GPCRs that signal through Gaq-mediated activation of phospholipase C (Exton,
1996; Rozengurt, 1998a). Intracellular calcium mobilisation was measured using
Fura-2-AM to demonstrate that functional receptors expressed in the selected stable
cell-lines could be activated by neuropeptide ligand.
In an initial series of experiments it was found that vector-transfected CHO-K1 cells
responded to lOnM bombesin with a small change in intracellular calcium levels
(Figure 3.1a). However, in comparison to the calcium response obtained in CHO-
G6H cells, the CHO-vector response to lOnM bombesin was relatively insignificant.
CHO-G6A cells did not respond to lOnM vasopressin and the response to lOnM
bombesin was greater than the response generated in the parental CHO-K1 cell-line.
There was no response in CHO-vector cells to lOnM vasopressin (Figure 3.1b). The
calcium response to lOnM vasopressin was much greater in CHO-V3B cells than
CHO-V4I cells. CHO-V3B cells did not respond to lOnM bombesin, but there was a
response generated in CHO-V4I cells which was similar in magnitude to its
response to lOnM vasopressin. Therefore, the CHO-V4I cell-line was not used in
any further experiments.
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In order to fully characterise the calcium mobilising properties of bombesin and
vasopressin, the effect of increasing concentrations of neuropeptide on [Ca2+]i was
measured in CHO-G6H, CHO-G6A and CHO-V3B cell-lines. Bombesin transiently
increased the level of intracellular calcium in CHO-G6H (Figure 3.2) and CHO-G6A
(Figure 3.3) cells in a concentration dependent manner. The concentration of
bombesin required to induce half-maximal effects (EC50) in the CHO-G6H and
CHO-G6A clones was 2.0 ± 0.45 nM and 8.6 ± 3.7 nM respectively (n=5).
Vasopressin similarly increased the intracellular calcium in a concentration-
dependent manner in CHO-V3B cells (Figure 3.4), with an EC50 of 3.1 ± 0.6 nM
(n=5).
To confirm that the increase in [Ca2+]i in CHO-G6H, CHO-G6A and CHO-V3B cells
in response to neuropeptides was mediated by specific Gq-coupled receptors, ligand
specific antagonists to bombesin and vasopressin were used. The addition of the
potent and specific bombesin peptide antagonist RC3940-II
(Hca6,Leu13v|/[CH2N]Tacl4-Bombesin(6-ll)) prior to adding agonist inhibited the
bombesin-induced increase in [Ca2+]i causing a rightward parallel shift in both
CHO-G6H (Figure 3.5) and CHO-G6A (Figure 3.6) dose response curves. The
addition of the selective vasopressin antagonist [P-mercapto-p-P-
cyclopentamethylene-propionyl1,0-Me-Tyr2,Arg8]-vasopressin, which binds to the
VlA receptor, similarly inhibited the increase in [Ca2+]j induced by vasopressin in
CHO-V3B cells (Figure 3.7). Stimulation of intracellular calcium release by FCS was
used as a positive control to ensure that a lack of response to neuropeptide was not
due to any abnormality in the mechanism of calcium mobilisation. The EC50 values
derived from the curves were used to determine the antagonist potency (pA2) of the
analogues for calcium flux inhibition, as described in materials and methods. The
bombesin antagonist potently inhibited bombesin-induced calcium mobilisation
with antagonist potencies (pA2) of 8.5 and 8.1 in CHO-GRP and CHO-G6A cells
respectively. The vasopressin antagonist similarly inhibited vasopressin-induced
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calcium mobilisation with pA2 of 8.4. The shift in dose response curves is consistent
with the activity of competitive antagonists.
The data confirms that the transfected receptors are capable of forming a productive
ligand-receptor interaction in the stable cell-lines and that the receptors are
effectively able to couple to Goiq.
3.1.2.2 Receptorbinding
The functional expression of stably transfected receptors was verified using [125I]-
labelled GRP or [125I]-labelled AVP. Confluent cultures of cells were incubated with
the appropriate radioligand and increasing concentrations of unlabelled
neuropeptide (competitor) added. After 30 minutes incubation at 37°C, cells were
washed and remaining radioactivity counted after solubilisation of the cells. The
resulting competition binding curves show that increasing the concentration of
unlabelled ligand causes a decrease in radioligand binding. The affinity of ligand
for the receptor (fCct) and receptor expression (£>max) were estimated from binding
curves as described in materials and methods.
In CHO-G6H cells, addition of unlabelled bombesin inhibited [125I]-GRP binding in a
concentration dependent manner (Figure 3.8) with an apparent affinity Kd = 2.55 ±
0.84 nM (n=4) and Bmax of 5086 ± 489 sites/cell (n=4). Concentration dependent
inhibition of [125I]-GRP binding by bombesin to CHO-G6A cells (Figure 3.9) occurred
with Kd = 0.82 ± 0.26 nM (n=4) and Bmax of 846 ± 168 sites/cell (n=4). Addition of
unlabelled AVP similarly inhibited [125I]-AVP binding to CHO-V3B cells in a
concentration dependent manner (Figure 3.10). In this cell-line, Via receptors were
expressed at a similar level as in CHO-G6A, with Bmax = 720 ± 90 sites/cell (n=4)
and Kd = 2.98 ± 0.71 nM (n=4). [125I]-GRP or [125I]-AVP binding to vector transfected
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CHO-K1 cells was minimal. Although lOnM bombesin stimulated a calcium
response in vector transfected CHO-K1 cells, the binding of [I25I]-GRP to these cells
was not significant enough to allow quantification of receptor. This indicates that
endogenous GRP receptors are expressed at very low levels in CHO-K1 cells.
Although in terms of receptor expression, CHO-G6A and CHO-V3B expressed
similar levels of receptor, CHO-G6H was selected for use in further experiments.
The selection was made on the basis of functional response to neuropeptide, since
the magnitude of calcium response generated in the CHO-V3B cell-line was more
similar to that produced in CHO-G6H than CHO-G6A cells. Therefore, the CHO-
G6H and CHO-V3B cell-lines were used to evaluate neuropeptide signalling and
Substance-P analogue activity from this point forward. The GRP and Via receptor




































Fig 3.1. Intracellular calcium mobilisation by neuropeptides. Measurement of
intracellular calcium mobilisation in Fura-2AM loaded cells was carried out as described in
materials and methods. A) Representative traces of changes in intracellular calcium levels in
response to lOnM Bombesin in vector and GRPR-transfected CHO-K1 cells. B)
Representative traces of changes in intracellular calcium levels in response to lOnM
vasopressin in vector and ViAR-transfected CHO-K1 cells.
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Figure 3.2. Concentration response curves for calcium mobilisation in CHO-
G6H cells. Quiescent cells loaded with FURA-2AM were stimulated with increasing
concentrations of bombesin and intracellular calcium release measured by ratiometric
fluorimetry as described in materials and methods. Data represents the mean ± s.e.m. of five
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Figure 3.3. Concentration response curves for calcium mobilisation in CHO-
G6A cells. Quiescent cells loaded with FURA-2AM were stimulated with increasing
concentrations of bombesin and intracellular calcium release measured by ratiometric
fluorimetry as described in materials and methods. Data represents the mean ± s.e.m. of five
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Figure 3.4. Concentration response curves for calcium mobilisation in CHO-
V3B cells. Quiescent cells loaded with FURA-2AM were stimulated with increasing
concentrations of vasopressin and intracellular calcium release measured by ratiometric
fluorimetry as described in materials and methods. Data represents the mean ± s.e.m. of five
experiments. ECso = 3.1 ± 0.6 nM
[Bombesin] M
Figure 3.5. Intracellular calcium mobilisation in CHO-G6H cells is inhibited
by GRP receptor antagonist RC-3940II. Quiescent cells loaded with FURA-2AM were
stimulated with increasing concentrations of bombesin alone (■) or in the presence of lOnM
(♦) or lOOnM (•) receptor antagonist. Intracellular calcium release was measured by
ratiometric fluorimetry as described in materials and methods and data represents the mean
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Figure 3.6. Intracellular calcium mobilisation in CHO-G6A cells is inhibited
by GRP receptor antagonist RC-3940II. Quiescent cells loaded with FURA-2AM were
stimulated with increasing concentrations of bombesin alone (■) or in the presence of lOnM
(♦) or lOOnM (•) receptor antagonist. Intracellular calcium release was measured by
ratiometric fluorimetry as described in materials and methods and data represents the mean























Figure 3.7. Intracellular calcium mobilisation in CHO-V3B cells is inhibited
by Via receptor antagonist [p-mercapto-P-P-cyclopentamethylene-
propionyll,0-Me-Tyr2,Arg8]-Vasopressin. Quiescent cells loaded with FURA-2AM
were stimulated with increasing concentrations of vasopressin alone (▲) or in the presence
of lOnM (□) or lOOnM (o) receptor antagonist. Intracellular calcium release was measured by
ratiometric fluorimetry as described in materials and methods and data represents the mean



















Figure 3.8. Dose-dependent inhibition of [125I]-GRP binding to CHO-G6H
cells by bombesin. Confluent, quiescent cultures of CHO-vector and CHO-G6H cells
were incubated with [,25I]-GRP and various concentrations of unlabelled bombesin added
(37°C; 30min). Results are expressed as total radioligand bound (cpm) and represent the
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Figure 3.9. Dose-dependent inhibition of [125I]-GRP binding to CHO-G6A
cells by bombesin. Confluent, quiescent cultures of CHO-vector and CHO-G6A cells
were incubated with [125I]-GRP and various concentrations of unlabelled bombesin added
(37°C; 30min). Results are expressed as total radioligand bound (cpm) and represent the
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Figure 3.10. Dose-dependent inhibition of [125I]-AVP binding to CHO-V3B
cells by vasopressin. Confluent, quiescent cultures of CHO-vector and CHO-V3B cells
were incubated with [125I]-AVP and various concentrations of unlabelled vasopressin added
(37°C; 30min). Results are expressed as total radioligand bound (cpm) and represent the
mean ± s.e.m. of four experiments performed in triplicate.
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3.2 Effect of Substance-P analogues on calcium response
SP-D and SP-G alone did not stimulate a calcium response in CHO-GRP or CHO-
VlA cells. However, the analogues were able to inhibit neuropeptide-induced
calcium release in both cell-lines. When neuropeptide-stimulated calcium
mobilisation was measured in the absence and presence of lpM and 10|uM SP-D or
SP-G there was a rightward parallel shift in concentration response curves in both
CHO-GRP (Figure 3.11) and CHO-Via cells (Figure 3.12). In CHO-GRP cells, SP-D
potently inhibited the bombesin induced calcium mobilisation with antagonist
potency (pA2) of 7.1. As shown in Figure 3.12b, lpM SP-G did not significantly
inhibit bombesin induced calcium mobilisation although 10|xM SP-G did (pA2 5.46).
However, SP-G was a more potent inhibitor of the vasopressin response in CHO-
Via cells (Figure 3.12b). pA2 values for AVP antagonism were 6.22 and 6.72 for SP-
G and SP-D respectively. This shows that the Substance-P analogues are effective
antagonists of the Gq-coupled calcium response.
Spantide is also an analogue of substance-P which only differs from SP-D by the
lack of an amino acid substitution at position 5. This analogue (initially referred to
as antagonist-B) had previously been shown to lack inhibitory effects on the growth
of H345 SCLC cells (Woll & Rozengurt, 1990) so it was anticipated that it would not
have any effects on neuropeptide induced calcium release. For comparison, the
ability of 30pM SP-D, SP-G and Spantide to inhibit the calcium response to a fixed
concentration of neuropeptide was therefore assessed in both cell-lines. At these
concentrations, none of the analogues alone stimulated any change in intracellular
calcium levels. In CHO-GRP cells, 30pM SP-D, SP-G and Spantide were similarly
able to inhibit the calcium response to InM bombesin (Figure 3.13). Likewise, all
three analogues almost completely inhibited the calcium response to InM
vasopressin in CHO-VIA cells (Figure 3.14). Therefore, at 30pM, all three analogues
are similarly able to inhibit the calcium response induced by InM bombesin or
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vasopressin. This shows that Spantide is also an effective antagonist of
neuropeptide-stimulated calcium release despite its apparent inability to block
SCLC cell growth.
3.3 Effect of Substance-P analogues on receptor binding
Competition binding experiments were performed using increasing concentrations
of SP-D or SP-G to compete with radioligand binding to receptors. Increasing
concentrations of analogue caused a decrease in specific binding of radioligand to
each cell-line. The resulting competition binding curves were used to determine the
affinity (Kj) with which the analogue inhibits radioligand binding to each receptor,
as described in materials and methods. The substance-P analogues SP-G and SP-D
inhibited [125I]-GRP binding to CHO-GRP cells (Figure 3.15) with affinities in the
micromolar range (SP-G Kj = 19.4 ± 6.3 pM (n=4), SP-D Ki= 0.64 ± 0.05 pM (n=4)). In
CHO-V^a cells, both analogues also inhibited Via receptor binding (Figure 3.16
(SP-G Ki = 3.50 ± 0.82 pM (n=4), SP-D Kj = 8.58 ± 1.47 pM (n=4)). This data shows
that SP-G is relatively (6 fold) more selective for the Via receptor whereas SP-D is
GRP receptor selective (13 fold).
In another series of experiments, the effect of a fixed concentration of analogue on
radioligand binding was assessed. Cells were incubated with lpM or 5pM analogue
and the appropriate radioligand followed by the addition of increasing
concentrations of unlabelled neuropeptide. lpM and 5pM SP-D caused a significant
reduction and complete inhibition of [125I]-GRP binding to CHO-GRP cells
respectively (Figure 3.17a). In comparison, lpM and 5pM SP-G had little effect on
the ability of unlabelled bombesin to inhibit [125I]-GRP binding to receptors (Figure
3.17b). In CHO-Via cells, lpM SP-D and SP-G both slightly inhibited [125I]-AVP
binding whereas binding was reduced to a greater extent similarly by both 5pM SP-
D and SP-G (Figure 3.18). Co-incubation with SP-D or SP-G did not significantly
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alter the IC50 of unlabelled GRP or AVP competing with radioligand for receptor
binding.
A direct comparison of Maximum Specific Binding in the presence and absence of
analogue in CHO-GRP cells revealed that the reduction in binding in the presence of
both lpM and 5pM SP-D was significant (PO.Ol, ANOVA) whereas in the presence
of SP-G it was not (P>0.05, ANOVA). A similar comparison of CHO-Via data
shows that whilst lpM SP-D and SP-G did not cause a significant change in
Maximum Specific Binding (P>0.05, ANOVA), the reduction in binding by both
5pM SP-D and SP-G was significant (P<0.01, ANOVA). The effective reduction in
maximum binding suggests that the analogues act non-competitively to inhibit
radioligand binding.
A similar experiment was performed on CHO-GRP cells using 5pM and 25pM
Spantide. The presence of 5 pM Spantide caused a significant reduction in [125I]-
GRP binding to the bombesin receptors while 25 pM Spantide completely abolished
specific [125I]-GRP binding (Figure 3.19). This shows that Spantide also inhibits
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Figure 3.11. Inhibition of intracellular calcium mobilisation in CHO-GRP by
substance-P analogues. Quiescent cells loaded with FURA-2AM were stimulated with
increasing concentrations of A) Bombesin alone (■) or in the presence of lpM (•) or 10pM (o)
SP-D. B) Bombesin alone (■) or in the presence of lpM (♦) or lOpM (0) SP-G. Intracellular
calcium release was measured by ratiometric fluorimetry as described in materials and





















• + 1 jiM SP-D















+ 10 |iM SP-G
[Vasopressin] M
Figure 3.12. Inhibition of intracellular calcium mobilisation in CHO-Vj^ by
substance-P analogues. Quiescent cells loaded with FURA-2AM were stimulated with
increasing concentrations of A) Vasopressin alone (A) or in the presence of lpM (•) or lOpM
(o) SP-D. B) Vasopressin alone (A) or in the presence of lpM (♦) or lOpM (0) SP-G.
Intracellular calcium release was measured by ratiometric fluorimetry as described in


































Figure 3.13. Effect of 30pM analogue on calcium response to InM Bombesin in
CHO-GRP cells. Quiescent cells loaded with FURA-2AM were stimulated with InM
bombesin alone (control) or in the presence of 30pM Spantide, SP-D or SP-G. Intracellular
calcium release was measured by ratiometric fluorimetry as described in materials and

































Figure 3.14. Effect of 30pM analogue on calcium response to InM Vasopressin
in CHO-Via cells. Quiescent cells loaded with FURA-2AM were stimulated with InM
vasopressin alone (control) or in the presence of 30pM Spantide, SP-D or SP-G. Intracellular
calcium release was measured by ratiometric fluorimetry as described in materials and




















Figure 3.15. Dose-dependent inhibition of [125I]-GRP binding to CHO-GRP
cells by substance-P analogues. Confluent, quiescent cultures of CHO-GRP cells were
incubated with [125I]-GRP and various concentrations of unlabelled competitor added (37°C;
30min). Results are expressed as % of total radioligand binding and represent the mean ±
s.e.m. of four experiments performed in triplicate.
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Figure 3.16. Dose-dependent inhibition of [125I]-AVP binding to CHO-VqA
cells by substance-P analogues. Confluent, quiescent cultures of CHO-V^ ceUs were
incubated with [125I]-AVP and various concentrations of unlabelled competitor added (37°C;
30min). Results are expressed as % of total radioligand binding and represent the mean ±
s.e.m. of four experiments performed in triplicate.
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Figure 3.17. Effect of substance-P analogues on [125I]-GRP binding to CHO-
GRP cells. Confluent, quiescent cultures of CHO-GRP cells were incubated with [125I]-GRP
binding media alone (control) or containing A) lpM or 5pM SP-D. B) lpM or 5pM SP-G,
then various concentrations of unlabelled bombesin were added (37°C; 30min). Results are
expressed as % of total radioligand binding and represent the mean ± s.e.m. of three
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Figure 3.18. Effect of substance-P analogues on [125I]-AVP binding to CHO-
VfA cells. Confluent, quiescent cultures of CHO-Vja cells were incubated with [125I]-AVP
binding media alone (control) or containing A) lpM or 5pM SP-D. B) lpM or 5pM SP-G,
then various concentrations of unlabelled vasopressin were added (37°C; 30min). Results
are expressed as % of total radioligand binding and represent the mean ± s.e.m. of three
experiments performed in triplicate.
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Figure 3.19. Effect of Spantide on [125I]-GRP binding to CHO-GRP cells.
Confluent, quiescent cultures of CHO-GRP cells were incubated with [125I]-GRP binding
media alone (control) or containing 5gM or 25gM Spantide, then various concentrations of
unlabelled bombesin were added (37°C; 30min). Results are expressed as % of total
radioligand binding and represent the mean ± s.e.m. of two experiments performed in
triplicate.
103
3.4 ERK activation by neuropeptide receptors
Extracellular regulated protein kinases (ERK 1 and 2) are activated by AVP and
bombesin in a variety of cell types expressing the cognate receptors (Thibonnier,
1992; Seufferlein, 1996b; Rozengurt, 1998a; Chiu et al, 2002). Although the majority
of the data suggests a Gq- and PKC-dependent mechanism, these observations are
thought to be cell type-dependent (Thibonnier, 1992; Seufferlein et al, 1996a;
Charlesworth & Rozengurt, 1997; Jian et al, 1999; Chiu et al, 2002). Previous studies
have shown that substance-P analogues reversibly inhibit ERK activation by
neuropeptides in Swiss 3T3 cells (Mitchell et al, 1995; Seckl et al, 1996). However,
studies in our lab revealed that in rat-1 fibroblasts and in human SCLC cells, in the
absence of bombesin, substance-P analogues activated ERK and c-jun kinase (JNK)
in a GRP receptor-dependent manner (MacKinnon et al, 2001). Having assessed the
antagonist properties of the Substance-P analogues by their effects on neuropeptide-
induced calcium responses and receptor binding, the following part of this study
was undertaken to investigate their agonist properties.
ERK activation was measured in CHO cells expressing GRP or Via receptors in
response to the appropriate neuropeptide or substance-P analogue. Lysates from
quiesced cells stimulated with either neuropeptide, SP-D or SP-G were separated on
12% gels and blotted for phospho-ERKl/2 or total ERK2. Activation was estimated
by quantification of pERK band intensity ratios using ImageQuant software
following chemifluorescent visualisation of immunoblots. Blots were also probed
for total ERK2 in order to ensure that any observed increase in ERK
phosphorylation was not due to a change in total ERK expression or unequal
loading of gels (observed as equivalent ERK2 bands in the absence and presence of
treatment).
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3.4.1 Neuropeptide stimulated ERK activation
Cells were stimulated with increasing concentrations of neuropeptide for 10
minutes and ERK activation measured. In CHO-GRP cells, bombesin increased ERK
phosphorylation in a concentration dependent manner. Quantification of 5 separate
experiments showed that bombesin produced a maximal 3.5 fold increase in ERK
phosphorylation at 1 nM with an EC50 of 0.56 nM (Figure 3.20a). AVP also
stimulated a dose-dependent increase in ERK phosphorylation in ViaR expressing
cells with an EC50 of 0.72 nM (n=4) and a maximal 4.2 fold increase stimulated by
InM AVP (Figure 3.20b). Neither AVP nor GRP stimulated ERK phosphorylation in
CHO-vector cells (Figure 3.21).
3.4.2 Substance-P analogue stimulated ERK activation
Cells were stimulated with increasing concentrations of SP-D or SP-G for 5 minutes
at 37°C and ERK phosphorylation measured. SP-D stimulated ERK in CHO-GRP
and CHO-Via ce^s 'n a concentration dependent manner (Figure 3.22), with
activation of ERK evident at 3 pM. Maximal stimulation with 50pM Sp-D caused a
2.8 fold (CHO-GRP) and 2 fold (CHO-Vja) increases in ERK phosphorylation but
this was still less than that observed with neuropeptide. SP-G also stimulated a
concentration dependent increase in ERK phosphorylation in both cell-lines (Figure
3.23). SP-G had greater efficacy in Vja receptor expressing cells stimulating a 4.3
fold increase in ERK phosphorylation at 50 pM compared to a 2.1-fold stimulation in
CHO-GRP cells. ERK stimulation by SP-D and SP-G was also observed in CHO-
vector cells but at a lower level than in receptor expressing cell-lines. These data
show that at concentrations which block neuropeptide binding and neuropeptide-
stimulated calcium release, SP-D and SP-G are agonists for ERK activation in both
GRP and Vja receptor expressing CHO cells.
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Interestingly, 30pm Spantide did not activate erk in cho-grp or CHO-Via cells
(Figure 3.24) although the same concentration completely inhibited neuropeptide-
stimulated calcium release as well as [125I]-grp binding.
Pre-treatment of CHO-GRP cells with the GRP antagonist RC3940-II (1 pM; 30 min)
completely blocked 1 nM bombesin-induced ERK1/2 phosphorylation but not 30 pM
SP-D stimulated ERK activation (Figure 3.25). Similarly, the selective Via receptor
antagonist [P-mercapto-p-P-cyclopentamethylene-propionyP,0-Me-Tyr2,Arg8]-
vasopressin (1 pM; 30 min) inhibited 1 nM vasopressin-induced but not 30 pM SP-G
stimulated ERK phosphorylation. Antagonists typically bind to the orthosteric
ligand binding site of a receptor (Boeynaems & Dumont, 1980) and would thus
prevent native ligand binding to the receptor and the subsequent activation of
downstream signals. Since the analogues are still able to activate ERK in the
presence of antagonist, this suggests that the analogues act at a site on the receptor
which is distinct from the neuropeptide binding site. This is in accordance with
findings from radioligand binding studies which also suggest that the analogues
bind to a site on the receptor which is distinct from the agonist binding site.
3.4.3 Kinetics of ERK activation
In order to determine the time-course for ERK phosphorylation by neuropeptide
and Substance-P analogues, CHO-Via cells were treated with InM AVP or 30pM
SP-G for increasing lengths of time. Both AVP and SP-G stimulated ERK
phosphorylation in a time-dependent manner. Neuropeptide-stimulated ERK
phosphorylation was rapid, reaching a maximum 4 fold increase within 2 minutes
(Figure 3.26). After 30 minutes exposure to AVP, the level of phosphorylation
decreased but remained above basal levels for up to 60 minutes post-stimulation. In
contrast, SP-G stimulated ERK phosphorylation peaked at 10 minutes, at levels up
to 2.5-fold above basal, and was sustained at this level thereafter. The divergent
106
kinetics of ERK activation indicated that the mechanism by which neuropeptide and
Substance-P analogue activate ERK may differ. The work in the following section
was subsequently undertaken to investigate the mechanisms by which
neuropeptides and Substance-P analogues activate ERK.
3.5 Mechanisms of ERK activation
The mechanisms of GRP- and Vj^-receptor mediated ERK activation are not fully
understood although it has been shown in some cell types that activation is
mediated by Gq-induced PKC activation and subsequent activation of raf. Other
GPCRs have been shown to activate ERK in a Gj and ras-dependent mechanism,
which may or may not involve the activation of PI3K. There is also a growing body
of evidence to implicate receptor tyrosine kinases such as the EGF receptor as being
central in the activation of ERK by GPCRs. Inhibitors of various intracellular
signalling intermediates were used to ascertain their respective roles in the
activation of ERK by neuropeptides and Substance-P analogues in CHO cells.
3.5.1. Role of G-proteins of Gj subtype
In order to establish whether Gj proteins play any role in the activation of ERK, cells
were treated overnight with 100 ng ml'1 pertussis toxin (PTx). The toxin catalyses
the ADP-ribosylation of Gi protein a-subunits which results in the uncoupling of Gj
from receptors (Kaslow & Burns, 1992). Figure 3.27 shows that in CHO-GRP cells
PTx produced a small but non-significant inhibition of bombesin-stimulated ERK
activation whereas the responses to 30 pM SP-D and SP-G were completely
abolished (P<0.05, ANOVA). In CHO-Vja expressing cells the response to AVP
was not significantly inhibited by PTx pre-treatment although the response to both
SP-G and SP-D (30 pM) was completely blocked (P<0.05, ANOVA). In addition, PTx
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had no effect on ERK phosphorylation induced by O.lnM bombesin and vasopressin
in CHO-GRP and CHO-V^a cells respectively (data not shown). In both cell types
ERK activation by 1 pM LPA (which activates ERK through the Gj-coupled LPA
receptor) was completely inhibited by PTx treatment (data not shown). This
differential sensitivity to pertussis toxin indicates that dual Gi/Gq-coupled
mechanisms activate the ERK 1/2 cascade via GRP and Via receptors expressed in
CHO cells.
The effect of pertussis toxin on neuropeptide-induced calcium mobilisation and the
ability of Substance-P analogues to inhibit this response were also assessed to
determine whether Gj proteins were involved. Figure 3.28 shows that PTx did not
affect 1 nM bombesin-induced calcium mobilisation or the ability of 30 pM Sp-D to
inhibit the calcium response in CHO-GRP cells. Similarly, in CHO-Via ceils
calcium mobilisation stimulated by 1 nM vasopressin and the inhibition of this
response by 30 pM SP-G was not affected by PTx. This shows that neuropeptide-
stimulated calcium mobilisation does not involve receptor coupling to Gi proteins
and that the inhibition of calcium release by substance-P analogues is not mediated
by Gj proteins.
In the following experiments, CHO-GRP and CHO-Via cells were stimulated with
both SP-D and SP-G. The various inhibitors had the same effects on SP-D and SP-G
stimulated ERK activation in each cell-line. Hence, for simplicity only the data for
SP-D stimulated ERK phosphorylation is shown for CHO-GRP cells and SP-G
stimulated ERK phosphorylation shown for CHO-Via cells in the following
sections.
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3.5.2. Role of Src kinases and PI-3 kinases
Src-family tyrosine kinases have been implicated in the activation of ERK mediated
by both pertussis toxin sensitive and pertussis toxin insensitive G proteins. Src
activation via a PKC-and calcium-independent pathway is thought to be specifically
mediated by G protein Py subunits (Igishi et al, 1998). The Gi protein Py subunits are
able to associate with and activate phosphotidylinositol-3-kinases (PI-3-K) (Crespo,
1994; Lopez-Ilasaca et al, 1997). Following PI-3-kinase activation, Src-family tyrosine
kinases phosphorylate adaptor proteins, e.g. She, recruiting Grb2-Sos complexes to
the membrane, enhancing the GDP-GTP exchange of Ras, and finally linking to the
ERK/MAPK cascade (Gutkind, 1998a; Dikic & Blaukat, 1999).
The effect of PP2, which is a selective Src-family kinase inhibitor (Hanke et al, 1996),
was tested. Cells were pre-treated with 5 pM PP2 for 30 minutes then stimulated
with 1 nM neuropeptide or 30pM analogue. In CHO-GRP cells, ERK activation by
Sp-D was completely blocked by Src kinase inhibition whilst inhibition of
bombesin-induced ERK phosphorylation was incomplete (Figure 3.29). Likewise,
SP-G-stimulated ERK phosphorylation was fully inhibited by PP2 treatment in
CHO-Via cells whereas AVP-stimulated ERK phosphorylation was incompletely
blocked. This shows that activation of ERK by substance-P analogues and
neuropeptides is dependent on Src-family kinases.
The role of PI-3-K was examined in cells pre-treated for 30 minutes with 100 nM
Wortmannin (Cross et al, 1995). Inhibition of PI3K significantly blocked substance-P
analogue- and neuropeptide-stimulated ERK activation in both GRP and VyA
receptor expressing cells (Figure 3.30). This shows that substance P analogue and
neuropeptide-induced ERK activation involves signalling via P1-3-K dependent
pathways.
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3.5.3. Role of small G-protein Ras
The small GTPase Ras is an upstream regulator of ERK activity and can be activated
by both receptor tyrosine kinases and non-receptor tyrosine kinases (Sadoshima &
Izumo, 1996). The Ras antagonist FTS (S-frans-trans-Farnesylthiosalicyclic acid)
dislodges Ras from its membrane-anchoring sites and accelerates degradation with
a resultant decrease in total cellular Ras (Haklai et al, 1998). Figure 3.31 shows that
FTS pre-treatment (50 pM; 30 minutes) inhibited neuropeptide and substance-P
analogue-induced ERK activation similarly in both Via and GRP receptor
expressing cells. This shows that the pathways leading to ERK activation by the
substance-P analogues and neuropeptides require Ras activation. Basal ERK
phosphorylation was also completely inhibited with FTS in both cell-lines indicating
that some level of constitutive Ras activity exists in CHO-K1 cells.
3.5.4. Role of Signalling Scaffolds
Various studies have indicated that both Gq and Gi coupled receptors are able to
induce ERK activation through transactivation of the EGF receptor tyrosine kinase
(Daub et al, 1997; Gutkind, 2000; Santiskulvong et al, 2001). Activated receptor
tyrosine kinases (RTKs) can function as scaffolds for the plasma membrane
recruitment and assembly of Ras activation complexes, such as the Grb2-mSos
guanine nucleotide exchange factor complex (Luttrell et al, 1997a; Delia Rocca, 1999).
So in order to determine whether EGF receptor transactivation was involved in
neuropeptide and substance-P analogue induced ERK phosphorylation, cells were
pre-treated with the specific inhibitor AG1478 (lpM; 30 minutes) to block EGF
receptor kinase activity. In CHO-GRP cells, AG1478 completely abolished
analogue-induced ERK1/2 phosphorylation but had no significant effect on
bombesin-induced ERK1/2 phosphorylation (Figure 3.32). AG1478 similarly
abrogated SP-G-induced but not AVP-stimulated ERK phosphorylation in CHO-
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VlA cells- This reveals that EGF receptor transactivation is required for ERK
activation by substance-P analogues in CHO cells.
Integrin-based focal adhesions serve as points of cell attachment to the extracellular
matrix and of cytoskeletal anchoring to the plasma membrane. They can also
function as scaffolds for the GPCR-induced assembly of Ras activation complexes
(Luttrell et al, 1999b). Disruption of the actin cytoskeleton with cytochalasin D (2pM;
30 minutes) inhibited neuropeptide and analogue stimulated ERK activity in both
CHO-GRP and CHO-V\a cells (Figure 3.33). This shows that focal adhesions
provide a scaffold upon which signalling complexes assemble for ERK activation
following GRP or Vja receptor stimulation.
To summarise, in CHO cells expressing neuropeptide receptors, neuropeptides
activate Gq (and to lesser extent Gj) leading to ERK phosphorylation through both
EGFR, Src and PI3K dependent and independent pathways. In contrast, the
substance-P analogues activate Gj leading to ERK activation via EGFR, Src and PI3K
dependent pathways only. Ras activation serves as a point of convergence for
signals emanating from receptor stimulation with substance-P analogues or
neuropeptides. In addition, ERK activation by both analogues and neuropeptides is
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Figure 3.20. Neuropeptide stimulated ERK phosphorylation in receptor
expressing cells. Confluent, quiescent cultures of A) CHO-GRP and B) CHO-Vj^ cells
were stimulated for 10 min with increasing concentrations of neuropeptide. Aliquots of cell
lysate were resolved by SDS-PAGE and western blots probed with monoclonal anti-pERKl/2
antibody (upper panel) or polyclonal anti-ERK2 antibody (lower panel). Representative
blots are shown. Bar graphs represent the mean band intensity ratios ± s.e.m. of four






















Figure 3.21. Neuropeptide stimulated ERK phosphorylation in CHO-vector
cells. Confluent, quiescent cultures of CHO-vector cells were stimulated for 10 min with
water, InM bombesin, InM vasopressin or lpM LPA. Aliquots of cell lysate were resolved
by SDS-PAGE and western blots probed with monoclonal anti-pERKl/2 anbbody (upper
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Figure 3.22. SP-D stimulated ERK phosphorylation. Confluent, quiescent cultures
of CHO-vector, CHO-GRP and CHO-Vj^ cells were stimulated for 5 min with increasing
concentrations of SP-D. Aliquots of cell lysate were resolved by SDS-PAGE and western
blots probed with monoclonal anti-pERKl/2 antibody (left panel) or polyclonal anti-ERK2
antibody (right panel). Representative blots are shown. Bar graphs represent the mean band
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Figure 3.23. SP-G stimulated ERK phosphorylation. Confluent, quiescent cultures
of CHO-vector, CHO-GRP and CHO-V^ cells were stimulated for 5 min with increasing
concentrations of SP-G. Aliquots of cell lysate were resolved by SDS-PAGE and western
blots probed with monoclonal anti-pERKl/2 antibody (left panel) or polyclonal anti-ERK2
antibody (right panel). Representative blots are shown. Bar graphs represent the mean band
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Figure 3.24. Effect of Spantide on ERK phosphorylation. Confluent, quiescent
cultures of A) CHO-GRP: stimulated with dH20 (control), 30pM Spantide, 30pM SP-D or
lpM BN (37°C; 5min). B) CHO-V^: stimulated with dH20 (control), 30pM Spantide, 30pM
SP-G or lpM AVP (37°C; 5min). Aliquots of cell lysate were resolved by SDS-PAGE and
western blots probed with monoclonal anti-pERKl/2 antibody (upper panel) or polyclonal
anti-ERK2 antibody (lower panel). Representative blots are shown. Experiments performed
>six times in duplicate.
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Figure 3.25. Inhibition of ERK phosphorylation by receptor-antagonists. A)
CHO-GRP stimulated with dH20 (control), 30pM SP-D or InM bombesin (37°C; 5min) with
or without lpM RC3940II pre-treatment. B) CHO-Vj^y stimulated with dH20 (control), 30pM
SP-G or InM vasopressin (37°C; 5min) with or without lpM [(3-mercapto-p-P-
cyclopentamethylene-propionyl!,0-Me-Tyr2,Arg8]-vasopressin pre-treatment. Aliquots of cell
lysate were resolved by SDS-PAGE and western blots probed with monoclonal anti-pERKl/2
antibody (upper panel) or polyclonal anti-ERK2 antibody (lower panel). Representative
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Figure 3.26. Kinetics of ERK phosphorylation in CHO-Vja cells. Confluent,
quiescent cultures of CHO-yj^ cells were stimulated with InM AVP or 30pM SP-G for the
indicated times at 37°C. Aliquots of cell lysate were resolved by SDS-PAGE and western
blots probed with monoclonal anti-pERKl/2 antibody (upper panel) or polyclonal anti-ERK2
antibody (lower panel). Representative blots are shown. Time-course plot represents the



































































Figure 3.27. Effect of pertussis toxin on ERK phosphorylation. Confluent cultures
were quiesced overnight in the presence or absence of lOOng ml-1 pertussis toxin (PTx).
Cells were stimulated for 5 min with 30pM SP-D or SP-G or InM neuropeptide as indicated.
Lysates were resolved by SDS-PAGE and western blots probed with monoclonal pERKl/2
antibody (upper panel) or polyclonal ERK2 antibody (lower panel). Representative blots are
shown. Bar graphs represent the mean band intensity ratios ± s.e.m. of four separate




























Figure 3.28. Effect of pertussis toxin on calcium mobilisation. A) Quiescent CHO-
GRP cells loaded with FURA-2AM were stimulated with InM bombesin alone (control) or in
the presence of 30pM SP-D. B) Quiescent CHO-V^ cells loaded with FURA-2AM were
stimulated with InM AVP alone (control) or in the presence of 30pM SP-G. Intracellular
calcium release was measured by ratiometric fluorimetry as described in materials and
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Figure 3.29. Effect of inhibition of Src-like kinases on ERK phosphorylation.
Confluent, quiescent cultures were pre-treated with PP2 (5pM; 30 min) at 37°C. A) CHO-
GRP cells stimulated for 5 min with 30pM SP-D or InM Bn. B) CHO-V^a cells were
stimulated for 5 min with 30pM SP-G or InM AVP. Aliquots of cell lysate were resolved by
SDS-PAGE and western blots probed with monoclonal pERKl/2 antibody (left panel) or
polyclonal ERK2 antibody (right panel). Representative blots are shown. Bar graphs














































































Figure 3.30. Effect of PI-3-K inhibition on ERK phosphorylation. Confluent,
quiescent cultures were pre-treated with Wortmannin (lOOnM; 30 min) at 37°C. A) CHO-
GRP cells stimulated for 5 min with 30pM SP-D or InM Bn. B) CHO-Vja cells were
stimulated for 5 min with 30pM SP-G or InM AVP. Aliquots of cell lysate were resolved by
SDS-PAGE and western blots probed with monoclonal pERKl/2 antibody (left panel) or
polyclonal ERK2 antibody (right panel). Representative blots are shown. Bar graphs
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Figure 3.31. Effect of Ras inhibition on ERK phosphorylation. Confluent,
quiescent cultures were pre-treated with FTS (50pM; 30 min) at 37°C. Cells were then
stimulated for 5 min with 30pM analogue or InM neuropeptide as indicated. Aliquots of cell
lysate were resolved by SDS-PAGE and western blots probed with monoclonal pERKl/2
antibody (left panel) or polyclonal ERK2 antibody (right panel). Representative blots are
shown. Bar graphs represent the mean band intensity ratios ± s.e.m. of three separate
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Figure 3.32. Effect of EGFR tyrosine kinase inhibition on ERK
phosphorylation. Confluent, quiescent cultures were pre-treated with AG1478 (lpM; 30
min) at 37°C. A) CHO-GRP cells stimulated for 5 min with 30pM SP-D or InM Bn. B) CHO-
Vja cel's were stimulated for 5 min with 30pM SP-G or InM AVP. Aliquots of cell lysate
were resolved by SDS-PAGE and western blots probed with monoclonal pERKl/2 antibody
(left panel) or polyclonal ERK2 antibody (right panel). Representative blots are shown. Bar
graphs represent the mean band intensity ratios ± s.e.m. of three separate experiments
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Figure 3.33. Effect of disrupting actin cytoskeleton on ERK phosphorylation.
Confluent, quiescent cultures were pre-treated with cytochalasin D (2pM; 30 min) at 37°C. A)
CHO-GRP cells stimulated for 5 min with 30pM SP-D or InM Bn. B) CHO-V^a cells were
stimulated for 5 min with 30pM SP-G or InM AVP. Aliquots of cell lysate were resolved by
SDS-PAGE and western blots probed with monoclonal pERKl/2 antibody (left panel) or
polyclonal ERK2 antibody (right panel). Representative blots are shown. Bar graphs
represent the mean band intensity ratios ± s.e.m. of three separate experiments performed in
duplicate (*P<0.05, ** P<0.01, ANOVA).
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3.6 Discussion
The question addressed in this chapter was whether substance-P analogues are
biased agonists of receptors other than the GRP receptor. Substance-P analogue
properties were studied using model cell systems stably expressing the GRPR or
VlAR- The hamster epithelial CHO-K1 cell-line was used to generate the model cell
systems as it is a non-transformed, non-neuroendocrine cell-line. It may also be of
relevance to SCLC since this tumour type may be derived from epithelial cells lining
the larger airways (Garber et al, 2001). The cell-line has an acceptable null
background for the transfection of neuropeptide receptors, unlike COS-7 cells which
are more amenable to transfection but endogenously express bombesin receptors.
CHO-K1 cells have previously been used for the over-expression of various GPCRs
and the subsequent investigation of intracellular signalling events. In particular,
CHO-K1 cells have been transfected with Via receptors in order to define the
signalling pathways which mediate vasopressin mitogenicity (Thibonnier et al,
2000).
Of the cell-lines created, CHO-GRP expressed 5086 ± 489 receptors/cell whereas
CHO-Vja expressed 720 ± 90 receptors/cell. The levels of receptor expression are
within the range measured in a variety of native and tumour tissues (100-50,000
sites/cell) (Cardona et al, 1992; Fay et al, 1994; Tahara et al, 1998a; Tahara et al, 1999;
Jensen et al, 2001). The affinities of GRP and AVP for their cognate receptors
expressed in CHO-GRP and CHO-Vja respectively are similar to previously
reported values (Cardona et al, 1992; Thibonnier et al, 1994; Ferris et al, 1997; Tsuda
et al, 1997; Tahara et al, 1998b). Stably expressed GRPR and V^aR effectively
mobilised intracellular calcium in response to neuropeptide stimulation, with EC50
values reflecting the affinity of each neuropeptide for its receptor. The EC50 values
for calcium mobilisation were in accordance with previous reports (Wang et al,
1996b; Tahara et al, 1998b). The pertussis toxin insensitivity of the calcium responses
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is also in accord with previous observations that the GRP and Vja receptors couple
to a pertussis toxin insensitive G-protein belonging to the Gq/11 family (Zachary et
al, 1987b; Thibonnier et al, 1994; Wang et al, 1996b; Dyer et al, 2005). The receptors
also responded to neuropeptide stimulation by activating ERK predominantly via
Gq-mediated signalling pathways. Neuropeptide stimulated calcium mobilisation
and ERK activation in CHO-GRP and CHO-V^a cells was blocked by specific
neuropeptide antagonists. This confirmed that the effects of BN and AVP on
calcium flux and ERK activity, in CHO-GRP and CHO-V^a cells respectively, were
elicited through specific receptors. Receptors expressed in the model cell-systems
were thus fully functional and could be regarded as physiologically relevant
models.
In vector-transfected cells, BN induced a small calcium response whereas AVP
produced no response. This implied that CHO-K1 cells endogenously express GRP
receptors. However, endogenous GRP or AVP receptor expression was low, as
shown by the lack of significant radio-labelled GRP or AVP binding. In addition,
these cells did not activate ERK in response to neuropeptide stimulation indicating
that the level of GRP receptor expression is not sufficiently high enough to activate
all cell signalling pathways. However, this also suggests that a relatively low
number of receptors are adequate for a calcium response to be observed in CHO-K1
cells but not an ERK response.
In order to better understand the substance-P analogues' mechanism of action, their
effects were studied at distinct steps of the VjaR and GRPR signalling process:
neuropeptide growth factor binding, calcium mobilisation and ERK1/2 activation.
The analogues inhibited neuropeptide binding and antagonised calcium
mobilisation but were agonists for ERK activation by the VjaR as well as the GRPR.
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The analogues SP-D and SP-G competitively inhibited natural ligand binding to
both the GRP and V^a receptors. SP-G exhibited greater affinity for the V^a
receptor whereas SP-D had greater affinity for the GRP receptor. The selectivity of
SP-G for the V^a receptor is in accordance with previous findings (Seckl et al,
1995b). Substance-P analogues are indeed able to inhibit the action of many different
neuropeptides but the mechanism underlying this broad-spectrum activity is
unclear. A comparative study of specific antagonists and substance-P analogues
against bombesin, vasopressin and bradykinin receptors in Swiss 3T3 cells showed
that only the substance-P analogues demonstrated cross-inhibition between
receptors (Woll & Rozengurt, 1988a). It was therefore proposed that whereas the
specific antagonists only interact with the ligand binding site the analogues must be
able to recognise a common domain shared by the three receptors.
Consistent with this theory, the analogues caused a reduction in the number of
binding sites, suggesting that they bind to a site which is distinct from the
orthosteric agonist binding site. In order for the analogues to be able to inhibit the
effects of a broad-spectrum of neuropeptides, the analogue binding site is likely to
be present within a common structural motif present amongst analogue-sensitive
receptors. The variable affinity with which the analogue binds to different
analogue-sensitive receptors probably reflects the contribution the respective
receptors primary structure makes to the configuration of the analogue binding site.
Thus, the data shows that substance-P analogue binding modulates the
conformation of the receptor through stabilising a receptor conformation which is
unable to bind the natural ligand.
A change in the steepness (Hill factor) of the binding curves is an indicator that the
unlabelled ligand is not simply competing for a single class of binding site and can
be used to identify co-operativity between binding sites. The steepness of each
binding curve (Figures 3.17 and 3.18) was determined using the sigmoidal dose
response (variable slope) equation to fit data in Prism, to provide the Hill (slope)
factor (data not shown). This showed that there was a reduction in the Hill
coefficient of binding curves in the presence of analogue, which indicates that
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negative co-operativity may exist between the analogue binding site and
neuropeptide binding site on the receptor. In this case, binding of the analogue may
distort the neuropeptide binding pocket thus preventing neuropeptide binding. A
structural basis for this can be implied from the phenomenon of receptor
dimerization. It is becoming apparent that most, if not all GPCRs, form dimers (Rios
et al, 2001). Indeed, receptors have been shown to constitutively form
homodimers during synthesis (Terrillon et al, 2003). It has been proposed that the
dimerization process can facilitate cross-talk between protomers which may be
manifest in the co-operative binding of ligands to these protomers (Durroux, 2005).
Models formulated to describe this process suggest that negative co-operativity
would result from the conversion of independent binding sites to dependent ones
(Durroux, 2005). In accordance with this, the neuropeptide ligand may bind to
independent sites (i.e. to monomers) whereas the analogue may bind to dependent
sites (i.e. sites dependent on dimer formation). This would also account for the
reduction in the number of binding sites in the presence of analogue and could also
have implications for signalling.
SP-D and SP-G were effective antagonists of the transient calcium responses
induced by neuropeptide stimulation of both V^a and GRP receptors. Previous
work has also shown that substance-P analogues inhibit bombesin and vasopressin
induced calcium mobilisation in Swiss 3T3 cells (Seckl et al, 1996a) and SCLC cell-
lines (Bunn et al, 1994). In accordance with findings from binding studies, SP-G
more potently inhibited the V[ aR calcium response. However SP-D, which
inhibited GRP binding more potently than AVP binding, inhibited the calcium
response to both neuropeptides with similar potency. The inhibition of
neuropeptide stimulated calcium release by the analogues was not altered by
pertussis toxin pre-treatment. This showed that antagonism of the calcium response
did not result from activation of Gi protein-dependent signalling by the analogues.
Inhibition of calcium mobilisation is therefore likely to be a consequence of bound
analogue preventing the neuropeptide from binding, which is necessary for
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activation of the receptor-Gq protein interaction. In Swiss 3T3 cells, SP-D did not
inhibit the activation of PLCp by a constitutively active Gq-like protein, indicating
that the peptide acts at a point upstream of the activated form of the G-protein alpha
subunit (Mitchell et al, 1995). Consistent with this finding, the data presented in this
chapter indicates that inhibition of neuropeptide stimulated calcium mobilisation is
a direct result of the analogue-binding to the receptor in a manner which stabilises a
receptor conformation which does not couple to Gq proteins.
In addition to the aforementioned antagonist properties of the analogues against
neuropeptide-mediated processes, as shown in this chapter, these compounds were
also agonists. Stimulation of the V^R as well as the GRPR with SP-D and SP-G
resulted in ERK activation in the absence of neuropeptides. SP-D and SP-G
activated ERK at concentrations which reflected their affinities for the GRPR and
V|y\R. ERK activation by SP-D and SP-G occurred in the absence of calcium
mobilisation and was facilitated entirely by receptor coupling with pertussis toxin
sensitive Gi proteins. In contrast, neuropeptide-stimulated ERK activation was
largely mediated through Gq proteins, with Gi-dependent signalling making only a
minor contribution and free calcium playing a role as a second messenger. Previous
work has shown that ERK can be activated in a calcium- and PKC-independent
manner (Faure et al, 1994; Mochizuki et al, 1999). GPCR coupling with Gj proteins, in
addition to Gq proteins, has also been demonstrated previously (Letterio et al, 1986;
Profrock et al, 1992). In particular, GRP receptor coupling to Gj in Swiss 3T3 cells
has previously been demonstrated to play a role in bombesin-induced mitogenesis
but not in bombesin-stimulated calcium mobilisation (Zachary et al, 1987b). In the
same cells, V] ^ receptors have exhibited cell-cycle dependent coupling to Gi
proteins for AVP-induced calcium mobilisation (Abel et al, 2000). SP-D has also
previously been shown to facilitate receptor association with Gi proteins, with SP-D
induced calcium mobilisation in human neutrophils being sensitive to pertussis
toxin pre-treatment (Jarpe et al, 1998). In contrast to neuropeptide stimulated Ca2+
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mobilisation in fibroblasts, in neutrophils the (3y subunits released upon activation
of Gi are thought to mediate stimulation of PLC(3 isoforms leading to calcium
mobilisation (Wu et al, 1993). The G-protein selectivity of substance-P analogues
demonstrated in this study is in agreement with previous results where GRP
receptor expressing rat 1A cells were stimulated with SP-D (Mackinnon et al, 2001).
Evaluation of the kinetics of ERK activation following VlA receptor stimulation
with AVP or SP-G showed distinct temporal patterns of activation. Unlike
neuropeptide induced ERK activation which was rapid and transient, activation of
ERK by SP-G was sustained. GRP stimulation of ratlA cells expressing GRP
receptors similarly resulted in rapid and transient ERK activation whereas SP-D
stimulated ERK activity was sustained although not delayed (Mackinnon et al,
2001). The peak level of ERK phosphorylation induced by SP-G was lower than that
obtained following AVP-stimulation. This could be a reflection of the different
intracellular pathways employed by SP-G and AVP for ERK activation and suggests
that Gq-stimulated ERK activity is necessary to attain the maximum levels of ERK
phosphorylation stimulated by AVP. The magnitude and duration of ERK
signalling is in itself believed to determine cell fate (Qui & Green, 1992; Traverse et
al, 1992; Cowley et al, 1994). The ability of a receptor to produce more sustained
activation of MAPK has been shown to determine the ability of a cell to differentiate
or proliferate, depending on the cell type (Thibonnier et al, 1997). In PC12 cells for
instance, sustained ERK activation is associated with ERK translocation to the
nucleus and results in neuronal differentiation, whereas transient activation causes
cytosolic activation and leads to proliferation (Dikic et al, 1994). It would be of
interest to determine whether the spatial localisation of ERK is altered following
receptor stimulation with analogues compared with neuropeptides as this may
contribute to the growth inhibitory response to neuropeptide receptor stimulation
with analogues. Following receptor activation, desensitization mechanisms control
receptor signalling and thus limit the amplitude and/or duration of the signal
transduction cascade (Grady et al, 1997). Ligand degradation, GPCR-kinase (GRK)
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mediated receptor phosphorylation, p-arrestin binding and receptor internalization
can all contribute to this process (Tiberi et al, 1996; Claing et al, 2002). GRP receptors
undergo desensitization upon exposure to bombesin and altered agonist responses
have been shown to result from differences in receptor desensitization and down-
regulation (Benya et al, 1994b). In ratlA fibroblasts expressing GRP receptors, it was
found that receptors stimulated with SP-D were less efficiently desensitized than
those stimulated with GRP (Mackinnon et al, 2001). Therefore, the delayed and
sustained ERK activation induced by SP-G in CHO-V^a cells could be attributed to
altered receptor desensitization. Ca2+/Calmodulin (CaM) dependent pathways have
also been implicated in Gj and Gq-mediated ERK activation (Delia Rocca et al, 1997;
Delia Rocca et al, 1999). As mentioned previously, ERK activation by SP-D and SP-G
occurs in the absence of calcium mobilisation. A change in the level of ERK1/2-
inactivating phosphatases could contribute to sustained ERK phosphorylation
induced by SP-G since the expression of at least one of the ERKl/2-inactivating
phosphatases, MKP1, is Ca2+ dependent (Cook et al, 1997). In addition, Bosch et al
(1998) have shown that CaM was essential for inhibition of sustained ERK1/2
activation following stimulation of cultured fibroblasts with growth factors.
Data presented in this chapter demonstrates that stimulation of ERK activity by
bombesin and AVP is dependent upon the formation of focal adhesion complexes.
In contrast, analogue stimulated ERK activation requires both EGFR and focal
adhesions to function as scaffolds for the assembly of ERK activation complexes.
Dissection of the molecular mechanisms underlying neuropeptide receptor
stimulated ERK activity showed that activation of ERK by bombesin and AVP is
predominantly independent of EGFR transactivation but requires Src and PI3K. In
contrast, the substance-P analogues stimulate ERK via EGFR, Src and PI3K
dependent pathways only. Nonetheless, Ras activation serves as a point of
convergence for signals transduced by either substance-P analogue or neuropeptide
stimulated GRP and VIA receptors.
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Previous work has demonstrated that stimulation of GRP receptors in Swiss 3T3
cells leads to inhibition of [125I]-EGF binding to its cellular receptor, via a process
mediated by protein kinase C (Zachary & Rozengurt, 1985; Zachary & Rozengurt,
1986a). MAPK activation by bombesin occurs in a PKC-dependent manner in Swiss
3T3 cells (Seufferlein et al, 1996a) and a PKC-independent manner in ratlA cells
(Charlesworth & Rozengurt, 1997). The activation of ERK following VlA receptor
stimulation in rat vascular smooth muscle cells and 3Y1 fibroblasts has been shown
to occur via both PKC dependent and independent pathways (Granot et al, 1993;
Nishioka et al, 1995). In addition, PI3K activation has been demonstrated to be a
component of the PKC-independent pathway (Nishioka et al, 1995). PI-3-K
activation has also been implicated in GRP stimulated ERK activity (Bocker &
Verspohl, 2001). In accordance with this, data presented in this chapter showed that
ERK activation following neuropeptide stimulation of transfected receptors in CHO-
K1 cells was partially dependent on PI-3-K. Conversely, analogue stimulated ERK
activity was fully dependent upon PI-3-K activity. G(3y-subunits directly activate PI-
3-Ky as well as the more widely distributed PI-3-Kp (Schwindinger & Robishaw,
2001). PI-3-kinases can be involved in ERK signalling both upstream and
downstream of EGFR transactivation. PI-3-K may induce Src-mediated EGFR
transactivation (upstream role) and recruitment of Ras activation complexes. In
addition, direct binding of the catalytic subunit of PI-3-K to activated Ras can lead to
further stimulation of PI-3-K activity (downstream role) following GPCR-induced
activation of PI-3-K (Cantley, 2002). While the role of PKC in neuropeptide and
analogue stimulated ERK activity in the CHO model systems was not determined in
this study, it is nevertheless conceivable that the EGFR independent pathway
leading to ERK stimulation by bombesin and AVP represents a PKC-dependent
pathway.
A requirement for transactivation of growth factor receptors for ERK activation has
previously been demonstrated for some G-protein-coupled receptors (Delia Rocca et
al, 1999). Stimulation of the Gj-coupled receptor for LPA has been shown to induce
ERK activation through a Gpy subunit mediated Ras dependent pathway (Crespo et
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al, 1994; van Biesen et al, 1995). Although the intermediates between (3y and Ras have
not been defined clearly, tyrosine kinases including Src and activated EGFR have
been implicated (Pierce et al, 2001b). This would be in accordance with the findings
presented here that Gj-mediated ERK activation by the substance-P analogues
involves EGFR activation and Src kinases. The Src kinases may play a role upstream
of EGFR transactivation and/or downstream. Transactivation of EGF receptors can
result from activation of Src-like kinases following GPCR stimulation (Luttrell et al,
1997b; Zhang et al, 2004). Src kinases have been shown to facilitate cleavage of
membrane bound EGF-like ligands by membrane bound metalloproteases leading
to EGFR activation in a classic autocrine manner (Prenzel et al, 2001; Zhang, 2004).
Alternatively, analogue signalling in the absence of calcium mobilisation may
account for EGFR transactivation since it has been suggested that CaM inhibits the
RTK transactivation process. Ca2+/CaM can modulate Src activity and directly or
indirectly affect Ras activity or signalling elements downstream of Ras (Belcheva &
Coscia, 2002). Inhibition of CaM has been demonstrated to stimulate cleavage of
several membrane proteins in CHO and human epithelial cells, including EGFR
binding ligands, and this process is PKC independent (Bosch et al, 1998). The
endocytic pathway has also been implicated in EGFR transactivation following
GPCR activation whereby a complex is formed within clathrin coated pits which
includes EGFR, p-arrestin and Src (Maudsley et al, 2000). In such cases, p-arrestin
functions as an adaptor which recruits Src to mediate EGFR phosphorylation (Miller
et al, 2000). Either way, activated EGFR recruits Grb2-Sos complexes directly or via
Src to activate Ras. Thus, analogue signalling may utilise Src kinases for EGFR
activation (EGFR upstream role) and Ras activation (EGFR downstream role) in a
number of ways.
Non-receptor tyrosine kinases are also implicated in EGFR independent pathways
leading to ERK stimulation. Gq-coupled receptors can use Src kinases to activate
Ras in a manner similar to that described for RTK activation of Ras (Sadoshima &
Izumo, 1996). Src-mediated phosphorylation of the adaptor protein She recruits
Grb2-Sos complexes to the plasma membrane facilitating Ras activation leading to
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ERK activation (Gutkind, 1998a; Dikic & Blaukat, 1999). Alternatively, neuropeptide
stimulated ERK activity may involve activation of the Ca2+-dependent focal
adhesion kinase, Pyk2 (Belcheva & Coscia, 2002). Stimulation of the Gq-coupled
bradykinin receptor induced Pyk2 activation, Src recruitment, Src mediated Pyk2
phosphorylation, and binding of Grb2 (Dikic et al, 1996). In addition, the
dependence of GPCR-mediated ERK1/2 activation on intact focal adhesions has
been found to correlate with Pyk2 expression in some cell types (Delia Rocca et al,
1999). Thus, neuropeptide signalling to ERK probably utilises Src to mediate Ras
activation.
It thus appears that activation of ERK by neuropeptides occurs simultaneously
through parallel signalling pathways, whereby the predominant (Gq) pathway in
CHO-K1 cells is likely to be mediated by PKC and is EGFR independent, whereas
PI3K, EGFR and Src activation contribute to the minor (Gi) pathway. In contrast,
substance-P analogues activate only a subset of the downstream signals available to
the neuropeptide receptor (Gi-mediated). Figure 3.34 illustrates the multiple
signalling pathways which may putatively link activated GRP and receptors to
ERK activation in transfected CHO-K1 cells, in accordance with the 'multi-track'
model for GPCR signalling to the ERK pathway as proposed by Wetzker and
Bohmer (2003).
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Figure 3.34. Multi-track signalling pathways leading to ERK activation
following neuropeptide receptor stimulation in receptor expressing CHO-K1
cells. A) ERK activation by bombesin or vasopressin. B) ERK activation by Substance-P
analogues SP-D and SP-G. Intermediates identified as being effectors of ERK activity in
the present study are highlighted in bold. Signalling components are shaped according
to their function as follows: G proteins as vertical ellipses; non-receptor tyrosine kinases
as horizontal ellipses; Ser-Thr kinases as larger hexagons; Ca2+ as circles. IP3=inositol
triphosphate; MMP=matrix metalloproteases; Ptdlns= phosphatidylinositide. (Figure
adapted from Belcheva et al, 2002).
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The analogues, particularly SP-G, also induced ERK activation in CHO-vector cells.
However, ERK activation in receptor-expressing cells was greater than that
observed in vector-transfected CHO-K1 showing that this effect is at least partly
receptor-mediated. Analogue induced ERK activation in CHO-vector cells may have
been via stimulation of the endogenously expressed GRPR present at low levels or
other endogenously expressed analogue sensitive neuropeptide receptors. As well
as binding to neuropeptide receptors, SP-D has also been shown to bind to non-
neuropeptide receptor members of the same GPCR subfamily (e.g. IL-8
chemoattractant receptor) (Jarpe et al, 1998). Sphingosine-l-phosphate induced
intracellular calcium mobilisation in CHO-K1 cells (data not shown) therefore the
cells probably express receptors for this chemoattractant. Therefore, it is conceivable
that the substance-P analogues may have stimulated ERK activation via such
receptors endogenously expressed in CHO-vector cells.
Alternatively, analogue stimulated ERK activity in CHO-vector cells could have
been due to direct G-protein activation by the analogues. Some substance-P
analogues have been shown to inhibit the interaction between receptor and G-
protein by directly binding to the G-protein (Mukai et al, 1992). In H69 SCLC
membranes, SP-G was found to stimulate G-protein activity and this activity was
not blocked by a selective V^a receptor antagonist (MacKinnon et al, 1999). It was
therefore suggested that SP-G may directly modulate G-protein activity as well as
interact with neuropeptide receptors.
However, analogue binding to a site distinct from the agonist/antagonist binding
site (as the radioligand binding studies suggest) could also account for the failure of
the Vja receptor antagonist to block SP-G stimulated G-protein activity. Data
presented in this chapter similarly showed that analogue induced ERK activation
was not blocked by selective receptor antagonists whereas neuropeptide stimulated
ERK was. This adds support to the indication that the analogues bind to a site
distinct from the orthosteric agonist binding site to mediate their effects.
Nonetheless, it is not possible at this point to conclude whether the distinct
analogue binding site is associated with direct interaction with G-proteins or not.
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As mentioned previously however (page 136), ERK activation by the analogues is
enhanced in receptor-expressing cells and thus cannot be attributed to direct G-
protein stimulation alone.
The ability of substance-P analogues to stimulate G-protein activity directly is based
upon the amphiphilic nature of the peptides. Amphiphilic peptides such as
mastoparan, bradykinin, substance-P and some analogues of substance-P are able to
directly promote G-protein activation (Mousli et al, 1990b). It has been suggested
that mastoparan and substance-P mimic agonist-bound receptors through direct
interaction with the C-terminus of G protein alpha subunits to stimulate G-protein
activity (Mousli et al, 1990a). The N-terminal portion of substance-P is believed to be
responsible for such receptor-independent effects whereas the C-terminal region is
thought to mediate receptor-dependent effects via interaction with specific
neurokinin receptors (Landry et al, 1990). Data presented in this chapter showed
that SP-G, SP-D and Spantide all inhibit radioligand binding and neuropeptide
induced calcium flux while only SP-G and SP-D activate ERK. ERK activation by SP-
D and SP-G via the GRP and Via receptors occurs at concentrations that completely
inhibit neuropeptide binding to receptors. Spantide used at a concentration which
completely inhibits neuropeptide binding to the GRP receptor does not activate
ERK. This illustrates that the process of inhibiting Gq mediated signalling can be
dissociated from G[ coupling for ERK activation. A structure-function analysis of
substance-P analogues indicates that the analogues could have similar properties to
substance-P to achieve such effects. In such a case, the C-terminal region of the
analogues would be responsible for receptor mediated effects such as inhibition of
radioligand binding and neuropeptide induced calcium mobilisation whereas the
N-terminal region would mediate receptor independent effects such as G-protein
stimulation for ERK activation. Further to this, it is only the N-terminal region
which differs between SP-D [D-Arg^D-PheyD-Trp^Leu11] and Spantide [D-Arg^D-
Trp'7'9,Leun], with Spantide lacking an amino acid substitution at position 5 of the
peptide. Whereas this residue is polar uncharged in Spantide, in SP-D it is
substituted with a residue which has an aromatic side chain. Thus substituting a
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hydrophilic moiety for a hydrophobic one at this position appears to be critical for
agonist activity, as well growth inhibitory capacity. The bulky hydrophobic side
chain may participate in hydrophobic interactions with the receptor to elicit steric
effects on the conformation of the receptor, facilitating efficient receptor coupling
with differential G-proteins (e.g. Gi for ERK activation). Alternatively, hydrophobic
interactions may occur directly with the G-protein for activation. Another
substance-P analogue, ICRT5 [D-ArgbD-Trp^Leu11], which was identified as being
the most potent inhibitor of SCLC growth (Seckl et al, 1997), has an even bulkier
aromatic side chain at this position. This may enable it to be even more effective in
stabilising a G protein-selective receptor conformation and/or stimulating G-protein
activity and thus account for its superior potency. Also in accordance with this
hypothesis, deletion of the C-terminal Leu of SP-D to yield [D-ArgkD-Phe^D-
Trp79]SPl-10 resulted in a selective loss of inhibitory activity of this analogue
against bombesin- but not vasopressin-stimulated DNA synthesis, Ca2+
mobilization, and MAP kinase activation (Seckl et al, 1996a). The data presented in
this chapter showed that SP-G which has Met11 at the C-terminus is selective for the
Via receptor. Since SP-D without Leu11 is selective for the Vja receptor (Seckl et al,
1996a), this suggests that the penultimate amino acid of SP-G and SP-D contributes
to Vja receptor selectivity whereas the final amino acid dictates GRP receptor
selectivity. Since Spantide lacks agonist activity, it appears to act no differently than
a classical antagonist other than that it binds to a site distinct from the orthosteric
agonist binding site. It could thus be the case that the C-terminal region confers
antagonist properties upon the peptides whereas the N-terminal portion dictates
agonist properties, with a biased agonist possessing both of these properties.
Further structure-function analyses of various substance-P analogues should be
carried out to verify this hypothesis.
To summarise, the question addressed in this chapter was whether substance-P
analogues are biased agonists of receptors other than the GRP receptor and the
mechanism underlying such activity was also investigated. As well as verifying that
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SP-D is indeed a biased agonist for the GRP receptor, this study has shown that SP-
G is also a biased agonist for this receptor. Importantly, these analogues are also
biased agonists of Via receptors. It could thus be advocated that the growth
inhibiting substance-P analogues are broad spectrum biased agonists. The
substance-P analogues modulate neuropeptide receptor signalling by stabilising a
receptor conformation (possibly dimers) which favours coupling to Gi rather than
Gq proteins and the subsequent activation of only a subset of possible downstream
signals. The inapt signalling transduced through the normally mitogenic receptor
may contribute to the growth inhibitory effects of these analogues and is the subject
of study in the following chapter.
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Chapter 4
Effect of Neuropeptide Receptor Expression and
Substance-P Analogues on Growth
The agonist-dependent transformation of cells through ectopic expression of wild-
type GPCRs (e.g 5-HT2C receptors) demonstrates that GPCRs have oncogenic
potential (Julius et al, 1989; Gutkind et al, 1991). SCLC-secreted neuropeptides can
contribute to tumourigenesis in a similar manner through chronic stimulation of
GPCRs in their role as cancer growth factors. GPCRs can also be constitutively
active in a manner dependent on the cellular environment in which the GPCR is
ectopically expressed and has been observed for the GRP receptor over-expressed in
a non-malignant human colon epithelial cell-line (Ferris et al, 1997). The work in this
chapter was carried out to determine whether expression of GRP and V]a receptors
can transform CHO-K1 epithelial cells. The characteristics of the wild-type CHO-K1
cells were compared with neuropeptide receptor expressing cells in terms of
growth, migration and adhesion. The chemosensitivity of the model cell systems
was also investigated to ascertain whether neuropeptide growth factor activity
plays a role in the acquisition of chemoresistance.
Substance P analogues can inhibit the growth of various tumour types and this has
been shown to correlate with GRP receptor expression (Waters et al, 2003). Since the
VlA receptor has been found to be expressed on all SCLC cell-lines tested to date, it
is important to determine whether cells expressing V|A receptors are sensitive to
growth inhibition by substance P analogues. The work presented in this chapter was
therefore performed to investigate the effect of SP-D and SP-G on growth of the
model cell systems. The ability of the analogues to modulate the motility of
neuropeptide receptor expressing cells was also investigated.
140
4.1. Sensitivity of SCLC cells to Substance-P analogues
A preliminary experiment was performed to verify the ability of the selected
analogues, SP-D and SP-G, to inhibit the growth of small cell lung cancer cells. The
proliferation of H345 SCLC cells was measured in the absence and presence of
various concentrations of substance-P analogues. Cell numbers were determined by
coulter counter at various time-points over a 12-14 day period. Data from cells in
exponential growth phase (day 12 counts) were used to determine the IC50 values
(concentration of drug required to cause 50% inhibition of control growth) for each
analogue.
The resulting time course in liquid culture revealed that both analogues inhibited
H345 growth in a dose-dependent manner. Concentrations of SP-D and SP-G at or
above 30pM reduced the number of cells present over time compared with
untreated cells. The IC50 for inhibition of H345 proliferation by SP-D was 14 ± 3 pM
(n=2, Figure 4.1). SP-G inhibited H345 proliferation less potently with an IC50 = 27.2
±1.6 pM (n=2, Figure 4.2). In contrast, spantide did not inhibit H345 proliferation
(Figure 4.3). This shows that H345 SCLC cells are sensitive to growth inhibition by
both SP-D and SP-G but not spantide.
4.2 Cell growth in liquid culture
4.2.1. Effect of neuropeptide receptor expression on cell
growth and morphology in liquid culture
Through the course of routine tissue culture, it became apparent that whereas the
parental CHO-K1 cells had regular, elongated shapes, CHO-GRP (Figure 4.4) and
CHO-Via (Figure 4.5) cells appeared more rounded. The neuropeptide receptor
expressing cells also exhibited increased membrane ruffling and possessed more
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Figure 4.1. Growth inhibition of H345 cells by SP-D. A) H345 SCLC cells were
incubated with increasing concentrations of SP-D. Cell number was determined using a
coulter counter at the intervals indicated. Graph is representative of at least two independent
experiments. Data points represent the mean ± s.e.m. of triplicate samples. B) IC50
determination for SP-D using day 12 counts from two independent experiments to plot
curve. Curve fitting was carried out using non-regression analysis of data in Prism. Mean
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Figure 4.2. Growth inhibition of H345 cells by SP-G. A) H345 SCLC cells were
incubated with increasing concentrations of SP-G. Cell number was determined using a
coulter counter at the intervals indicated. Graph is representative of at least two independent
experiments. Data points represent the mean ± s.e.m. of triplicate samples. B) IC50
determination for SP-G using day 12 counts from two independent experiments to plot
curve. Curve fitting was carried out using non-regression analysis of data in Prism. Mean


















Figure 4.3. Growth inhibition of H345 cells by Spantide. H345 SCLC cells were
incubated with increasing concentrations of Spantide. Cell number was determined using a
coulter counter at the intervals indicated. Graph is representative of at least two independent
experiments. Data points represent the mean ± s.e.m. of triplicate samples.
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Figure 4.4. Morphology of sub-confluent vector and GRPR transfected CHO-K1 cells. Top:
Vector transfected CHO-K1 cells have regular elongated shapes. Bottom: CHO-GRP cells are
more rounded and numerous ruffled edges and granules are more apparent (arrows). 32X
magnification DIC images.
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Figure 4.5. Morphology of sub-confluent vector and V^R transfected CHO-K1 cells. Top:
Vector transfected CHO-K1 cells have regular elongated shapes. Bottom: CHO-V^a cells are
more rounded and numerous ruffled edges and granules are more apparent (arrows). 32X
magnification DIC images.
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The growth characteristics of the CHO-GRP and CHO-V^a cells also appeared to
differ from the parental CHO-K1 cells. An investigation into the growth of these
cells in normal liquid culture showed that in the presence of 5% FCS, the CHO-GRP
and CHO-V]a cells initially proliferated at a similar rate to untransfected CHO-K1
cells. However, differences in the growth rates became apparent by the fourth day
after seeding (Figure 4.6). Six days post-seeding, CHO-GRP cells had reached a
density of 4.5 x 106 cells per 100 mm dish. At confluence, the cells did not appear to
be contact inhibited and exhibited the rounded morphology. Cells over grew one
another and significant numbers of cells were observed to be detached and growing
in clusters (Figure 4.7). Trypan blue exclusion revealed that the detached cells were
>95% viable. A similar though less pronounced effect was observed with the CHO-
VlA cells, which reached a density of 3.1 x 106 cells per 100 mm dish. The parental
cell line exhibited normal contact inhibition, had flat epithelial morphology and did
not show significant detachment. The endpoint density of these cells was 2.1 x 106
cell per 100 mm dish. These observations suggest that transfection of GRP and V^a
receptors cause CHO-K1 cells to lose contact inhibition and adopt a more
transformed phenotype.
4.2.2. Effect of substance-P analogues on growth in liquid
culture
The effect of substance-P analogues on CHO-vector, CHO-GRP and CHO-Vja ceU
growth in normal liquid culture was determined by counting cells after a 5 day
incubation with media containing 5% FCS in the presence or absence of 30pM SP-D
or SP-G. Figure 4.8 shows that SP-D inhibited CHO-GRP and CHO-Vja ce"
growth (PO.01, n=2) but not the growth of CHO-vector cells. Similarly, SP-G did not
inhibit the growth of CHO-vector cells whereas CHO-GRP (P<0.01, n=2) and CHO-
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Via (P<0.01, n=2) cell growth was inhibited. This shows that neuropeptide receptor















Figure 4.6. Effect of neuropeptide receptor expression on cell growth. CHO-K1
cells expressing vector, the GRP or Via receptor were plated at a density of lxlO4 cells/100
mm tissue culture dish in 5% FCS and incubated at 37°C. Cells were harvested at various




Figure 4.7. Cell morphology of vector and neuropeptide receptor transfected
CHO-K1 cells at confluence. The rounded cobblestone features and higher cell density
are evident in neuropeptide receptor expressing cells (CHO-GRP- middle panel; CHO-V|^-
right panel) compared to the elongated contact inhibited monolayer exhibited by vector
transfected controls (left panel).
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Figure 4.8. Effect of Substance-P analogues on liquid growth. Vector and
neuropeptide receptor expressing CHO-K1 cells were seeded at a density of lxlO4 cells/100
mm tissue culture dish in 5% FCS media alone (control) or with 30pM SP-D or SP-G. Cells
were harvested following 5 days incubation at 37°C and counted using a coulter counter.
Data is expressed as % of cell numbers in untreated control and represents the mean ± s.e.m.
of 2 experiments performed in duplicate (** P<0.01; ANOVA).
CHO-K1
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4.3 Cell growth in semi-solid media
4.3.1. Effect of neuropeptide receptor expression on growth in
semi-solid media
Growth in semi-solid media is widely regarded as being a hallmark of the
transformed phenotype. The effect of neuropeptide receptor expression on growth
in semi-solid media containing 1% or 5% FCS was examined over an 11 day period.
Cells were trypsinised and suspended in 0.3% agarose in DMEM (1 x 104 cells ml"1)
over a 0.5% layer of agarose in DMEM. Clusters of cells (>6 cells) were visualised by
MTT staining and counted to enable the cloning efficiency of the cells to be
determined. Figure 4.9 shows that following 9 days of growth in 5% FCS, the
cloning efficiency was higher in the GRP expressing cells (14.1 ± 1.5%, P<0.05,
ANOVA) and the receptor expressing cells (8.5 ± 1.0%, P<0.05, ANOVA) than
the vector control cells (5.5 ± 0.02%). Colony formation was also evident in low
serum, although a statistically significant difference in cloning efficiency did not
occur at every time-point. Nevertheless, a trend of increased cloning efficiency was
exhibited, particularly by the CHO-GRP cell line. The results suggest that
neuropeptide receptor expression confers anchorage-independent growth capability
upon CHO-K1 cells.
4.3.2. Effect of substance-P analogues on growth in semi-solid
media
In a separate series of experiments the effects of SP-D and SP-G on cell growth in
semi-solid media were examined. During an 8 day incubation with 30|aM SP-D or
SP-G, both analogues significantly reduced colony formation by CHO-GRP and
CHO-Vja cells, but had no effect on the cloning efficiency of vector control CHO-
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K1 cells (Figure 4.10). This shows that neuropeptide receptor expression confers




































Figure 4.9. Effect of neuropeptide receptor expression on growth in semi-solid
media. Sub-confluent CHO-vector, CHO-GRP or CHO-V^a cells were trypsinised and
suspended (1 x 104 cells ml1) in 0.3% agarose in DMEM containing 1% FCS (top) or 5% FCS
(bottom) over a 0.5% layer of agarose in DMEM. At various time-points, cells were stained
with MTT and colonies (>6 cells) counted at X10 magnification. Bar graph represents the




Figure 4.10. Effect of Substance-P analogues on growth in semi-solid media. Sub-
confluent CHO-vector, CHO-GRP or CHO-V^^ cells were trypsinised and suspended (1 x
104 cells ml ') in 0.3% agarose in 5% FCS-DMEM in the absence (open bar) or presence of
30pM SP-D (black bar) or SP-G (grey bar) over a 0.5% layer of agarose in DMEM. After an 8
day incubation at 37°C, cells were stained with MTT and colonies (>6 cells) counted at XI0
magnification. Bar graph represents the mean ± s.e.m. of three experiments performed in
duplicate (*P<0.05, ANOVA).
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4.4 Cell growth in suspension
4.4.1. Effect of neuropeptide receptor expression on growth in
suspension
An alternative method for evaluating the transformed phenotype is through an
aggregation assay where cells are prevented from adhering to solid substrata and
instead grow as aggregates in suspension. The effect of receptor expression on
growth in suspension was examined. Stably transfected CHO-K1 cells were
suspended in DMEM containing 1% or 5% FCS and seeded at a density of 2xl04 cells
per well into ultra low attachment tissue culture plates over a solid base of 0.5%
agar. Cells were maintained in culture for up to 9 days and viable cell number
determined at various time-points by T0-PR03 exclusion. There was no significant
difference between the ability of these cell-lines to grow as aggregates in media
containing 1% FCS (Figure 4.11). However, by the fifth day of growth in suspension
in media containing 5% FCS, a small difference in growth was observed in receptor
expressing cell-lines relative to CHO-vector cells. This provides further evidence to
suggest that neuropeptide receptor expression leads to CHO-K1 cell transformation.
In addition, the morphology of the cell aggregates also differed between vector and
receptor transfected cells growing in 5% FCS. Figure 4.12 shows that whereas CHO-
vector cells formed large, compact aggregates when grown in suspension, receptor
expressing cells grew in numerous small clusters.
4.4.2. Effect of substance-P analogues on growth in
suspension
The effect of SP-G on cell growth in suspension was examined by treating cells with
increasing concentrations of SP-G. After 7 days, cell clusters were disaggregated and
viable cells counted. Figure 4.13 shows that SP-G inhibited CHO-GRP and CHO-
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VlA ce" growth and a slight effect on the growth of CHO-vector cells. This shows
that neuropeptide receptor expression confers sensitivity to substance-P analogue-
induced growth inhibition.
4.5 Effect of neuropeptide receptor expression on
chemosensitivity
Since neuropeptide receptor expression led to cell transformation, it was of interest
to determine whether receptor expression had any impact on sensitivity to
chemotherapeutic drugs. This was assessed through treating vector and receptor
transfected cells with etoposide in the absence or presence of neuropeptides and
measuring cell growth by MTT accumulation in viable cells. As shown in Figure
4.14, after a 48h treatment with etoposide in serum-free media, a dose-dependent
inhibition of proliferation was observed in all cell types (IC50 = 12.4 ± 3.1, 8.1 ± 2.3
and 14.2 ± 4.0 pg ml1 in CHO-vector, CHO-GRP and CHO-Vja ce"s respectively).
Co-incubation of CHO-GRP and CHO-V^a cells with 50 nM bombesin or AVP
respectively, produced a small but significant protection from etoposide which was
not observed when both neuropeptides were added to CHO-vector cells (IC50 = 13.0
and 26.9 pg ml"1 in control and AVP treated CHO-Vja ceHs respectively; and 6.30
and 12.7 pg ml1 in control and bombesin treated CHO-GRP cells respectively). At
40 pg ml 1 etoposide, vasopressin treated CHO-Vja cells accumulated 92% more
MTT than control cells (P<0.01). In GRPR expressing cells, bombesin treatment
caused a 52% increase in MTT accumulation compared to untreated cells (P<0.01).
































Figure 4.11. Effect of neuropeptide receptor expression on growth in suspension.
CHO-vector, CHO-GRP and CHO-V^a ce^s were seeded (2 xlO4 cells in media containing
1% FCS (top) or 5% FCS (bottom)) into low adhesion tissue culture plates over a base layer of
0.5% agarose in DMEM. Cells were incubated at 37°C for various time intervals. At each
time-point, cells were briefly trypsinised to disaggregate clusters and viable cells counted by
T0-PR03 exclusion using FACS. Bar graphs represent the mean ± s.e.m. of two experiments





Figure 4.12. Morphology of cell aggregates. Morphology of CHO-vector, CHO-GRP
and CHO-Vja cells after 9 days growth in suspension in media containing 5% FCS. CHO-
vector cells grow as large, compact aggregates whereas neuropeptide receptor expressing
cells form smaller, but more numerous clusters. Representative images are shown (xlO
magnification)
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Figure 4.13. Effect of SP-G on growth in suspension. CHO-vector, CHO-GRP and
CHO-Vja cells were seeded (2 xlO4 cells in media containing 5% FCS) into low adhesion
tissue culture plates over a base layer of 0.5% agarose in DMEM with increasing
concentrations of SP-G. Cells were incubated at 37°C for 7 days then briefly trypsinised to
disaggregate clusters. Viable cells were counted by TO-PR03 exclusion using FACS. Data
represents the mean ± s.e.m. of two experiments performed in duplicate.
CHO-vector CHO-GRP CHO-V1A
[Etoposide] pg ml-1 [Etoposide] pg ml-1 Etoposide] pg ml"1
Figure 4.14. Effect of neuropeptide on chemosensitivity. CHO-vector (left), CHO-
GRP (middle) and CHO-Vj^ (right) cells were plated at a density of 1 xlO4 cells per well of a
96 well tissue culture plate in 10% FCS-DMEM and incubated overnight at 37°C. Cells were
then incubated in serum-free media containing etoposide as indicated and in the absence
(filled squares) or presence of 50nM GRP (open circles), 50nM AVP (open squares) or both
neuropeptides (CHO-vector cells) for 48 hrs at 37°C. Cell viability was assessed by MTT
staining. Results are expressed as % viability in the absence of neuropeptide and represents
mean ± s.e.m. of four independent experiments (* P<0.05 = significantly different from
control cells, ANOVA).
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4.6 Effect of neuropeptide receptor expression on cell
adhesion and migration
A combination of events contribute to the invasive process in cancer, with initial
changes in adhesive properties allowing transformed cells to migrate, gain access to
the circulation and form metastatic colonies (Aprikian et al, 1997). Various
neuropeptides have been shown to stimulate monocyte and human tumour cell
chemotaxis (Ruff et al, 1985; Cuttitta et al, 1985; Festuccia et al, 1998). In addition,
monocyte chemotaxis towards SP-D has been demonstrated to occur via bombesin
receptors suggesting that the biased agonist activity of these analogues may play a
role in normal and tumour cell migration. The work described in this section was
carried out in order to investigate the migratory and adhesive properties of the
neuropeptide receptor expression-transformed cells.
4.6.1. Modulation of cell migration by neuropeptide receptor
expression
Chemotactic migration of vector and neuropeptide transfected cells through
fibronectin coated filters (8pm pore) was measured in a 96 well format following
four hours incubation at 37°C. Cells suspended in 0.1% BSA were added to the
upper chamber and chemoattractants added to the lower chamber of the transwell
migration plates. In experiments assessing chemotaxis towards FCS (lower
chamber), it was found that CHO-GRP and CHO-Vja cells migrated more than
CHO-vector cells (Figure 4.15). Similarly, receptor expressing cells migrated more
than CHO-vector cells towards IGF-1 (Figure 4.16). However, the magnitude of the
chemotactic response to substance-P analogues was similar in all three cell-lines
(Figure 4.17). Together these results show that expression of neuropeptide receptors
enhances CHO-K1 cell migration generally to growth factors but is not agonist-
specific.
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4.6.2. Modulation of cell adhesion by neuropeptide receptor
expression
Cell interaction with extracellular matrix (ECM) proteins influences a tumour cell's
ability to form metastases at distant sites. CHO-vector, CHO-GRP and CHO-Vja
cell adhesion to the ECM component fibronectin (Fn) was measured by incubating
cells (suspended in 0.1% BSA) for 20 min at 37°C in Fn-coated 96 well tissue culture
plates. CHO-GRP and CHO-V^a cell adhesion to Fn was reduced (50 ± 9% and 55 ±
13% respectively) compared with the adhesiveness of CHO-vector (69 ± 5%) cells
(Figure 4.18). The basal level of adhesion of each cell-line to Fn-coated plates was
not significantly altered by incubation with neuropeptides, substance-P analogues
or IGF-1 (data not shown). This suggests that neuropeptide receptor expression





Figure 4.15. Effect of neuropeptide receptor expression on chemotactic response to
ECS. Sub-confluent CHO-vector, CHO-GRP and CHO-y^A ce"s were resuspended in
DMEM containing 0.1% (w/v) BSA and 1x10s cells added to the upper chamber of a 96
transwell migration plate with fibronectin (1 Oug ml1) coated filters. FCS was added to the
lower chamber and migration allowed to proceed for 4hrs at 37°C. Migration was evaluated
as described in materials and methods. Bar graphs represent the OD of agonist-induced
migration relative to OD of BSA-induced migration and are the mean ± s.e.m of at least two
experiments performed in quadruplicate (^significantly different from vector control cells
P<0.05, ANOVA).
Figure 4.16. Effect of neuropeptide receptor expression on chemotactic response to
IGF-1. Sub-confluent CHO-vector, CHO-GRP and CHO-y^ cells were resuspended in
DMEM containing 0.1% (w/v) BSA and 1x10s cells added to the upper chamber of a 96
transwell migration plate with fibronectin coated filters (10pg ml"1). IGF-1 [lOOng ml1] was
added to the lower chamber and migration allowed to proceed for 4hrs at 37°C. Migration
was evaluated as described in materials and methods. Data represents the OD of agonist-
induced migration relative to OD of BSA-induced migration and is the mean ± s.e.m of at
least two experiments performed in quadruplicate (*P<0.05, **P<0.01, significantly different







Figure 4.17. Effect of neuropeptide receptor expression on chemotactic response to
substance-P analogues. Sub-confluent CHO-vector (A), CHO-GRP (B) and CHO-V^a (C)
cells were resuspended in DMEM containing 0.1% (w/v) BSA and 1x10s cells added to the
upper chamber of a 96 transwell migration plate with fibronectin (10pg ml4) coated filters.
30pM SP-D or SP-G was added to the lower chamber and migration allowed to proceed for
4hrs at 37°C. Migration was evaluated as described in materials and methods. Data
represents the OD of agonist-induced migration relative to OD of BSA-induced migration



















Figure 4.18. Effect of neuropeptide receptor expression on cell adhesion. Sub-
confluent CHO-vector, CHO-GRP and CHO-y^A cells were resuspended in DMEM
containing 0.1% (w/v) BSA. 2xl04 cells were added to fibronectin-coated (10pg ml1) wells of
a 96 well tissue culture plate and allowed to adhere for 20 min at 37°C. Adhesion was
evaluated as described in materials and methods. Results represent the % adhesion relative
to control where all cells adhered and are the mean ± s.e.m of at five experiments performed




The oncogenic nature of GPCRs was first highlighted through screening analyses for
novel oncogenes whose expression caused the cellular transformation of NIH3T3
mouse fibroblasts. The first GPCR identified to possess transforming properties in
this manner was the product of the mas oncogene (Young et al, 1986). It has since
been discovered that chronic stimulation or mutational activation of mitogenic
receptors can also lead to oncogenic transformation (Whitehead et al, 2001). The
effect of GRP and receptor expression, the two most common neuropeptide
receptors present on SCLC, on growth and transformation of the epithelial CHO-K1
cell-line was examined. Data presented in this chapter shows that expression of
these receptors transforms CHO-K1 cells and also leads to increased sensitivity to
substance-P analogues. Ectopic expression of neuropeptide receptors in epithelial
CHO-K1 cells led to morphological transformation of the cells, increased saturation
density, in monolayer culture and an anchorage-independent phenotype. The study
also found that expression of neuropeptide receptors had an impact on the adhesive
and migratory properties of CHO-K1 cells.
The morphological and behavioural characteristics of transformed cells are distinct
from those of counterpart normal cells. The acquisition of anchorage-independent
growth is an indicator of the transformed status of a cell population and is
commonly demonstrated through colony formation assays in semi-solid media
(MacPherson & Montagnier, 1964; DiPaolo et al, 1969; DiPaolo et al, 1972). Although
in vivo tumourigenicity provides verification for cell transformation, it has been
demonstrated that colony formation in soft-agar does not necessarily indicate
tumourigenic potential (Steuer et al, 1977). In contrast, the ability of various
clonogenic cell types to survive in suspension in aggregate form has been shown to
correlate with tumourigenicity (Steuer et al, 1977). Using fibroblast and epithelial
cell types from various species (including humans) it was demonstrated that only
those cells which were tumourigenic were able to survive and grow in aggregate
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form. Thus, growth in suspension can be used as an alternative assessment of cell
transformation.
Data presented in this chapter showed that neuropeptide receptor expressing cells
proliferated more than vector-transfected control cells when cultured as
monolayers. In addition, although vector-transfected CHO-K1 cells were able to
form colonies in soft agar and grow as multicellular aggregates in suspension, these
capabilities were enhanced in cells expressing neuropeptide receptors. Under
normal circumstances, detachment of non-transformed epithelial cells from their
substratum induces a specialised form of apoptosis called anoikis (Wei et al, 2001).
The cell-type dependent phenomenon is thought to constitute a protective
mechanism which operates to prevent growth of displaced epithelial and
endothelial cells in inappropriate environments (Bretland et al, 2001). In the present
study, only around 5% of the cell population was non-viable following 9 days
growth in suspension (data not shown) which indicates resistance to detachment
induced apoptosis. The establishment of epithelial cell-lines can be hindered by
sensitivity to anoikis, a factor which has been found to affect the development of
non-transformed colonic epithelial cell-lines but not colonic tumour cell-lines
(Bretland et al, 2001). Therefore, through the initial process of establishing the CHO-
K1 cell-line, a degree of anoikis-resistance may have been acquired which could
account for the ability of this cell-line to survive detachment from the ECM and
grow under anchorage independent conditions at all.
Since cell growth in suspension occurs in the absence of cell-ECM interaction,
growth as multicellular aggregates has also provided a means of assessing the
involvement of intercellular adhesion (Kantak & Kramer, 1998). Data presented in
this chapter showed that when grown in suspension, neuropeptide receptor
expressing cells formed morphologically different aggregates to vector transfected
CEIO-Kl cells which could be attributed to altered intercellular adhesion. In
accordance with the findings of the present study, alteration of cultured epithelial
cell morphology by another neuropeptide receptor (gastrin/cholecystokinin-2
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receptor) has been demonstrated recently and the receptors found to modulate
intercellular adhesion and cell differentiation in vivo (Bierkamp et al, 2004).
Cadherins mediate intercellular adhesion as components of adhesion junctions and
play an important role in epithelial morphogenesis (Vizirianakis et al, 2002). Human
breast cancer cells transfected with a dominant-negative form of E-cadherin fail to
compact and remain as loosely associated cells (similar here to neuropeptide
receptor expressing cells) whereas wildtype cells form multicellular aggregates that
tightly compact into spheroids (similar here to vector transfected CHO-K1 cells)
(Vizirianakis et al, 2002). Also, just as the dominant-negative E-cadherin transfected
breast cancer cells had an increased proliferation rate; neuropeptide receptor-
expressing cells similarly demonstrated increased growth in suspension. Metastatic
fibroblasts have also been shown to form morphologically different aggregates, with
normal cells forming compact aggregates and transformed cells forming loose
aggregates (Matsuyoshi et al, 1992). As a consequence of neuropeptide receptor
expression in cells, it is conceivable that fluctuations in E-cadherin mediated cell
adhesion could arise due to signals transduced by the receptors. This has previously
been demonstrated for other GPCRs such as the M3 muscarinic acetylcholine
receptor (mAChR) in SCLC (Williams et al, 1993), and led to the hypothesis that
neoplastic transformation induced by activation of this neurotransmitter receptor or
other GPCRs may involve receptor mediated changes in adhesion molecule activity.
The degree of altered morphology observed in the present study may correlate with
neuropeptide receptor expression levels since CHO-V^a cells, which express less
receptors than CHO-GRP, form aggregates which are more CHO-like in appearance
or intermediate between CHO-vector and CHO-GRP in appearance. This suggests
that a correlation between neuropeptide receptor expression and modulation of
intercellular adhesion may also exist.
In addition to increased proliferation, neuropeptide receptor expressing cells were
not subject to density-dependent inhibition of growth. This provides further
evidence that the neuropeptide-receptor expressing cells are able to over-ride
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growth inhibitory signals, consistent with a transformed phenotype. Glover et al
(2005) maintain that GRP acts as a morphogen when it and its receptor (GRP-R) are
aberrantly upregulated in colon cancer, primarily modulating processes which
contribute to the assumption or maintenance of tumour differentiation. Studies
using a colon cancer cell-line showed that when cells were plated at subconfluent
densities, GRP/GRPR were rapidly upregulated followed by their progressive
decrease as confluence was achieved (Glover et al, 2005). Relative to this finding,
constitutive receptor expression in GRP or receptor expressing cell-lines may
enable the cells to continue growth even after confluence has been achieved.
CHO-GRP and CHO-Via cells also exhibited a rounded morphology and increased
membrane ruffling compared with CHO-vector cells, which could be taken as a
primary indication that increased Rho/Rac activity exists in the neuropeptide
receptor expressing cells. Small GTPases of the Rho family, primarily Rac, cdc42 and
Rho, regulate actin organisation and have been identified as key regulators of
epithelial architecture, as well as of cell migration (Sugimoto et al, 2003). Activation
of Rho GTPases is mediated by G protein alpha 12 and alpha 13 subunits (Buhl et al,
1995), and both bombesin and vasopressin have been shown to stimulate Rho-
dependent responses through receptor coupling to G12/G13 proteins (Gohla et al,
1999; Yuan et al, 2001). Rho mediates LPA- and bombesin-induced formation of focal
adhesions and actin stress fibres in Swiss 3T3 cells, whilst Rac is required for the
PDGF-, insulin- and bombesin-stimulated actin polymerisation at the plasma
membrane that results in membrane ruffling (Nobes et al, 1995). In addition, Rho
GTPase activity has been shown to contribute to cell rounding, transformation and
hypertrophic growth (Morissette et al, 2000; Sah et al, 2000). Studies of the signalling
and transforming properties of numerous GPCR oncoproteins have also shown that
abnormal growth regulation is promoted through Rho GTPase activation
(Whitehead et al, 2001). It could therefore be informative to determine whether Rho
family GTPases play a role in the changes in morphology and growth effected by
neuropeptide receptor expression in CHO-K1 cells.
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As mentioned previously, as well as having a greater propensity to form non¬
adherent clusters in suspension, cells expressing neuropeptide receptors also
formed colonies in semi-solid agarose with greater efficiency than vector-transfected
control cells. Since colony growth was also evident in low serum, these findings
suggest that expression of these receptors allows for anchorage- and serum-
independent growth consistent with transformation. Moreover it suggests that these
receptors may be constitutively active, as wild type receptor expression alone was
sufficient to increase transformation in the absence of exogenously added
neuropeptide. Alternatively, the effect of neuropeptide receptor expression on
CHO-K1 cell growth could be attributed to the existence of an autocrine growth
loop.
Constitutive receptor activity has been observed at low and high GPCR expression
levels, in native and recombinant systems, and has been reported for GPCRs
irrespective of G-protein coupling specificity (Seifert & Wenzel-Seifert, 2002). In
accordance with the findings here, Ferris et al (1997) also found that expression of
GRPR in a non-malignant human colon epithelial cell-line led to increased
proliferation. However, since the GRPR does not cause proliferation of all cells in
which it is expressed (Benya et al, 1994b), the tissue milieu is thought to influence
the ability of a GPCR to act as an oncogene (Ferris et al, 1997). In addition, the
intrinsic molecular properties of the GPCR studied can also contribute to basal
GPCR activity. Differences in GPCR expression level, GPCR desensitization, G-
protein complement and GPCR/G-proteiri stoichiometry can all contribute to
variations in constitutive activity observed in different systems (Seifert & Wenzel-
Seifert, 2002). This could explain why GRP receptors expressed in NCM460 cells, a
non-malignant human colon epithelial cell line are constitutively active (Ferris et al,
1997) but are not in other cell types (Benya et al, 1994a). A physiological
requirement for constitutive GPCR activity is likely to exist. For example, it is
thought that constitutive neurotransmitter GPCR activity may be necessary to
support basal neuronal activity (Seifert & Wenzel-Seifert, 2002).
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The activation of multiple cell-specific signal transduction pathways following GRP
or AVP receptor stimulation controls cell proliferation through the induction of
immediate early gene expression (Rozengurt, 1991; Schulze-Lohoff et al, 1993; Benya
et al, 1994b). The immediate-early gene products c-fos and c-jun form heterodimers
that stimulate expression of genes containing API activation elements (Schulze-
Lohoff et al, 1993; Hipskind et al, 1994; Beno et al, 1995). Since the GRP gene has a 5'-
upstream API binding site (Kim et al, 2000), GRP expression can potentially be
stimulated through GRP receptor activation (Bajo et al, 2002) which would result in
the formation of an autocrine growth loop. Analysis of the AVP gene promoter
region has identified the presence of AP-1, AP-2, E-box and neuron-restrictive
silencer element (NRSE) binding sites which are involved in the regulation of AVP
expression (Grace et al, 1999; Coulson et al, 1999b; Coulson et al, 1999a). Selective
vasopressin gene expression in SCLC but not normal lung or NSCLC has been
attributed to differential activity of the transcriptional regulator Upstream
Stimulatory Factor (USF) in the lung tissues (Coulson et al, 2003b). In principle,
neuropeptide receptor activity could thus stimulate transcription factors which
result in neuropeptide gene expression and the subsequent formation of an
autocrine growth loop. Whether the neuropeptide receptor expressing cells
expressed the associated neuropeptide ligand was not determined in this study.
However, numerous granules were observed to be present in the cytoplasm of
neuropeptide receptor expressing cells and less apparent in vector-transfected
CHO-K1 cells. It is quite possible that these dense granules, reminiscent of the intra-
cytoplasmic vesicles which characterise SCLC cells, were storage vesicles for
synthesised neuropeptide. If this were the case, it would indicate regulated rather
than constitutive secretion of the neuropeptide since there is no storage of peptides
in cells with constitutive secretion (Rehfeld, 1998). Had these cell-lines been assessed
for neuropeptide secretion (e.g. by immunofluorescent staining of cells using
antibodies against bombesin or vasopressin), the existence of an autocrine growth
loop could have been determined. This would provide a biological basis for receptor
activity and increased growth in the absence of exogenously added ligand in the
167
CHO cell systems. It is important to note that although receptor expressing cells
demonstrated increased growth in the absence of exogenously added ligand, this
does not demean the findings presented in chapter 3 which resulted from
stimulation of cells with neuropeptide. Together these findings show that although
neuropeptide receptors expressed in CHO-K1 cells may be constitutively active,
they are still able to respond to stimulation with neuropeptide with subsequent
changes in intracellular calcium levels and ERK activity.
Whatever the precise basis for increased neuropeptide receptor activity, the present
study demonstrates that Vq a receptors, as well as GRP receptors, are oncogenic
when expressed in epithelial cells. As discussed earlier, while GRP receptor
expression has been shown to transform some cell-types, to my knowledge, this has
not previously been demonstrated directly for receptors. This finding may be
of particular relevance to lung cancer biology since all SCLC cell-lines have been
shown to express an AVP autocrine system (Coulson et al, 1999; Waters et al, 2003).
The actual mechanisms governing the survival advantage gained in neuropeptide
receptor expressing cells are poorly understood. During colon cancer progression,
increased expression of GRP receptors leads to tumour cell differentiation, increased
motility and adhesion to extracellular matrix via an increased activation of focal
adhesion kinase (FAK) (Glover et al, 2004). As discussed in chapter 3 (page 132),
transactivation of EGF receptors can occur through GPCR stimulation. The
significance of GPCR/EGFR cross-talk in SCLC growth is demonstrated through the
finding that the Bn/GRP antagonist RC-3095 inhibits SCLC growth through a
mechanism which involves downregulation of both GRP and EGF receptors
(Halmos & Schally, 1997; Koppan et al, 1998). IGF-1 stimulation of COS-7 cells also
results in EGFR transactivation (Roudabush et al, 2000) which is of significance since
the IGF-I/IGF-IR autocrine loop plays a prominent role in SCLC growth
(Warshamana-Greene et al, 2004). Bombesin antagonists in combination with GHRF1
antagonists have been shown to down regulate IGF-1, IGF-II, IGF receptors, GRP
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and EGF receptors in SCLC and prostate cancer xenografts (Plonowski et al, 2000;
Kanashiro et al, 2003). Bombesin antagonists also inhibit the expression of bFGF,
IGF-II and vEGF-A in human experimental breast cancers (Bajo et al, 2004), therefore
heterologous regulation of RTKs by bombesin is not restricted to effects on the
EGFR alone. Further to this, it is conceivable that similar transmodulation of other
tyrosine kinase growth factor receptors by neuropeptide receptors may facilitate
regulation of signalling pathways that control survival. Transactivation of the IGF-
1R by GRP or receptors may particularly contribute to anchorage-independent
growth as the receptor mediates signalling through both proliferative and anti-
apoptotic pathways (Roudabush et al, 2000).
Dysregulated growth is believed to constitute an early event in the transformation
process, with alterations in adhesive, migratory and invasive properties
contributing to the subsequent development of metastatic potential. It has been
hypothesised that increased cell motility (migration) is necessary for cells to become
metastatic since metastatic tumour cells generally migrate at a faster rate than
normal cells or non-metastatic tumour cells (Parsons et al, 2002). It has previously
been postulated that high bombesin/GRP receptor mRNA levels correlate with more
invasive characteristics of human colon tumours (Saurin et al, 1999). In the same way
that bombesin/GRP receptor expression may contribute to the cellular events that
are critical for invasion/migration of colorectal carcinoma cells (Saurin et al, 2002), a
similar role for GRP and receptor expression in CHO-K1 cells may exist. Data
presented in this chapter showed that neuropeptide receptor expressing cells
displayed greater chemotactic migration towards FCS and IGF-1 than vector
transfected control cells in transwell migration assays. Previous reports have shown
that GRP receptors can activate insulin-like growth factor-1 receptors (IGF-IR) in
prostate cancer cells (Sumitomo et al, 2001) and that human chorionic
gonadotrophin (hCG) upregulates IGF-1 expression in ovarian cancer cells (Kuroda
et al, 1998). Transmodulation of IGF or other growth factor receptors by
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neuropeptide receptors may therefore underlie the enhanced chemotactic response
of neuropeptide receptor expressing cells towards growth factors.
Monocyte chemotaxis towards SP-D has previously been demonstrated to occur via
bombesin receptors suggesting that the biased agonist activity of these analogues
may play a role in normal and tumour cell migration (Djanani et al, 2003). In the
present study however, cell-lines transfected with vector or neuropeptide receptors
displayed similar chemotactic responses to SP-D or SP-G suggesting that the effects
were not neuropeptide receptor-mediated. Previous work has shown that SP-D
stimulates migration of human neutrophils, which express various chemoattractant
receptors (including two IL-8 receptor subtypes) as well as the substance-P receptor
(NK-1) (Jarpe et al, 1998). Although the identity of the receptor involved in the
chemotactic response of neutrophils to SP-D was not determined, it was proposed
that the IL-8 receptor may mediate this effect since SP-D binds to this receptor (Jarpe
et al, 1998). As mentioned in chapter 3 (page 136), sphingosine-1-phosphate induced
intracellular calcium mobilisation in CHO-K1 cells indicating the cells express
receptors for this chemoattractant. Sphingosine-l-phosphate performs a variety of
roles, including the regulation of cell migration, mediated through members of the
EDG (endothelial differentiation gene) family of GPCRs (Okamoto et al, 2000).
Therefore, it is conceivable that the substance-P analogues may have stimulated a
chemotactic response via such receptors endogenously expressed in CHO-K1 cells.
Neuropeptide receptor expressing cells failed to demonstrate a chemotactic
response to the cognate neuropeptide (data not shown) and this could be attributed
to the receptor's being constitutively active. In this case, it is likely that a
chemotactic response was not elicited at the concentrations of neuropeptide tested
(InM and lOnM; data not shown) because the receptors are already active. It is
important to note that the interpretation of data from the migration assay will differ
from that of the growth assays since the former is measuring the response to the
chemotactic gradient presented to cells whereas the latter is measuring basal levels
of growth in the absence of exogenously added neuropeptide.
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Since cell movement is controlled by a complex coordinated series of
rearrangements of the actin cytoskeleton and changes in adhesion, the intracellular
regulators of cytoskeletal organisation and cellular adhesion strength are likely to be
crucial determinants of cell motility (Fincham & Frame, 1998). Cell adhesion is
thought to occur through a 3-step process: 1) attachment, 2) spreading and 3) focal
adhesion and stress fiber formation (Murphy-Ullrich, 2001). The second step is
considered to be an intermediate state between that of weak contact and strong
adhesion and is believed to be the level of cellular adhesive strength at which
migration occurs (Schwarzbauer, 1997). In accordance with this, data presented in
this chapter showed that more migratory neuropeptide receptor expressing cells
were less adherent than vector transfected CHO-K1 cells on the ECM component
fibronectin. The level of adhesiveness was not significantly altered by
neuropeptides, substance-P analogues or IGF-1. This suggests that neuropeptide
receptor expression influences cellular adhesiveness overall, consequently enabling
cell migration to be increased in response to particular chemotactic gradients. In
order to do this, neuropeptide receptors may influence intracellular signalling
pathways which regulate cell-cell and cell-ECM interactions. In this respect, the
focal adhesion components FAK and paxillin have recently been implicated in
facilitating cross-talk between cell-cell and cell-ECM adhesions (Schaller, 2004). The
findings of abnormal intercellular adhesions, together with reduced cell-ECM
interactions in neuropeptide receptor expressing cells could be relevant to the ability
of cells to detach from tumours and metastasise. Thus neuropeptide receptor
expression may make a greater contribution to tumour development and
progression than has previously been recognized.
Sensitivity to AVP and GRP has previously been shown to increase during the
progression to chemoresistance in a set of SCLC cell lines (Waters et al, 2003). This
would be analogous to the development of autocrine and paracrine growth loops in
tumour development in vivo, with tumour cells becoming more dependent on
neuropeptide growth factors for survival and subsequently developing
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chemoresistance. Likewise, data presented in this chapter showed that stimulation
of neuropeptide receptor expressing cells with neuropeptides led to a small but
significant increase in resistance to the cytotoxic effects of etoposide. Although it is
presently unclear how this change in sensitivity relates to the development of
chemoresistance in vivo, this finding highlights an important area for future
investigation. However, these findings do suggest that the increase in neuropeptide
receptor expression that occurs as cells become more differentiated may contribute
to the development of chemoresistance. Since the acquisition of chemoresistance by
SCLC cells underlies the extremely poor prognosis associated with this form of lung
cancer, a greater understanding of the mechanism underlying chemoresistance of
neuroendocrine tumours may lead to the identification of novel treatment strategies.
A possible mechanism leading to the development of chemoresistance in
neuroendocrine cells may involve transactivation of IGF-1 receptors by
neuropeptide receptors since the stimulation of growth by IGF-1 has been shown to
enhance SCLC resistance to the apoptotic effect of chemotherapy (Krystal et al, 2002).
Data presented in this chapter showed that SP-D and SP-G inhibited H345 SCLC
growth, providing confirmation that the substance-P analogues selected for
investigation do indeed inhibit the growth of SCLC cells. The finding that these two
analogues, but not spantide, inhibit H345 growth is in accordance with previous
results (Woll & Rozengurt, 1990). During the phase I clinical trial of SP-G, plasma
levels up to 40pM were obtained in the absence of dose limiting toxicity (Clive et al,
2001). The IC50 values for both SP-D and SP-G obtained in this study are well
within this limit. Substance-P analogues effectively inhibit the growth of
chemoresistant tumour cells and can increase the sensitivity of such cells to
etoposide-mediated cell death (Waters et al, 2003). In addition, the sensitivity of
diverse tumour types to SP-D correlates with GRP receptor expression (Waters et al,
2003). In accordance with this, data presented in this chapter similarly shows that
GRP receptor expressing CHO-K1 cells are more sensitive to growth inhibition by
substance-P analogues. In addition, expression of V]A receptors in CHO-K1 cells
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confers sensitivity to substance-P analogue induced growth inhibition. This was
demonstrated through the inhibition of anchorage dependent and independent
growth by substance-P analogues in receptor-transfected but not control cells.
Substance-P analogues have previously been shown to inhibit anchorage
independent growth of SCLC, ovarian, cervical and pancreatic cancer cells (Bepler et
al, 1988; Everard et al, 1992; Guha et al, 2005). Also consistent with the findings here,
SP-D has previously been shown to have more potent antiproliferative effects on
tumour cells than normal cells (Everard et al, 1992). Since anti-cancer drugs should
preferably exert minimal side-effects, this suggests that substance-P analogues may
be ideal candidates for specifically targeting transformed neuropeptide-dependent
cells with minimal effects on normal cells.
Bunn et al (1994) previously demonstrated that substance-P analogues were more
effective in inhibiting SCLC growth than specific bombesin and vasopressin
antagonists. As demonstrated in chapter 3, the substance-P analogues functioned as
biased agonists of the GRP and Vj a receptor in CHO-GRP and CHO-V^a cell-lines
respectively. The substance-P analogues modulated GRPR and Vj^R signalling,
causing blockade of Gq-mediated Ca2+ release while inducing Gpmediated ERK
activation via a pertussis toxin-sensitive pathway. Data presented in the current
chapter shows that these biased agonist properties selectively result in anti¬
proliferative effects in neuropeptide receptor expressing cells. These findings
support the concept that the biased agonist properties of substance-P analogues are
central to the growth inhibitory effects of these compounds. Maudsley et al (2004)
have similarly demonstrated that the anti-proliferative effects of Gonadotrophin-
releasing hormones (GnRH) and GnRH analogues in reproductive tumour cells
correlate with the ligand-selective activation of a Gap-coupled form of the type I
GnRH receptor. They found that structurally related antagonistic GnRH analogues
displayed divergent anti-proliferative efficacies but equal efficacies in inhibiting
GnRH-induced Gaq-based signalling, indicating that the growth inhibitory effects
were determined by the ability of the ligands to stabilise/induce a Gj-coupled state
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of the GnRH receptor. Spantide does not inhibit SCLC growth although it is able to
inhibit GRP binding and block Gq-based signalling (as demonstrated in chapter 3).
Thus, enhanced anti-proliferative activity can be related to the ability of substance-P
analogues to activate a Gi-coupled state of neuropeptide receptors. This should have
implications for the future identification of drugs which can effectively target SCLC
and other neuropeptide-dependent tumours.
In summary, introduction of neuropeptide receptors into CHO-K1 cells led to
phenotypic transformation of the cells, suggesting a role for neuropeptide receptors
in tumour development and progression. In particular, neuropeptide receptor
expression conferred an advantage upon the cells growing under both anchorage
dependent and independent conditions. Neuropeptide receptor expression altered
cell-cell and cell-ECM interaction and led to changes in cell motility. All of these
effects were observed in the absence of exogenously added neuropeptides
suggesting that these receptors may be constitutively active when expressed in
CHO-K1 cells. It was also found that neuropeptide receptor stimulation may
contribute to an increase in chemoresistance. Neuropeptide receptor expression
conferred sensitivity to the growth inhibitory effects of these agents since A and
GRP receptor expressing cells were more sensitive to substance-P analogue induced
growth inhibition than vector-transfected CHO-K1 cells. Moreover, the anti¬
proliferative effects of the analogues in neuropeptide receptor expressing cells
correlated with biased agonist properties in those cell-lines. The study demonstrates
that the therapeutic use of these compounds need not be restricted to tumours
expressing GRP receptors only, and could be extended from SCLC therapy to
targeting various transformed cell types with neuropeptide dependence. In
addition, these biased agonist compounds may be particularly effective in targeting
well-differentiated tumours that have developed resistance to chemotherapy.
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Chapter 5
The underlying basis for Substance-P analogue
biased agonism of Vasopressin receptors
Biased agonism is the ability of a ligand to interact with a receptor and differentially
regulate each of the multiple signalling pathways coupled to a receptor. It is also
known as 'functional selectivity', 'stimulus trafficking' and 'Agonist Directed
Trafficking of Receptor Stimulus' (ADTRS) (Clarke, 2005). The mechanism
underlying this behaviour is thought to be dependent on the ability of ligands to
promote unique, ligand-selective receptor conformations that regulate signal
transduction pathways with distinct efficacies. Receptor number and receptor:G
protein stoichiometry as well the specific identity of the G-proteins activated are
factors which can influence the efficacy with which a compound activates different
signalling cascades (Cussac et al, 2002). Alteration of the receptor/G-protein
stoichiometry has been shown to change the coupling specificity of various GPCRs.
Agonist-directed trafficking at human a2A-adrenoreceptors was found to be
dependent on the level of receptor expression and the presence of receptor reserve
(Brink et al, 2000). Low level expression of the Vib receptor in CHO cells resulted in
receptor coupling to G-proteins of the Gq family whereas at higher expression
levels, Gi- and Gs- coupling was also observed (Thibonnier et al, 1997). A similar
study using the Gs-coupled V2 receptor revealed that the receptors coupled to Gq-
proteins when expressed in high numbers (Zhu et al, 1994). The first part of this
study (sections 5.1 and 5.2) was conducted in an attempt to evaluate whether the
receptor:G protein stoichiometry influenced the biased agonist activity of substance-
P analogues on neuropeptide receptors. The receptor:G protein stoichiometry was
altered in two ways: by changing receptor density while maintaining endogenous
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G-protein expression levels (section 5.1) and through over expression of specific G-
protein sub-units at a fixed receptor density (section 5.2).
5.1. Effect of altering receptor numbers on SP-G activity
5.1.1. Generation of cells with varying Via receptor densities
Cell-lines stably expressing different numbers of V^a receptor were generated
through transfecting CHO-K1 cells with lOpg, 20pg or 30pg V^aR cDNA as
described in materials and methods. Individual clones were obtained through
selection and screening in a manner analogous to that used to establish CHO-GRP
and CHO-Via cell-lines (as described in section 3.1). Receptor expression in seven
clones (positive for AVP calcium response) was assessed by measuring [3H]-AVP
binding to cell membranes in order to identify three clones with varying levels of
receptor expression (Figure 5.1). Of the seven clones, 30b, 20i and lOd were chosen
to represent a high (V^AR-high), medium (VjAR"med) and low (V|aR"1°w)
expressing cell line respectively. Competitive binding experiments with [3H]-AVP
using membrane preparations from these cells were carried out in order to define
the binding parameters Bmax and K<d for each cell-line, as described in materials
and methods. Via receptors were expressed with a Bmax of 383, 265 and 111
fmoles mg-1 protein in V^R-high, ViAR~med and V^aR-Iow cell-lines respectively.
[3H]-AVP had similar affinity for receptors expressed in all three cell-lines (Table
5.1). This showed that the differences in receptor number did not alter the affinity
of vasopressin for its receptor.
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5.1.2. Intracellular calcium mobilisation
Intracellular calcium mobilisation was measured in the three cell-lines using Fura-2-
AM in order to first assess whether level of receptor expression had any affect on
this response. AVP stimulated a concentration-dependent increase in intracellular
calcium levels in all three cell-lines with EC50 values of 3.1 ± 0.6 nM, 3.7 ± 0.84 nM
and 6.3 ± 0.84 nM in Vp^R-high, Vj aR-med and Vq /^R-low cell-lines respectively
(Figure 5.2). While the efficacy of the AVP response increased with increasing
receptor numbers, the EC50 was not significantly different between the high and
medium expressing cells and reflected the affinity (Kd) of AVP for the Vq a receptor
expressed in these cell-lines in receptor binding experiments (Table 5.1). This
suggests that there is little receptor reserve for stimulation of a calcium response by
AVP.
The effect of SP-G on intracellular calcium mobilisation was assessed in the three
cell-lines expressing different Via receptor numbers. Neither lpM nor lOpM SP-G
alone stimulated a calcium response in any of the cell-lines. This showed that,
irrespective of receptor numbers, the analogue had zero efficacy for coupling VqA
receptors with Gq proteins for PLC activation and subsequent calcium mobilisation.
However, measurement of AVP-stimulated calcium mobilisation in the presence of
lpM SP-G resulted in a rightward parallel shift in the concentration response curve
in VjA^'High (Figure 5.3) and V^A^Med (Figure 5.4) but not VqAR~L°w (Figure
5.5) cells. In addition, lOpM SP-G resulted in a rightward parallel shift in the
concentration response curves in all three cell-lines. The antagonist potency for SP-
G was lowest in the V^aR-Low cells (pA2 5.66) but similar in Vq^R-Med (pA2 6.42)
and V^AR-High (pA2 6.27) cells. This shows that SP-G maintains antagonism of the
Gq-coupled calcium response regardless of VqA receptor numbers.
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5.1.3. ERK activation
ERK activation was measured in V^^R-High, V^R-Med and V|/^R-Low cells in
response to AVP or SP-G. Lysates from quiesced cells stimulated for 10 minutes
with either AVP or SP-G were separated on 12% gels and blotted for phospho-
ERK1/2 or total ERK2. Activation was estimated by quantification of pERK band
intensity ratios using ImageQuant software following chemifluorescent
visualisation of immunoblots. Blots were also probed for total ERK2 in order to
ensure that any observed increase in ERK phosphorylation was not due to a change
in total ERK expression or unequal loading of gels (observed as equivalent ERK2
bands in the absence and presence of treatment).
ViA^-High, V^R-Med and Vj^R-Low cells were stimulated with increasing
concentrations of AVP and ERK activation measured. AVP stimulated a
concentration dependent increase in ERK phosphorylation in all three cell-lines
(Figure 5.6). A relatively small response was obtained in V|^R-Low cells, with only
a maximal 1.5 fold increase in ERK activity stimulated by lOOnM AVP. However,
the magnitude of the response increased with increasing receptor numbers.
Although it was not possible to determine the EC50 for the response in V^R-Low
cells, similar EC50 values were obtained in V^R-Med and V^R-High cells
(3.18nM and 2.84nM respectively). The maximal stimulation observed with AVP
increased with receptor expression, showing 3 and 4 fold stimulation with 100 nM
AVP in the medium and high expressing cells respectively. Stimulation with
increasing concentrations of SP-G resulted in a concentration dependent increase in
ERK activation in Vi^R-High, V^R-Med and V^aR-Low ceHs (Figure 5.7). In
contrast to AVP, maximal activation by SP-G (50pM) was not achieved but there
was no difference in the magnitude of ERK activation between medium and high
Via receptor expressing cells and the dose-response curves were super imposable.
Together this data shows that while the efficacy of AVP for ERK activation
continues to increase with increasing receptor numbers, the efficacy of SP-G does
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not. The difference in efficacy between AVP and SP-G for ERK activation in Vja
receptor expressing cells further indicates that the two agonists activate ERK by
different mechanisms.
As shown in chapter 3 (page 107), ERK activation by AVP is mediated
predominantly through coupling to Gq-proteins whereas SP-G stimulated ERK
activation is entirely dependent on Gi-protein coupling. V^R-High, V-j y^R-Med
and V-] aR-Low cells were pre-treated overnight with lOOng ml1 pertussis toxin
(PTx) then stimulated with 30pM SP-G or InM AVP in order to assess whether
changes in receptor number influence G-protein coupling specificity for this
response. SP-G stimulated ERK activity was inhibited by PTx in all three cell-lines
whereas AVP stimulated ERK activity was not affected (Figure 5.8). This shows that




























Figure 5.1. Specific binding of [3H]-AVP to clones isolated from CHO-K1 cells
stably transfected with receptors. Cell membranes were incubated with InM
[3H]-AVP in the presence (non-specific binding) and absence (total binding) of an excess of
unlabelled vasopressin (37°C; 30min). Results are expressed as specific radioligand binding
and represent the mean ± s.e.m. of a single experiment performed in triplicate. Clones 30b,
30b, 20i and lOd were chosen to represent a high (V^^R-high), medium (Vj^R-med) and
low (ViaR-Iow) expressing cell line respectively.
Table 5.1. receptor expression in stably transfected CHO-K1 cells
[3H]-AVP binding Bmax Kd
(fmoles mg"1 protein) (nM)
ViAR-high 382 ± 74 3.27 ± 1.57
vlAR-mec' 265 ± 22 1.5 +0.77
VIAR-I°w 111 ± 5 1.13 + 0.29
Cell membranes from clones of CHO-K1 cells stably expressing different numbers of
receptors were incubated with InM [3H]-AVP and increasing concentrations of unlabelled
vasopressin (37°C; 30min). The binding parameters Bmax and Kj were calculated from the
competition binding isotherms as described in materials and methods. The results represent











Figure 5.2. Concentration response curves for calcium mobilisation in CHO-K1
cells expressing different V^a receptor numbers. Quiescent V^AR-high, V^R-med
and V1AR-low cells loaded with FURA-2AM were stimulated with increasing
concentrations of vasopressin and intracellular calcium release measured by ratiometric
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Figure 5.3. Inhibition of intracellular calcium mobilisation in V^A^'high by SP-
G. Quiescent cells loaded with FURA-2AM were stimulated with increasing concentrations
of vasopressin alone (A) or in the presence of lpM (♦) or lOpM (0) SP-G. Intracellular
calcium release was measured by ratiometric fluorimetry as described in materials and











Figure 5.4. Inhibition of intracellular calcium mobilisation in ViAR-med by SP-
G. Quiescent cells loaded with FURA-2AM were stimulated with increasing concentrations
of vasopressin alone (A) or in the presence of lpM (♦) or lOpM (0) SP-G. Intracellular
calcium release was measured by ratiometric fluorimetry as described in materials and
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Figure 5.5. Inhibition of intracellular calcium mobilisation in V^R-low by SP-G.
Quiescent cells loaded with FURA-2AM were stimulated with increasing concentrations of
vasopressin alone (A) or in the presence of lpM (♦) or lOpM (0) SP-G. Intracellular calcium
release was measured by ratiometric fluorimetry as described in materials and methods and










Figure 5.6. Vasopressin stimulated ERK phosphorylation in receptor
expressing cells. Confluent, quiescent cultures of VjAR-high, Vj AR-med and V| AR-low
cells were stimulated for 10 min with increasing concentrations of neuropeptide. Aliquots of
cell lysate were resolved by SDS-PAGE and western blots probed with monoclonal anti-
pERKl/2 antibody (left panel) or polyclonal anti-ERK2 antibody (right panel).
Representative blots are shown. Graphs represent the mean band intensity ratios ± s.e.m. of
four experiments performed in duplicate.
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Figure 5.7. SP-G stimulated ERK phosphorylation in V^A receptor expressing
cells. Confluent, quiescent cultures of ViAR-high, V^AR-med and V-[AR-]°w cells were
stimulated for 10 min with increasing concentrations of SP-G. Aliquots of cell lysate were
resolved by SDS-PAGE and western blots probed with monoclonal anti-pERKl/2 antibody
(left panel) or polyclonal anti-ERK2 antibody (right panel). Representative blots are shown.
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Figure 5.8. Effect of pertussis toxin on ERK phosphorylation. Quiescent cultures of
A) V|AR-high, B) V]AR-med and C) VjAR-low cells were quiesced overnight in the
presence or absence of lOOng ml-1 pertussis toxin (PTx). Cells were stimulated for 10 min
with 30pM SP-G or InM AVP. Lysates were resolved by SDS-PAGE and western blots
probed with monoclonal pERKl/2 antibody (top) or polyclonal ERK2 antibody (bottom).
Representative blots are shown. Bar graphs represent the mean band intensity ratios + s.e.m.
of 3 separate experiments performed in duplicate (*P<0.05, ANOVA).
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5.2. Effect of altering G-protein levels on SP-G activity
CHO-Vi a cells were transiently transfected with G-protein alpha subunits of wild-
type Goq_3 and Gctq or dominant-negative Ga,q(Q209L/D277N) sub-types, as described in
materials and methods. The effects of G-protein over-expression on SP-G activity in
the pathways leading to calcium mobilisation (via stimulation of PLC) or ERK
activation were subsequently examined. Unfortunately, G-protein over-expression
was not consistently obtained throughout this series of experiments making it
difficult to draw proper conclusions from this study (data not shown for over-
expression of Gaj subunits). In particular, the dominant-negative Ga,q subunit often
appeared to be expressed at similar levels as wild-type Ga.q. Over-expression of the
dominant-negative Ga.q would have been expected to inhibit AVP-stimulated
calcium mobilisation since this is a Gq-coupled response. The fact that this effect
was not observed during this study is probably because the dominant-negative Ga,q
subunit was never expressed at sufficiently high levels to suppress wild-type Gctq
activity. In contrast, over-expression of the wild-type Ga.q subunit, at a level two¬
fold greater than basal (as determined by western blotting; data not shown), was
obtained more frequently. Successful over-expression of Ga.q resulted in an
increase in the amplitude of AVP-stimulated calcium release, confirming that the
Via receptor coupled to a Gq-like protein for PLC activation (Figure 5.9a). The
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Figure 5.9. Effect of Gotq over-expression on calcium mobilisation. Quiescent CHO-
V^ cells (control) or CHO-V^a cells transiently transfected with Gctq were loaded with
FURA-2AM. A) Cells were stimulated with InM AVP (bar graph represents % of response to
InM AVP in control cells). B) Cells were stimulated with InM AVP in the presence of 3pM
or 30pM SP-G (bar graph represents the % of maximum response to InM AVP in respective
cells). Intracellular calcium release was measured by ratiometric fluorimetry as described in
materials and methods and data represents the mean ± s.e.m. of three experiments.
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5.3. Biased agonism of chimeric Via receptors
The data presented in chapter 3 demonstrated that the substance-P analogues
activate ERK exclusively through activation of Gi-proteins. Using a linear V]a
receptor antagonist, it has been demonstrated that in the absence of ligand the V ] a
receptor is pre-associated with G-protein subtypes Goiq/n, Gaj3 and Gas in rat
liver membranes (Strakova et al, 1997). Experimental data reported in the literature
suggest that heterotrimeric G-proteins interact with parts of the activated receptor at
the transmembrane helix-intracellular loop interface (Sgourakis et al, 2005). While
the second intracellular loop of the Via receptor has been shown to be essential for
receptor coupling to Gq proteins (Liu & Wess, 1996), at present it is unknown which
intracellular region of the receptor is involved in coupling to Gi proteins.
Chimeric Via receptors, where the second (V-j a'2) or third (V-|Ai3) intracellular
loops have been replaced with the corresponding sequence of the V2 (Gs-coupled)
receptor, were used to determine whether the analogues directly affect the
intracellular G-protein coupling domains of the receptor to induce Gj-mediated ERK
activation. CHO-K1 cells were transiently transfected with wild-type V] a or
chimeric V\pj2 or V] a!3 receptors (as described in materials and methods) and a
preliminary study of the effects on receptor signalling carried out.
Binding studies using [3H]-AVP on membranes prepared from VjaR' VjAi2R or
V] a'3R cells showed that AVP had similar affinity for the V^a and V1i2 receptors
(Kd = 5.71 ± 2.54 nM and 2.64 ± 0.65 nM respectively). AVP had slightly greater
affinity for the Vli3 receptor than for the wild-type receptor (Kd= 1.14 ± 0.57 nM).
Competitive binding experiments using SP-G as unlabelled competitor similarly
showed that the analogue had similar affinity for the Vja ar,d Vja^ receptors (Kj =
4.2 ± 1.3juM and 3.9 ± l.lpM respectively) and slightly greater affinity for the VjaU
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receptor (Ki= 1.5 ± 0.6gM). This shows that the chimeric receptors retain the ability
to bind both AVP and SP-G.
Inositol triphosphate production was measured in the three cell-lines in order to
examine the effect of replacing the intracellular loops on this response to AVP. AVP,
at concentrations up to lOOnM, was unable to increase the generation of inositol
triphosphate in Vj^i2 receptor expressing cells (Figure 5.10). In contrast, a 4-fold
increase in inositol phosphates was observed in V^^i3R cells which was comparable
to the activation observed in wild-type receptor expressing cells (EC50 for AVP was
0.89 ± 0.10 nM and 1.04 ± 0.12 nM in V^a and V^a^ receptor expressing cells
respectively). This suggests that the second intracellular loop is essential for V^a
receptor activation of PLC.
Preliminary measurements of intracellular calcium mobilisation in response to AVP
in the three cell-lines were made using FURA-2-AM. Stimulation with lOnM AVP
resulted in an increase in intracellular calcium levels in VjaR and V^a^R
expressing cells whereas cells expressing the Vja^ chimera gave only a weak
response (Figure 5.11). At concentrations of 3, 10 and 30pM SP-G was still able to
inhibit the Vja^R calcium response to lnJVI AVP, but less effectively than in VjaR
expressing cells (Figure 5.12). This data similarly indicates that the Gq-coupled
calcium response is dependent upon the second intracellular loop of the Vja
receptor and also shows that changing the third intracellular loop does not prevent
SP-G from inhibiting this event.
The efficacy of AVP and SP-G in stimulating ERK activation via the chimeric
receptors was compared with wild-type V-j a receptor stimulation. CHO-K1 cells
transiently expressing V}a> VlA^ or V^a^ receptors were stimulated for 5
minutes with increasing concentrations of AVP or SP-G and western blot analysis of
lysates performed. Preliminary experiments showed that AVP stimulation of the
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Vj/^i3 chimera resulted in more potent ERK activation than that observed following
wild-type receptor stimulation (Figure 5.13). In contrast, SP-G had lower efficacy for
ERK activation in these cells; producing significant stimulation only at 30pM. AVP
was less effective at stimulating ERK activation via the chimeric V^i2 receptor
than the wild-type receptor. However, the efficacy of SP-G for ERK phosphorylation
was not altered by the V^i2 chimera. This data shows that the second and third
intracellular loop of the Via receptor is required for effective ERK activation by
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Figure 5.10. PLC activation in chimeric receptor expressing cells. CHO-K1 cells
transiently transfected with V^/JR, 12R or 13R were incubated overnight in serum-
and inositol-free medium containing lgCi mh1 myo-[2-3H]-inositol. Cells were washed prior
to stimulation with the indicated concentrations of AVP (30 min; 37°C). [3H]-inositol
phosphate production was measured as described in materials and methods. Results are
expressed as % of unstimulated cells and represent the mean ± s.e.m. of three independent
experiments.
Figure 5.11. Intracellular calcium mobilisation in chimeric receptor expressing
cells. Quiescent CHO-K1 cells transiently transfected with V^R, V|^i2R or Vj^i3R were
loaded with FURA-2AM. Cells were stimulated with lOnM AVP and intracellular calcium
release measured by ratiometric fluorimetry as described in materials and methods. Data

















Figure 5.12. Inhibition of intracellular calcium mobilisation in chimeric receptor
expressing cells by SP-G. Quiescent CHO-K1 cells transiently transfected with V^R,
V|^i2R or V}a'3R were loaded with FURA-2AM. Cells were stimulated with InM AVP in
the absence or presence of 3pM, 10p.M or 30pM SP-G and intracellular calcium release
measured by ratiometric fluorimetry as described in materials and methods. Data represents
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Figure 5.13. ERK activation in chimeric receptor expressing cells. Confluent,
quiescent cultures of CHO-K1 cells transiently transfected with V] ^R, V^i2R or V^i3R
were stimulated for 5 min with increasing concentrations of AVP (left panel) or SP-G (right
panel). Aliquots of cell lysate were resolved by SDS-PAGE and western blots probed with
monoclonal anti-pERKl/2 antibody. Representative blots are shown.
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The data presented in chapter 3 showed that neuropeptides induced receptor
coupling with Gq proteins for PLC and ERK activation. In contrast, the substance-P
analogues inhibited neuropeptide-stimulated calcium release (event downstream of
PLC activation) and exclusively activated ERK through receptor coupling to Gj
proteins. In this chapter, an attempt was made to investigate the factors which
control the biased agonist activity of the substance-P analogues.
Alteration of the receptor/G-protein stoichiometry has been shown to change the
coupling specificity of various GPCRs. Low level expression of the Vib receptor in
CHO cells resulted in receptor coupling to G-proteins of the Gq family whereas at
higher expression levels, Gp and Gs- coupling were also observed (Thibonnier et al,
1997). A similar study using the Gs-coupled V2 receptor revealed that the receptors
coupled to Gq-proteins when expressed in high numbers (Zhu et al, 1994).
Alteration of the Vj/y receptor expression level in CHO-K1 cells therefore may
potentially have resulted in changes in the G-protein selectivity of SP-G and/or
AVP. The data presented in this chapter showed that increasing receptor
number did not alter the affinity of AVP or its potency for calcium mobilisation.
Tsuda et al (1997) similarly found that increasing the GRP receptor number had no
effect on the affinity of GRP for receptor in binding studies and did not alter the
potency (EC50) f°r activating PLC. Similarly here, the efficacy of AVP-induced
calcium mobilisation (a PLC-coupled response) increased with increasing receptor
numbers, as did the efficacy of AVP-induced ERK activation. In contrast, the
efficacy of ERK activation by SP-G was not altered between medium and high
expressing cells, suggesting that this response may be limited. Limitations could be
imposed upon Gi-induced ERK activation through low availability of Gi proteins at
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the expression level, restraint/ regulation of Gi-proteins by cytoplasmic proteins or
sequestration of Gi-proteins by other receptors.
An extended ternary complex model in which multiple receptors couple to a single
G protein has been used to predict limitations of agonist, receptor and G-protein
interaction which were experimentally investigated using neuroblastoma-glioma
cells that express alpha 2b-adrenergic, m4 muscarinic, and delta-opiate receptors
which all utilise Gj proteins as a transducer (Graeser & Neubig, 1993). Theoretical
simulations of the simple ternary complex model predicted that agonist binding
with differential affinity only occurred when G-protein was limiting, whereas
measurements showed that a significant excess of G-protein over receptor existed in
the neuroblastoma-glioma cell system. A second prediction of this model was that
binding of an agonist at one receptor would produce competition for G-protein used
by another receptor; if the G-protein pool were limiting and freely mobile, this
would result in an unlabeled agonist at one receptor decreasing binding of a
radiolabeled agonist to another receptor. Experimentally, the Gj-protein was made
limiting by a partial pertussis toxin treatment, but no cross-talk was observed
between the three Gj-coupled receptors in the neuroblastoma-glioma cell-line. It
was therefore suggested that instead limitations are probably imparted by
regulation of G-protein mobility in the membrane through 1) attachment to
structural elements, such as the cytoskeleton, 2) sequestration in lipid pools, or 3)
organisation into slowly exchanging supramolecular complexes.
Since the efficacy of AVP for calcium mobilisation and ERK activation increased
with increasing receptor density without a change in potency, this indicates that
there is little receptor reserve for these responses. The ratio of K1/EC50 for a
particular G-protein mediated response can also be used as an indicator of the
magnitude of receptor reserve for the response (Brink et al, 2000). A large K1/EC50
ratio suggests a large receptor reserve and vice versa. In this study, the potency for
calcium mobilisation and ERK activation by AVP was equivalent to the affinity of
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AVP for the Via receptor. This reflects small Kj/EC50 ratios which further suggest
that there is a small receptor reserve for these responses to AVP. Conversely, since
the efficacy of SP-G for ERK activation did not change between medium and high
expressing cells, this suggests that there is a higher receptor reserve for SP-G
induced ERK activation. The different effect altering receptor density has on the
efficacy of AVP and SP-G for ERK activation via the Vja receptor further indicates
that the two ligands have distinct mechanisms of action.
Fitzgerald et al (1999) showed that by increasing h5-HT2C receptor numbers, the
partial agonist LSD became a full agonist in HEK 293 cells due to the existence of a
receptor reserve for PLC activation. Pre-treatment with pertussis toxin showed that
SP-G maintained Gi-coupling for ERK activation regardless of Vja receptor
number. Therefore, although there may have been a large receptor reserve for SP-G
induced ERK activation, altering V]a receptor numbers did not enable SP-G to
induce Gq-mediated activation of ERK. Similarly, changes in receptor density did
not permit SP-G to couple Via receptors with Gq proteins for PLC activation and
subsequent calcium mobilisation. In fact, SP-G maintained antagonism of the Gq-
coupled calcium response regardless of Vja receptor density. Together, the data
shows that SP-G retains biased agonist activity across the range of receptor densities
tested. It should be mentioned that a potential limitation of this study may be that
the fold differences in receptor numbers between the high, medium and low
expressing cells were relatively small. There was a 3.45 fold difference in receptor
numbers between low and high expressing cells and a 2.4 fold difference between
low and medium expressing cells. Greater fold differences in receptor numbers
between the cell-lines may have provided more robust conclusions as it is possible
that at extremely high receptor densities SP-G may have behaved differently.
Nevertheless, the findings of this part of the study suggest that endogenous G-
protein expression may instead be limiting analogue activity.
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Alteration of G-protein expression may have clarified this premise, had the various
G-protein subunits of interest been sufficiently over-expressed. Only Ga.q over-
expression was successfully obtained in CHO-Vja ce^s and resulted in an increase
in the efficacy of AVP for calcium mobilisation and ERK activation. This confirmed
that the V-| a receptor coupled to a Gq-like protein to stimulate these responses. Goiq
over-expression did not enable SP-G to stimulate a calcium response and the
analogue maintained antagonism of the AVP-induced calcium response. The latter
finding provides further support for the hypothesis that inhibition of neuropeptide-
stimulated calcium mobilisation by substance-P analogues does not involve Gq-
proteins and is instead dependent upon stabilisation of a receptor conformation
which does not couple to Gq proteins for PLC activation.
The data presented in chapter 3 indicated that the substance-P analogues bind to a
site on the neuropeptide receptors which is distinct from the neuropeptides' binding
site (page 127). This is corroborated by the finding that the alternate set of receptor
chimeras in which the V2 receptor intracellular loops were replaced by those from
the Via receptor shows that although these receptors are still able to bind AVP with
high affinity, they are no longer able to bind substance-P analogues (M. Seckl,
unpublished observations). Substance-P analogues must therefore interact at site
distinct from the ligand recognition site. This differential interaction may enable the
analogues to stabilise a receptor conformation which differs from that induced by
neuropeptide allowing it to couple more effectively to Gi proteins. Many GPCRs are
able to couple to G proteins from more than one family (Gudermann, 1997). G-
protein coupling is proposed to involve the C-terminal end of the G protein a-
subunit binding in a pocket constituted by the intracellular loops of the various
GPCR families (Tsuda et al, 1997). Previous studies have shown that in addition to
activating Gj-protein coupled responses, the 0-2A-AR is capable of stimulating
adenylyl cyclase through activation of Gs proteins, albeit less effectively (Eason et al,
1992). Chimeric analysis of the intracellular loops of this receptor showed that the i2,
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N-terminal i3 and C-terminal i3 regions were required for Gs-coupling (Eason et al,
1995). In contrast, the N-terminal i3 or C-terminal i3 region were independently
capable of supporting Gi coupling and activation (Eason & Liggett, 1996). Previous
studies have shown that the second intracellular loop of the V^a receptor is
necessary for Gq-coupling and subsequent PLC activation (Liu & Wess, 1996;
Erlenbach & Wess, 1998). It has been suggested that the differential involvement of
the intracellular domains in coupling to G proteins might represent the molecular
basis for agonist-selective responses through G protein-coupled receptors
(Skrzydelski et al, 2003). Preliminary experiments using chimeric V^a receptors,
where the second (Vja^) or third (Vi/j^) intracellular loops were replaced with
the homologous region of the V2 (Gs-coupled) receptor, were carried out to
determine whether SP-G required the intracellular G-protein coupling domains of
the receptor to elicit biased agonist activity.
Binding studies showed that the chimeric receptors retained the ability to bind both
AVP and SP-G. However, the Vjai3 receptor had slightly greater affinity for AVP
than the wild-type receptor did. It has been suggested that the i3 loop may exert
indirect conformational effects on the configuration of the AVP binding site (Liu &
Wess, 1996). The finding that the affinity of SP-G for the Vi/pS receptor was also
slightly increased indicates that some degree of overlap between the analogue and
neuropeptide binding sites may exist.
Data presented in this chapter showed that the second intracellular loop was
essential for V^a receptor activation of PLC, which subsequently leads to
intracellular calcium mobilisation. Preliminary calcium flux assays similarly
indicated that the Gq-coupled calcium response required the second intracellular
loop of the Via receptor, and exchanging the third intracellular loop of the receptor
did not abolish SP-G antagonism of this event. The observation that SP-G inhibited
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the Vj/^i3R calcium response less effectively than the calcium response may
be related to the increased affinity the receptor has for AVP. Binding of SP-G to the
may alter the conformation of the i3 loop to facilitate Gj-protein coupling and
simultaneously prevent the i3 loop from contributing to the configuration of the
neuropeptide binding site, thus reducing AVP binding and Gq-coupling. Increased
affinity of AVP for the V^i3R may thus sustain the contribution of the i3 loop to
the configuration of the neuropeptide binding site, making it more difficult for SP-G
to distort the binding pocket.
AVP was less effective at stimulating ERK activation via the chimeric V-[^i2
receptor than the wild-type receptor. However, the efficacy of SP-G for ERK
phosphorylation was not altered by the Vj/^i2 chimera. Given that substitution of
the second intracellular region of the Via receptor did not affect SP-G-induced ERK
activation coupled with the finding that SP-G increases ERK via Gi suggests that the
i2 region may not be involved in Via receptor coupling to Gi although it is crucial
for receptor binding to Gq. The increased affinity of AVP for the V] a'3R correlated
with more potent ERK activation, whereas SP-G also had greater affinity for VjaBR
but was less able to activate ERK. This suggests that the i3 domain may be involved
in Via receptor coupling to Gi and is required for Gi-mediated ERK activation by
SP-G. This lends further credibility to the existence of agonist selective states, as
different agonists would be expected to alter receptor conformation so as to expose
different G-protein interacting sequences leading to selective activation of
downstream signaling events.
Maudsley et al (2004) have similarly demonstrated the existence of agonist selective
receptor states using GnRH I, GnRH II and GnRH analogues. Their studies showed
that these ligands are able to selectively inhibit the growth of peripheral
reproductive tumours and this ability correlates with ligand-selective activation of a
Gcq-coupled form of the type I GnRH receptor. The human gonadotropin-releasing
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hormone (GnRH) type I receptor binds GnRH I (with greater affinity than it binds
GnRH II) and couples to Gq proteins in pituitary cells to mediate aclivation of PLC
and calcium mobilisation, culminating in the release of pituitary gonadotrophin
hormones. Structurally related antagonistic GnRH analogues displayed divergent
anti-proliferative efficacies but demonstrated equal efficacies in inhibiting GnRH-
induced Gaq-based signalling and this was proposed to be a consequence of their
relative abilities to stabilise an active form of the receptor that is capable of coupling
productively to Gai (GnRH ligand-induced selective signalling).
Whereas GnRH I is more potent in the activation of Gq proteins in the gonadotrope,
GnRH II is more potent in the stimulation of apoptosis and anti-proliferative effects
through activating Gi-protein mediated signalling. This ligand-induced selective
signalling is proposed to be a consequence of the binding of GnRH I and II
selectively stabilising different receptor-active conformations (Lu et al, 2005). The
molecular basis for this hypothesis was provided through Ala mutagenesis of
highly conserved GPCR TM residues in the human GnRH type I receptor, which
resulted in an increase in GnRH II binding with little effect on GnRH I binding (Lu
et al, 2005). Of the three amino acids which differ between the ligands, Tyr8 of GnRH
II was important for the increased affinity of the receptor mutants for GnRH II. It
was suggested that mutagenesis created a high affinity GnRH II binding site
through disruption of particular sets of receptor-stabilising intramolecular
interactions which facilitated intermolecular interactions between Tyr8 and receptor
contact residues. They interpreted that GnRH ligand binding to the human GnRH
receptor breaks intramolecular constraint networks that stabilise the receptor in
inactive conformations, resulting in the ligand-specific generation of new sets of
inter- and intra-molecular contacts stabilising the receptor in particular active
conformations which dictate downstream signalling selectivity. The manner of
ligand binding can thus affect downstream signalling from a receptor.
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The fact that ERK activation was observed at all in response to SP-G stimulation of
the V|y\i3R may have been due to direct G-protein activation as discussed
previously (chapter 3). However, previous studies using the V^^BR chimera have
shown that AVP is able to induce Gs-coupling to this receptor, resulting in the
generation of cAMP (Liu & Wess, 1996). This shows that agonist-induced exposure
of the G-protein coupling sequences present in this particular (V2R) i3 loop
facilitates receptor coupling to the cognate G-protein. In light of this, it is entirely
conceivable that SP-G selects a receptor conformation which exposes G-protein
coupling sequences present within the third intracellular loop and facilitates Gs-
coupling to the V^BR for ERK activation. The pertussis toxin insensitivity in such
a case would confirm this possibility. Indeed, preliminary results have shown that
SP-G stimulated ERK activation via the V|^i3R is not PTx sensitive (data not
shown). However, if SP-G stimulated ERK activation via the Vj^i3R is PTx
sensitive, this could still provide evidence for targeted effects at the G-protein
coupling domains. A BBXXB motif (in which B represents a basic residue and X a
non-basic residue) located in the C-terminal portion of the third intracellular loop is
proposed to be involved in Gj-protein activation via the ot2A'AR (Ikezu et al, 1992;
Wade et al, 1996). Basic residues present within this motif have been shown to
contribute to the activation of Gj but are not required for receptor-G protein
coupling (Wade et al, 1999). This motif is present in the C-terminal region of both the
VlA and V2 receptor i3 loops. Thus it is also conceivable that SP-G is able to activate
Gi (albeit less effectively) via the normally Gs-coupled i3 loop of the V2 receptor due
to direct conformational effects on this particular region. Either way, the
preliminary study discussed here suggests that the analogue does exert direct
conformational effects at the G-protein coupling domains of the receptor to
induce pathway selective signalling.
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To summarise, the data presented in this chapter showed that altering the density of
Via receptors did not enable SP-G to activate downstream signalling in a manner
analogous to AVP stimulation of the same receptors. Similarly, increasing Gciq-
protein levels did not result in SP-G inducing Gq-coupling of the Vja receptor and
stimulating a calcium response as the endogenous receptor agonist does. These
findings, together with chimeric receptor studies confirm that SP-G functions as a
dual efficacy ligand which promotes an agonist state of the Via receptor that
couples to Gi leading to activation of ERK but which blocks AVP-induced activation
of PLC and subsequent release of intracellular calcium. The molecular basis for this
activity appears to involve a region of the receptor out with the second intracellular
loop which is involved in receptor coupling to Gq. This study provides a tentative
basis for the hypothesis that the substance-P analogues induce specific activation
states of the receptor and selectively activate downstream signalling through





The idea of drugs inducing selective activation states has been widely hypothesised
and 'biased agonists' or dual efficacy ligands have been described for 5HT, a2A/ 5-
opiate and P2 receptors (Brink et al, 2000; Cussac et al, 2002; Martin et al, 2002; Azzi et
al, 2003). Theoretically this activity has important applications for future drug
discovery, but has yet to be proven to be clinically relevant in any pathological
condition. In endocrine cancers such as SCLC, mitogenic neuropeptide receptors
such as the receptor and the GRP receptor activate downstream signals which
control proliferation and differentiation but may also activate death signals leading
to JNK activation and apoptosis. A biased agonist agent which could block the
proliferative effects of Ca2+ mobilising mitogenic neuropeptides whilst stimulating
receptor-dependent apoptosis would be highly advantageous in the management of
tumour growth. In this respect, the broad spectrum neuropeptide receptor
antagonists substance-P analogues, which inhibit the growth of tumour cells, have
previously been found to be biased agonists of the GRP receptor.
This project intended to determine whether substance-P analogues exhibit 'biased
agonist' activity at receptors other than the bombesin/GRP receptors and investigate
factors which influence their ability to modulate neuropeptide signalling. Towards
this end, model cell systems comprising of CHO-K1 cells expressing GRP or Vja
receptors were created. It was found that neuropeptide receptor expression altered
the usual characteristics of the epithelial cell line. The impact of neuropeptide
receptor expression on CHO-K1 cell growth and motility was therefore studied in
order to reveal the extent of change induced. In addition, the sensitivity of the
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model cell systems to substance-P analogue induced growth inhibition was also
determined in order to establish a link between the mechanistic basis of analogue
activity and the biological consequences of such activity. Although it was found that
expression of neuropeptide receptors led to cellular transformation, the sensitivity
of cells to substance-P analogue-induced growth inhibition was also increased. As
well as being dependent on neuropeptide receptor expression, the anti-proliferative
effects of the substance-P analogues correlated with their biased agonist effects
upon the neuropeptide receptors.
The novel findings from this study are that 1) GRP and Via receptor expression
leads to the development of a transformed phenotype in CHO-K1 cells. 2) Receptor
expressing cells show some increased resistance to the chemotherapeutic agent
etoposide. 3) Expression of V|a receptors, as well as GRP receptors, confers
sensitivity to substance-P analogue induced growth inhibition. 4) Substance-P
analogues act as biased agonists at V^a receptors, as well as GRP receptors. 5) Like
SP-D, the analogue SP-G also has biased agonist properties against neuropeptide
receptors. 5) This pharmacological activity is crucial for the anti-proliferative effects
of these agents and may be of particular benefit in more differentiated cancers that
have developed resistance to chemotherapy. 6) The molecular basis for this activity
involves a region of the receptor out with the second intracellular loop which is
involved in receptor coupling to Gq. 7) The substance-P analogues bind to a site
which is distinct from the neuropeptide binding site.
This study demonstrated that GRP or V^a receptor expression transformed CHO-
K1 cells since these cells exhibited various hallmarks of cancer. The self-sufficiency
in growth these cells exhibited was thought to be responsible for increased growth
of these cells under anchorage dependent and independent conditions. This may
have been a consequence of constitutive neuropeptide receptor activity in this cell-
type since these observations were made in the absence of exogenously added
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neuropeptides. However, investigation into the existence of an autocrine growth
loop should be carried out as this may provide a biological basis for the constitutive
receptor activity. Neuropeptide receptor induced transformation is likely to be of
relevance to the development and progression of neuropeptide dependent tumours.
Bombesin has been implicated in the progression of prostate cancer to androgen
independence by virtue of synergistic effects which promote androgen receptor
mediated signalling (Dai et al, 2002). Cross-talk between neuropeptide receptors and
receptor tyrosine kinases may facilitate optimal mitogenic signal pathway
activation; therefore the involvement of various RTKs in neuropeptide receptor
induced transformation should be investigated further. In particular, it would be of
interest to see whether transactivation of the IGF-1R by neuropeptide receptors
contributes to the ability of the transformed cells to evade detachment induced
apoptosis (anoikis) and promotes anchorage independent growth since this RTK is
able to mediate anti-apoptotic signalling. Constitutive FAK activity has been shown
to confer anchorage-independence (Frisch et al, 1996) and may be responsible for the
anchorage independent growth capabilities of neuropeptide receptor expressing
CHO-K1 cells. A comparison of FAK activity in vector and neuropeptide receptor
transfected cells would determine whether this kinase plays a role in the anchorage-
independent growth of these cells. In the present study it was shown that
neuropeptide receptor expression alone resulted in increased migration and
decreased adhesion to fibronectin. It should be pointed out that the static adhesion
assay used in this study primarily investigates cell attachment and that in vivo,
because of the presence of shear stress, cell detachment (which is not necessarily a
biologically equivalent process) would play an important part in governing the
metastatic potential of a tumour cell. A recent study by Glover et al (1994) showed
that phosphorylation of Tyr 397 of FAK was essential for GRPs effects on adhesion
and migration and suggested that the GRP acts as a morphogen which causes
increased adhesion and decreased deformability; effects which would result in
increased tumour differentiation and decreased metastasis in colon cancer. As in the
present study addition of GRP to the cells produced no further effect on adhesion or
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migration. It was suggested therefore that the GRP receptor in colon cancer cells
was activated fully by an autocrine mechanism. This present study however has
shown that expression of GRP and VIA receptors in hamster epithelial cells leads to
decreased adhesion to fibronectin and increased motility which would fit with a
more metastatic phenotype. Overall, investigating the mechanism underlying
neuropeptide receptor induced transformation using these model cell systems may
contribute to a greater understanding of the role of neuropeptide receptors in the
development and progression of neuropeptide-dependent tumours. This may lead
to the identification of novel targets for anti-cancer therapy.
The mechanism underlying neuropeptide-induced chemoresistance should be
investigated further as this may reveal novel targets for treating neuroendocrine
tumours which have developed chemoresistance. Inhibitors of P13K and Akt could
be used to determine whether P13K-Akt signalling is involved in this process as this
pathway is known to promote survival under apoptotic stress.
A correlation was previously found to exist between GRP receptor expression and
SP-G induced growth inhibition of a panel of tumour cell-lines (Waters et al, 2003).
In addition, SP-D had previously been shown to be a biased agonist against GRP
receptors but it remained unclear whether the growth inhibitory effects could be
attributed to such activity at these receptors alone. This thesis has illustrated that
SP-D and SP-G act as biased agonists at the V^a receptor as well as the GRP
receptor and that such activity has growth inhibitory consequences irrespective of
which receptor is stimulated. Thus it can be postulated that discordant signalling
stimulated by biased agonist activity is central to the growth inhibitory properties of
this group of analogues. It would be of further interest to determine whether the
analogues are able to synergistically inhibit the growth of cells expressing different
analogue-sensitive neuropeptide receptors (as SCLC cells do). This could be
examined using the GRP or V^a receptor model cells transfected with other
neuropeptide receptors. This would indicate whether further biased agonists of
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neuropeptide receptors need essentially be designed to similarly have broad-
spectrum activity for maximum effect.
The finding that V^a or GRP receptor expression in CHO-K1 cells leads to increased
sensitivity to substance-P analogue induced growth inhibition suggests that
screening biopsy samples for expression of GRP and V^a receptors could be useful
in predicting clinical responsiveness to treatment with substance-P analogues. In
addition, since the substance-P analogues exhibit selectivity towards different
neuropeptide receptors there may be potential for tailoring treatment to a specific
tumour phenotype. For example, SP-G may be more beneficial in Via receptor
expressing tumours while SP-D may be better for tumours which express both GRP
and Via receptors. Given that SP-D and SP-G inhibited the growth of neuropeptide
receptor transformed cells and not normal CHO-K1 cells, this suggests that these
anti-cancer drugs should have minimal side-effects. In the phase I clinical trial of SP-
G, patient plasma levels of SP-G were achieved which were equivalent to the IC50
values of in vitro pre-clinical studies, with side-effects (e.g. facial flushing) being
generally well tolerated (Clive et al, 2001). Thus, these analogues may be clinically
effective against a broad spectrum of neuropeptide-dependent tumours.
The V^a receptor expressing cell-line, which expressed a five fold lower density of
receptors than the GRP receptor expressing cell-line, was still susceptible to growth
inhibition by substance-P analogues indicating that sensitivity to the compounds
may not be limited by a critical receptor density. A possible molecular basis for this
was provided through experiments which were carried out in an attempt to
understand what facilitates substance-P analogue biased agonism. The ratio of
receptors to G-proteins was altered and the subsequent effects on analogue activity
examined. The preliminary data obtained showed that for the activation of ERK
there appears to be a greater receptor reserve available to SP-G for coupling
receptors to Gj proteins than exists for AVP to couple receptors to Gq proteins. This
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indicates that the analogues only need to activate a small proportion of the available
receptors for Gi-mediated ERK stimulation, so the analogues could well be effective
against tumours regardless of their level of receptor expression. SP-G also
maintained coupling to Gi-proteins for ERK activation following Gq protein over-
expression which similarly suggests that these analogues may be able to maintain
activity irrespective of which G-protein is in abundance in different tumours.
However, these findings need to be confirmed through further studies, preferably
using cell-lines expressing greater fold differences in receptor numbers and also
with a greater level of G-protein over-expression of both Gq and Gj proteins. Since
conventional transfection of the CHO-K1 cells with bacterial vectors encoding wild
type and dominant negative G-protein a-subunits was disappointing it would be
interesting to increase expression using an adenoviral or retroviral system and to
inhibit expression using Ga minigenes or siRNA. It may also be informative to
examine the role of GPy subunits in the transduction of biased agonist signalling
through expression of the carboxy-terminal domain of G protein-coupled receptor
kinase 2 (GRK2-ct), which is a Gpy-sequestering polypeptide.
Investigations into the mechanism of action of the substance-P analogues showed
that SP-D and SP-G inhibited neuropeptide binding and antagonised calcium
mobilisation but were agonists for pertussis-toxin sensitive ERK activation by Vy/^R
as well as the GRPR. The anti-proliferative effects of the analogues on CHO-K1 cells
were dependent on the expression of GRP or VyA receptors. The biased agonist
activity thus correlates with anti-proliferative effects. To further strengthen this
hypothesis, spantide, despite having only a single amino acid substitution
difference from SP-D, did not act as a biased agonist at GRP or VyA receptors, but
did bind to GRP receptors with high affinity and blocked calcium responses.
Moreover, spantide did not inhibit the growth of the H345 SCLC cell-line. This
would confirm that uncoupling of receptors from Gq proteins is not sufficient to
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induce growth inhibition, and Gi-protein-mediated signalling (i.e. through biased
agonism) is required for the anti-proliferative effects of the analogues.
In CHO-K1 cells expressing neuropeptide receptors, the analogues modulated
neuropeptide receptor signalling so that ERK activation was mediated through
enhanced coupling to Gj proteins, in comparison with the largely Gq mediated ERK
activation induced by the natural ligand. This presumably shifts the balance of
intracellular signalling and it would be of interest to investigate further what impact
the substance-P analogue induced differences in duration and manner of
intracellular signalling (e.g. ERK or JNK activity) have on biological outcome.
Previous work in our laboratory has shown that ERK activity at least partially
contributes to the pro-apoptotic effects of SP-D on GRPR expressing fibroblasts and
H69 SCLC cells. A mechanism by which cells are able to detect differences in the
duration of intracellular signalling has been revealed which involves the immediate
early gene product c-Fos behaving as a sensor for ERK1/2 signal duration (Murphy
et al, 2002). Sustained ERK signalling leads to stable c-Fos phosphorylation and
exposes an ERK docking site, facilitating additional phosphorylation and thus c-Fos
mediated signalling. Putative ERK binding sites have also been identified in other
immediate early gene products, including c-Jun which is a target of activated JNK
(Murphy et al, 2002). Sustained ERK signalling can therefore potentially influence
JNK activity. Substance-P analogues stimulate JNK activity in SCLC cells which is
sustained over time (MacKinnon et al, 1999) and has been shown to occur through
receptor coupling to G12 proteins in GRPR expressing fibroblasts (Mackinnon et al,
2001). A number of attempts were made to evaluate JNK activation and apoptosis in
response to substance-P analogues using the model cell systems but were
unsuccessful. This aspect of the study should be re-visited and if accomplished, the
possibility that the sustained pattern of substance-P analogue stimulated ERK
activity contributes to the induction of the apoptotic pathway investigated.
Substance-P analogue induced JNK activation in SCLC cells in the presence and
absence of ERK inhibition could also be measured. Since the intracellular
localisation of activated ERK has been shown to have an impact on cell fate, confocal
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imaging could be used to determine whether the subcellular localisation of
substance-P analogue and neuropeptide stimulated ERK differs. Growth inhibition
may involve modulation of receptor trafficking since it has previously been
demonstrated that SP-D does not induce GRP receptor desensitization to the same
extent as bombesin (Mackinnon et al, 2001). Arrestins have traditionally been
implicated as mediators of GPCR desensitization and internalisation but have
recently been shown to play an important role in the suppression of GPCR-
mediated apoptosis (Beekman et al, 1998). Therefore it may be informative to
investigate whether the substance-P analogues interfere with P-arrestin function in
order to transduce an anti-proliferative signal through neuropeptide receptor
stimulation instead of a mitogenic one. Such investigation of the consequences of
biased agonist induced signalling events may facilitate a better understanding of
how dysregulated signalling can influence cell fate; consideration of which may be
useful in the design of pathway selective drugs.
Also along the line of investigating the apoptotic effects of the analogues, the
contribution that Gi-mediated signalling makes to this process could also be
investigated to gain a better understanding of the mechanism underlying growth
inhibition through biased agonism. Lack of Substance-P analogue induced growth
inhibition following Gi-protein inactivation using Pertussis Toxin or siRNA to
decrease expression of Goq, would confirm a requirement for Gi-mediated
signalling in the anti-proliferative effects of these compounds.
The finding that the substance-P analogues were capable of stimulating ERK activity
in vector-transfected CHO-K1 cells suggested that the compounds may have
receptor-independent effects on cells. However, it has previously been
demonstrated that SP-G induced apoptosis and JNK activation in SCLC cells is
dependent on the generation of reactive oxygen species (ROS) (MacKinnon et al,
1999). Gcq/o proteins are targets of ROS, resulting in Gj-protein activation and the
subsequent activation of ERK (Nishida et al, 2000). Therefore, it is possible that the
generation of ROS by substance-P analogues could account for the activation of ERK
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observed in CHO-vector cells. It is promising that despite stimulating ERK activity
in CHO-vector cells, the analogues did not inhibit the growth of these cells. This
maintains that substance-P analogue induced growth inhibition is a consequence of
receptor-mediated effects, i.e. biased agonism.
A body of evidence has accumulated which supports the concept that GPCRs exist
as dimers and studies have shown that a number of receptor properties are altered
as a consequence (Rios et al, 2001). Although the physiological relevance of GPCR
dimerisation is unclear, the agonist-induced dimerisation of bradykinin receptors
has been demonstrated to have consequences on receptor mediated signalling
(AbdAlla et al, 1999). Alterations in ligand properties when used in dimeric form
rather than monomeric form suggest that receptor dimerisation may be involved in
the mechanism of action of such a molecule (Carrithers & Lerner, 1996). In
accordance with this, receptor dimerisation may underlie the anti-proliferative
effects of the bradykinin antagonist dimer (CU201), which functions as a biased
agonist, in contrast with the non-growth inhibiting monomer which functions as an
antagonist (Chan et al, 2002a). V]a receptors have been demonstrated to form
constitutive homodimers during the biosynthetic process (Terrillon et al, 2003) and
homodimerisation of bombesin receptors has been suggested previously (Carrithers
& Lerner, 1996). Therefore, receptor dimerisation may similarly play a role in the
biased agonism of substance-P analogues. A greater understanding of the roles of
receptor dimerisation will undoubtedly influence the direction of future drug
design.
The work presented here suggests that substance-P analogues are able to promote a
neuropeptide receptor conformation which couples more efficiently to Gi proteins
for ERK activation but is not favourable for calcium mobilisation. Consistent with
the ability to recognise and bind a range of unrelated receptors to antagonise the
effects of various neuropeptides, this study also showed that substance-P analogues
bind to a site on the receptor which is distinct from the neuropeptide binding site in
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order to do this. Using chimeric Via receptors, preliminary studies into the basis of
the subsequent generation of Gj-mediated signalling suggested that SP-G exerts
direct conformational effects on the G-protein coupling domains of the V^a
receptor to induce pathway selective signalling. These findings demonstrate that
targeting the G-protein coupling domains of GPCRs to induce pathway selective
signalling can be an effective way of influencing cell fate. This work also shows that
biased agonists can be useful tools for dissecting receptor mediated signal
transduction. However, further work should be carried out to determine the precise
mechanism underlying the effects of the substance-P analogues on the G-protein
coupling domains.
Since low potency and a short half-life are detrimental to the further development of
these substance-P analogues, designing new drugs to supersede these compounds is
likely to be a beneficial endeavour. Given that the substance-P analogues are dual
efficacy ligands, high throughput screening of compounds (which bind mitogenic
neuropeptide receptors) for the ability to activate Gi or G12 proteins (i.e. activate
ERK or JNK with increased efficacy) but not Gq proteins (i.e. block calcium
mobilisation) could be used to identify molecules with similar properties. Lead
compounds could then be optimised to have greater stability (increased
effectiveness) and/or generate non-peptide ligands (reduced cost of synthesis). Due
to the existence of an extensive network of autocrine and paracrine growth loops
sustaining SCLC growth, novel biased agonists for SCLC treatment developed in
the future should ideally incorporate activity against a range of neuropeptide
receptors. In order to facilitate this, future work should focus on exactly how
substance-P analogues are able to act upon different receptors whose ligands are
structurally unrelated. Molecular modelling of the interaction between
neuropeptide receptors and substance-P analogues may be informative in this
respect. Although neuropeptide receptor structures have not yet been resolved due
to difficulties in crystallisation, it may be possible to use the Rhodopsin GPCR
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structure as a framework for modelling studies in the meantime. Mutant receptors
could be used to identify the GPCR region(s) which contribute to the analogue
binding site. Sequence analysis of receptors may subsequently be used to determine
whether the site is conserved amongst analogue sensitive receptors. Rational drug
strategies are traditionally aimed at identifying high potency drugs to keep the
dosage of drug as low as possible and thus minimise side effects. However, it may
be that the low affinity with which substance-P analogues bind to the receptors
determines their ability to interact with a broad-spectrum of neuropeptide
receptors.
This thesis has shown that substance-P analogues, previously characterised as
broad-spectrum neuropeptide antagonists, can also be regarded as broad-spectrum
neuropeptide biased agonists. It could be anticipated that substance-P analogues
which have previously been demonstrated to be antagonists of the mitogenic effects
of other neuropeptides are also likely to be biased agonists of their receptors. This
widens the range of tumour types which could be sensitive to the growth inhibitory
effects of these compounds from those which only express GRP receptors to
potentially any tumour possessing growth loops comprising of at least one
substance-P analogue sensitive neuropeptide receptor. Biased agonism is important
for the antiproliferative and apoptogenic effects of substance-P analogues and this
type of pharmacological activity may have clinical relevance in the treatment of
neuropeptide-dependent tumours. Finally data from this work shows that SCLC
tumours which are resistant following chemotherapy may show increased
sensitivity to substance-P analogues. This has far reaching implications for therapy
as currently there is no effective therapy for SCLC which has relapsed. In vivo
studies focussing on the effectiveness of conventional chemotherapy on SCLC cell
xenografts manipulated in vitro to express varying levels of neuropeptide receptor
would go some way to answering this question. Conversely, the effectiveness of
substance-P analogue therapy on chemosensitive and chemoresistant tumour
growth could be studied.
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Expression of V)A and GRP receptors leads to cellular
transformation and increased sensitivity to substance-P
analogue-induced growth inhibition
AC MacKinnon1, U Tufail-Hanif1, CD Lucas1, D Jodrell2, C Haslett1 and T Sethi*'1
'Centre for Inflammation Research, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK; 2Cancer Research UK,
Medical Oncology Unit Western General Hospital, Crewe Rood South, Edinburgh EH4 2XU, UK
Small-cell lung cancer (SCLC) is a particularly aggressive cancer, which metastasises early. Despite initial sensitivity to radio- and
chemo-therapy, it invariably relapses, so that the 2-year sutvival remains less than 5%. Neuropeptides particularly arginine vasopressin
(AVP) and gastrin-releasing peptide (GRP) act as autocrine and paracrine growth factors and the expression of these and their
receptors are a hallmark of the disease. Substance-P analogues including [D-Arg',D-Phe5,D-Trp7,9,Leu"]-substance-P (SP-D) and
[Arg6,D-Trp7,9,NmePhe8]-substance-P (6-1 I) (SP-G) inhibit the growth of SCLC cells by modulating neuropeptide signalling. We
show that GRP and V|A receptors expression leads to the development of a transformed phenotype. Addition of neuropeptide
provides some protection from etoposide-induced cytotoxicity. Receptor expression also leads to an increased sensitivity to
substance-P analogue-induced growth inhibition. We show that SP-D and SP-G act as biased agonists at GRP and V!A receptors
causing blockade ofGq-mediated Ca2+ release while directing signalling to activate ERK via a pertussis toxin-sensitive pathway. This is
the first description of biased agonism at V|A receptors. This unique pharmacology governs the antiproliferative properties of these
agents and highlights their potential therapeutic potential for the treatment of SCLC and particularly in tumours, which have
developed resistance to chemotherapy.
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Lung cancer is the most common fatal malignancy in the
developed world. Small-cell lung cancer (SCLC), which constitutes
25% of the total, is a particularly aggressive form of lung cancer. It
metastasises early and over 90% of patients have widespread
metastasis at presentation precluding curative surgery. Despite
initial sensitivity to radio- and chemo-therapy, SCLC almost
invariably relapses, so that the 2-year survival remains less than
5% (Smyth et al, 1986). Small-cell lung cancer is a paradigm for
neuropeptide-driven tumourigenesis. Small-cell lung cancer cells
proliferate in response to a range of neuropeptide growth factors
and in many cases these neuropeptides are involved in autocrine
and paracrine growth loops, which fuel unrestrained proliferation
(Moody et al, 1981; Sethi and Rozengurt, 1991; Sethi et al, 1992;
North, 2000). This is thought to be part of a special process of
oncogenic transformation called Selective Tumour gene Expres¬
sion of Peptides essential for Survival (STEPS) (North, 2000). The
expression of neuropeptides and their receptors in tumour cells
may render them sensitive to pharmacological therapeutic
intervention and may be of diagnostic importance for the early
detection of lung cancer and for the selection of appropriate
treatment. Much of the recent studies in SCLC have focused on the
*Correspondence: Dr T Sethi; E-mail: T.sethi@ed.ac.uk
Revised 18 November 2004; accepted 7 December 2004; published
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roles of the specific mitogens gastrin-releasing peptide (GRP, the
mammalian homologue of bombesin) and arginine vasopressin
(AVP).
Gastrin-releasing peptide receptors are frequently aberrantly
expressed in human neuroendocrine tumours of the breast,
prostate, lung and colon (Carroll et al, 1999; Jensen et al, 2001)
where they have both mitogenic and morphogenic roles and confer
a survival advantage in proliferating cancer cells. It has been
suggested that the detection of these markers in the peripheral
blood of patients may be useful as early markers of SCLC.
Scintigraphy with the labelled peptide ligand 99mTc-bombesin/
GRP has been shown to detect prostate cancer and invasion of
pelvic lymph nodes and should be applicable to other endocrine
tumours particularly SCLC (De Vincentis et al, 2004). Monoclonal
antibodies have been developed against circulating bombesin and
one such antibody 2All has been shown to inhibit the growth of
SCLC in vitro and as xenografts in nude mice (Chaudhry et al,
1999); however, it has limited efficacy in human trials.
The presence of AVP and V1A receptors on SCLC tumours has
been extensively studied and the potential presence of an autocrine
growth loop has been established. Small-cell lung cancer patients
frequently display symptoms of inappropriate antidiuretic hor¬
mone secretion such as hyponatremia and urinary hyperosmolality
(Johnson et al, 1997). Independent studies have shown the
expression of VIA receptors in five out of five SCLC lines and
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jero out of four non-small-cell lung cancer (NSCLC) lines (Ocejo-
jarcia et al, 2001) while we showed expression of V1A receptors in
four out of four SCLC lines (Waters et al, 2003). Expression of VIA
(eceptors and vasopressin is the most useful diagnostic tool for
differentiating SCLC from NSCLC and other cancers (Coulson et al,
2003). Therapy that targets V1A receptors may be of potential
benefit for SCLC. Small-cell lung cancer cells can also express the
jVP gene as provasopressin, which remains attached to the cell
membrane and conceivably contributes to the autocrine-driven
mitogenesis (Friedmann et al, 1994). Antibodies recognising this
cell surface antigen have been developed as a potential diagnostic
and therapeutic tool that targets SCLC tumours in vivo (Keegan
ital, 2002).
However, the main focus of research in this drug development
strategy has been in the development of broad-spectrum
neuropeptide antagonists. Synthetic analogues of substance-P for
example, [Arg6,D-Trp7,9,NmePhe8]-substance-P (6-11) (SP-G) were
initially identified as antagonists of substance-P-mediated cellular
effects and were subsequently found to also antagonise the cellular
effects of bombesin (Jensen et al, 1984). SP-G and its analogue SP-
D inhibit calcium mobilisation stimulated by bombesin and
vasopressin in SCLC cells (Woll and Rozengurt, 1988; Langdon
ital, 1992; Sethi et al, 1992). They also inhibit mitogenesis by the
same neuropeptides in both Swiss 3T3 cells and SCLC cells (Woll
and Rozengurt, 1988; Sethi et al, 1992; Seckl et al, 1995) In addition
to the in vitro growth inhibitory effects of substance-P analogues,
these compounds inhibit the growth of tumours in xenograft
models in nude mice (Langdon et al, 1992) and are more effective
than specific neuropeptide receptor antagonists. SP-G has recently
completed a phase I clinical trial where it shows minimal toxicity
at therapeutic plasma concentrations (Clive et al, 2001). However,
its mechanism of action is still being investigated.
Our previous work has shown that SP-G and SP-D do not act as
simple competitive antagonists of GRP receptors but rather act as
biased agonists, inhibiting GRP-stimulated PLC activation via Gq
while directly stimulating JNK and ERK via G12 and G;, respectively
(Tallet et al, 1996; Jarpe et al, 1998; MacKinnon et al, 1999, 2001)
The prolonged stimulation of JNK and ERK coupled with an
inhibition of intracellular Ca2+ is fundamental for the antiproli¬
ferative and proapoptotic effects of these agents (MacKinnon et al,
2001, Waters et al, 2003). It is not known whether these compounds
interact with vasopressin receptors in the same fashion.
It was the objective of the present study to examine the effect of
GRPr and VIAr expression, the two most common neuropeptide
receptors present on SCLC, on growth and transformation of the
epithelial cell line, CHO-K1. We show that expression of these
receptors leads to an increase in basal and anchorage-independent
growth in low serum, and an increased sensitivity to substance-P
analogues. As well as directing GRP receptor signalling, substance-
P analogues also act as biased agonists at V1A vasopressin
receptors. These combined effects will be useful for SCLC therapy
and particularly in targeting well-differentiated tumours, which
have developed resistance to chemotherapy.
METHODS
Materials
CHO-K1 cells were purchased for the European Cell Culture
Collection; Dulbecco's modified Eagle's medium (DMEM), GRP,
bombesin and monoclonal antibody to diphosphorylated ERK 1 and
2 (M 8159) were from Sigma (Poole, UK); ([D-Arg'.D-Phe5^-
Trp7,9,Leuu]-substance-P (SP-D) and [D-Arg6,D-Trp7, .W'The8]-
substance-P (6-11) (SP-G) were synthesised by Cancer Research
UK (London, UK). The human VjA receptor construct in pcDNA3.1
was a kind gift from M Thibonnier (Case Western Reserve
University School of Medicine, OH, US). The human GRP receptor
in pcDNA3.1 was from J Battey (Albert Einstein College ofMedicine,
NY, USA). [I25I]-Arginine vasopressin (2000Cimmol_1) and [125I]-
GRP were from Amersham International (Amersham, UK).
Cell culture and transfection
CHO-K1 cells were maintained in DMEM supplemented with 10%
(vv_I) foetal bovine serum (heat-inactivated at 57°C for 1 h)
50Uml_1 penicillin, 50pgml_1 streptomycin and 5pgml_I L-
glutamine in a humidified atmosphere of 5% C02:95% air at 37°C.
CHO-K1 cells were transfected with full-length human GRP
receptor or human V1A receptor using lipofectamine plus
(Invitrogen) as per the manufacturer's instructions. Stable cell
cultures were maintained in the presence of 400pgml_1 G418-
sulphate.
Receptor binding
Receptor binding was carried out in confluent and quiescent
cultures of CHO-Kl-V1Ar and GRPr cells in a binding medium
containing DMEM, lmgml-1 bovine serum albumin and radi¬
oligand (1.0 nM GRP containing 2nCi [125I]-GRP or 0.6nM AVP
containing 45nCi [125I]-AVP. Incubations were carried out at 37°C
for 30min in the presence of inhibitors as indicated. Nonspecific
binding was defined in the presence of 1 pM GRP or AVP,
respectively. The reaction was stopped on ice and unbound ligand
was removed by washing x 3 with ice-cold phosphate-buffered
saline. After solubilisation in 0.1 M NaOH, 2% Na2C03 containing
1% SDS, bound ligand was estimated by liquid scintillation
counting. The binding parameters Kd and Bmax were calculated
from competition binding isotherms with unlabelled ligand
(DeBlasi et al, 1989). The IC50 (concentration of drug displacing
50% specific binding) was converted to the inhibitory constant
(K;), where Ki = IC50/(l + [ligand]/Kd) (Cheng and Prusoff, 1973).
Growth assays
Liquid growth Exponentially growing CHO-K1 cells were trypsi-
nised and suspended in DMEM with 5% FCS at a density of
5 x 104 cells per plate in the presence or absence of mediators in
triplicate. Cells were grown for 1-9 days and cell number
determined using a Coulter Counter (model Zl, Coulter).
MTT assay In some assays, MTT (3-[4,5-dimethylthiazol-2yl]-
2,5-diphenyl tetrazolium bromide) formazan production (Sigma)
was used to measure proliferation as per the manufacturer's
instructions.
Clonogenic assay CHO-K1 (2xl04) viable cells were mixed with
DMEM containing 0.3% agarose in the presence or absence of
mediators and layered over a solid base of 0.5% agarose in DMEM
in 35 mm plastic dishes. The cultures were incubated at 37°C for
1-10 days, and then stained with 1 mgml-1 nitro-blue tetrazolium
(NBT, Sigma) overnight at 37°C. Colonies from 10 separate fields
were counted using a microscope with a x 4 objective. Cloning
efficiency is calculated as the percentage of original number of
seeded cells forming colonies of >6 cells.
Aggregation assay CHO-K1 cells were suspended in DMEM in the
presence of 5% FCS and seeded into low adhesion tissue culture
plates on top of a layer (1 ml) of 0.5% agar. Under these conditions,
the cells did not adhere. Cells were maintained in culture for 7 days
briefly trypsinised to disaggregate clusters and viable cells counted.
Determination of intracellular Ca2 + concentration
CHO-K1 cells expressing the GRP or V1A receptor were grown to
confluence on 10 cm plates and quiesced overnight in DMEM
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containing 0.1%. FCS. Cells were trypsinised and loaded with fura-
2-tetraacetoxymethylester AME (FURA-2-AM, 1 /im) in calcium-
free Hank's balanced salt solution for lOmin at 37°C. The cells
were pelleted and resuspended in 2ml of Hank's balanced salt
solution containing 1.8 mM CaCl2. Fluorescence was recorded in a
fluorescence spectrophotometer (Perkin Elmer). Alternate dual
wavelength excitation at 380 and 410 nm allowed ratiometric
analysis of bound and unbound FURA-2AM when measured at
505 nm. [Ca2 + ] was calculated according to the equation
[Ca2 + ] =JC(F—Emi„)/(Fmax—E), where F is the ratio of the
unknown sample, Fmax is the ratio after the addition of 0.1%
Triton X-100 and Fmin is the ratio after Ca2+ chelation with 10mM
EGTA. K is the dissociation constant for Fura-2, which is 224 nM.
Western blotting
Quiescent cell cultures in six-well plates were treated as described
in figure legends and lysed at 4°C in 0.25 ml lysis buffer containing;
25 mM HEPES pH 7.4, 0.3 m NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5% Triton X-100, 20 mM /l-glycerphosphate, 0.5 mM dithiothrei-
tol, 1 mM sodium orthovanadate and protease inhibitors (Boeh-
ringer Mannheim, Sussex, UK; prepared as per the manufacturer's
instructions). Lysates were clarified by centrifugation, equilibrated
for protein using BCA protein assay reagent (Perbio Science,
Cheshire, UK) and denatured by boiling (5min) in SDS-PAGE
loading buffer. In all, 20/d lysate/lane was resolved on 12% SDS-
PAGE gels and electroblotted onto nitrocellulose membranes.
Membranes were blocked in 3% bovine serum albumin in PBS
containing 0.05% Tween-20. ERK1/2 phosphorylation was deter¬
mined using 1:1000 dilution of the primary antibody followed by
the appropriate HRP-labelled goat IgG (DAKO, UK) diluted
1: 5000. Bands were visualized using enhanced chemiluminescence




To assess receptor expression, stable cultures of CHO-K1-GRP and
CHO-Kl-V[A cells were incubated with the appropriate radioli¬
gand, and receptor number and affinity were measured from
competition binding curves with unlabelled ligand. Figure 1 shows
that GRP receptors were expressed with Kd = 2.55 + 0.84 nM and
Bmax of 1151 + 326 sites/cell (n = 4). ViA receptors were expressed
at a slightly lower level with a Bmax = 450 + 80 sites/cell and
Kd = 2.98 + 0.71 nM (n = 4, Figure IB). The substance-P analogues
SP-G and SP-D inhibited [ 25I]-GRP binding with affinities in
the micromolar range (SP-G K;= 19.4 + 6.3^m (n = 4), SP-D
K; = 0.64+ 0.05 pM (n = 4, Figure 1)). Both analogues also inhibited
V1A receptor binding ((SP-G K) = 3.50 + 0.82 /.im (n — 4), SP-D
K; = 8.58 +1.47/tM (n = 4)). This data show that SP-G is relatively
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Figure I Receptor binding. Gastrin-releasing peptide (A, C) orV!A (B, D) receptor expressing CHO cells were incubated wrth [l2SI]-GRP or [l25l]-AVP
for 30 min at 37°C as described in Methods in the presence of various concentrations of unlabelled GRP (A), unlabelled AVP (B), SP-D or SP-G (C, D).
Results are expressed as % total binding and represent the mean + s.e.m. of four experiments performed in triplicate.
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Effects of V1A and GRP receptor expression on cell growth
ji liquid culture and semisolid media
figure 2A shows that in liquid culture, in the presence of 5% FCS,
lie GRP and the V1A expressing cells proliferated at a similar rate
lo untransfected CHOs, but on day 6 after seeding, the GRP cells
iad reached a density of 4.5 x 106 cells per 100mm dish. The cells
did not appear to be contact inhibited and exhibited a rounded
morphology. Cells over grew one another and significant numbers
of cells were observed to be detached and growing in clusters
(Figure 2B). Trypan blue exclusion revealed that the cells were
>95% viable. A similar, though less pronounced, effect was
observed with the V1A-transfected cells, which reached a density of
3,1 x 106 cells per 100mm dish. The parental cell line exhibited
normal contact inhibition and had flat fibroblast morphology and
did not show significant detachment. The end point density of
these cells was 2.1 x 106 cells per 100mm dish. These observations
suggested that transfection of GRP and ViA receptors caused CHO-
K1 cells to lose contact inhibition and adopt a more transformed
phenotype. These findings led us to examine their growth in
semisolid media, which is widely regarded as being a hallmark of
the transformed phenotype. Cells were trypsinised and suspended
in 0.3% agarose in DMEM (1 x 104cellsml_1) layered over a 0.5%
layer of agarose in DMEM. Figure 2C shows that at day 9 after
seeding, clusters of cells (> 6 cells) were visible with MTT staining.
The cloning efficiency was significantly higher in the GRP-
expressing cells (14.1 + 1.5%, P<0.05, ANOVA) and the V1A
receptor-expressing cells (8.5 + 1.0%, P<0.05, ANOVA) than the
vector control cells in the presence of 5% FCS (5.5 + 0.02%). In a
separate series of experiments, the effects of SP-D and SP-G were
examined (Figure 3A). At 30 fiM, both analogues significantly
reduced colony formation in the GRP and V1A receptor expressing
cells but had no effect on the cloning efficiency of vector control
CHO-K1 cells. The effect of receptor expression was also examined
in an aggregation assay where cells are prevented from adhering
and form aggregates in suspension. After 6 days, cells are briefly
trypsinised and viable cells counted. These experiments showed
that expression of the GRPr and V1Ar increased anchorage-
independent growth compared to wild-type cells or vector control
cells. Similarly SP-G and SP-D were able to inhibit cell growth in
receptor expressing cells (Figure 3B). Together, these data suggest
that expression of the GRP and V1A receptors induce a more
transformed phenotype in CHO cells and induce sensitivity to
substance-P analogue-induced growth inhibition.
Chemosensitivity
The response to etoposide in control and receptor-transfected cells
was measured byMTT accumulation. Figure 4 shows that after 48 h
in culture in the absence of serum, etoposide produced a dose-
dependent inhibition of proliferation in all cell types
(IC50 = 12.4±3.1, 8.1+2.3 and 14.2±4.0pgmr1 in CHO-WT,
CHO-GRPr and CHO-V1Ar cells, respectively). Incubation with
50 nM of either bombesin or AVP added to CHO-GRPr or CHO-
ViAr produced a small but significant protection from etoposide,
which was not observed when both neuropeptides were added to
wild-type cells (IC50 = 13.0 and 26.9pgml-1 in control and AVP-
treated V1Ar-expressing cells, respectively; and 6.30 and
12.7 pgml-1 in bombesin-treated GRPr-expressing cells, respec¬
tively). At 40pgml_I etoposide, vasopressin-treated V1Ar-expres-
sing cells accumulated 92% more MTT than control cells
B
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Figure 2 Effect of neuropeptide receptor expression on cell growth liquid growth (A) CHO-KI cells expressing vector, the GRP or V!A receptor were
plated at a density of I e4 cells/100 mm tissue culture dish and incubated at 37°C. Cells were harvested at various times and counted. Results represent the
mean + s.e.m. of three experiments performed in duplicate (*significantly different from vector control cells P< 0.05, ANOVA). (B) Representative images
showing morphological features of transfected cells are shown. The rounded cobblestone features and higher cell density are evident in neuropeptide
receptor expressing cells compared to the elongated contact inhibited monolayer exhibited by vector transfected controls. Clonal growth vector (open bars),
GRP receptor (black bars) and V|A receptor (grey bars) transfected cells were plated at I e4 cellswell"' in 0.3% agar in DMEM containing I % (C) or 5% (D)
FCS. At various time points, cells were stained with MTT and colonies counted at x 10 magnification. Results represent the mean ± s.e.m. of three
experiments performed in duplicate (*significantly different from vector control cells P<0.05, ANOVA).
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Figure 3 Effect of SP-D and SP-G on clonal growth. (A) Cells were
grown in 0.3% agar with l% FCS for 8 days in the presence or absence
(open bar) of 30/jm SP-D (black bar) or SP-G (grey bar). Results represent
the mean + s.e.m. of three experiments performed in duplicate ^sig¬
nificantly different from wild-type controls P<0.05, ANOVA). Aggregation
assay. (B) Wild-type, GRPR-transfected and V|AR-transfected CHO-KI
cells were plated into low adhesion tissue culture plates on top of a layer of
0.5% agar in DMEM containing 5% FCS at a density of 5 x I04 ml"' in the
presence of varying concentrations of SP-G. Cells were maintained in
culture for 7 days, briefly trypsinised to dissagregate clusters and viable cells
counted by propidium iodide exclusion.
(P<0.01). In GRPr-expressing cells, bombesin treatment caused an
increase of 52% MTT accumulation compared to untreated cells
(P<0.01). These results suggest that neuropeptide receptor
stimulation may contribute to an increase in chemoresistance.
Intracellular [Ca2 ' ];
The mobilization of calcium from intracellular stores is one of the
earliest events triggered by neuropeptide receptor activation of Gaq
leading to PLC activation and subsequent generation of IP3. In
untransfected CHO-KI cells, neither GRP nor AVP produced a
significant change in [Ca2 + ], (data not shown). In the CHO-GRP
cells, GRP produced a concentration-dependent increase in
[Ca2 + ]; (EC50 = 2.00± 0.4 nM, n = 5, Figure 5A). SP-D and SP-G
produced no change in [Ca2 + h on their own but inhibited GRP-
induced [Ca2 + ]; elevation. Figure 5A and B show that SP-D and
SP-G inhibited GRP-induced [Ca2 + ]j with resultant pA2 values of
7.21 and 5.72 for SP-D and SP-G respectively. In V1A-express-
ing cells, AVP increased calcium mobilisation with an
EC50 = 3.1 + 0.60 nM (n = 4, Figure 5C and D). As in the GRP-
expressing cells, SP-D and SP-G did not mobilise intracellular
calcium directly but inhibited the response to AVP (Figure 5C and
D). SP-G was more efficacious in inhibiting the vasopressin
response than the GRP response. PA2 values for AVP antagonism
were 7.23 and 6.53 for SP-D and SP-G, respectively. Together, these
data suggest that when stably transfected into CHO cells the GRP
and the ViA receptor effectively couple to G,q to increase
intracellular calcium and that the substance-P analogues are
effective antagonists of this response.
ERK activation
AVP and bombesin have been shown to activate extracellular
regulated protein kinases (ERK 1 and 2) in a variety of cell types
expressing the receptors. Much of these data suggest a Gq- and
PKC-dependent mechanism although these observations may be
cell type-dependent (Delia Rocca et al, 1999; Sinnett-Smith et al,
2000). Previous studies have shown that substance-P analogues
reversibly inhibit ERK activation by neuropeptides in Swiss 3T3
cells; however, our studies suggest that in rat-1 fibroblasts and in
human small-cell lung carcinoma cells (SCLC), in the absence of
bombesin, substance-P analogues can activate ERK and c-jun
kinase (JNK) in a GRP receptor-dependent manner (MacKinnon
et al, 2001). In this study, ERK activation was measured in CHO
cells expressing GRP or V1A receptors in response to the
appropriate neuropeptide or substance-P analogue. Activation
was estimated in immunoblots from stimulated lysates using a
cho-k1
100
Etoposide concentration (/ig ml
Figure 4 Effect of neuropeptide on chemosensitivity. Wild-type CHO-KI cells (left) and cells expressing the V|A (middle) or GRP (right) receptor were
plated at a density of I e4 cells per well of a 96-well tissue culture plate in DMEM with 10% FCS and incubated overnight 37°C. Cells were then incubated in
serum-free media containing etoposide as indicated and in the absence (filled squares) or presence of either 50 nM AVP (open squares) or 50 nM bombesin
(open circles) or both neuropeptides (wild-type cells) for 48 h at 37°C. Cell viability was assessed by MTT staining. Results are expressed as % viability in the
absence of neuropeptide and are mean + s.e.m. of four independent experiments (*significantly different from untreated etoposide control, P<0.05
ANOVA).
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Figure 5 Intracellular calcium release. Quiescent GRP (A, B) or V| A (C, D) receptor expressing CHO cells were incubated with FUF3A-2AM for 15 min
at 37°C and ratiometric fluorescence monitored at 37°C. Concentration-response curves to bombesin were carried out in control cells and in cells
pretreated for 2min with I or 10//M SP-D (A) or SP-G (B). Concentration-response curves to vasopressin were carried out in control cells and in cells
treated with I or 10 pM SP-D (C) or SP-G (D). Results are expressed as % maximum control response to neuropeptide and represent the mean + s.e.m, of
four experiments.
phosphorylation state-specific antibody. Lysates from quiesced
cells stimulated for 10min with either neuropeptide or SP-D or SP-
G were separated on 12% gels and blotted for pERK2 or total
ERK1/2. Figure 6A shows that bombesin stimulated ERK
phosphorylation in GRP-expressing CHO cells. Quantification of
five separate experiments showed that bombesin produced a
maximal 3.5-fold increase in ERK phosphorylation at 1 nM with an
I EC50 of 0.56 nM. In V1A-expressing cells, AVP produced an increase
in ERK phosphorylation of 4.2-fold with an EC50 of 0.72 nM, which
j correlated with its affinity for V1A receptors measured in binding
studies and for the stimulation of intracellular calcium. Neither
AVP nor GRP produced any stimulation of ERK phosphorylation
in untransfected CHO cells (data not shown).
SP-D and SP-G stimulated ERK activation in GRP receptor
expressing CHO cells (Figure 6B). Activation ofERK was evident at
3pM for SP-D, but the maximal stimulation was less than that
observed with bombesin (2.8-fold for SP-D and 2.1-fold for SP-G at
50/im). The substance-P analogues also stimulated ERK in V1A-
expressing cells. However, in these cells SP-G was more efficacious
than SP-D giving a 4.3-fold stimulation at 50 qM compared to a 2-
fold stimulation by the same concentration of SP-D. The observed
increase in ERK phosphorylation was not due to a change in total
ERK expression, as ERK1/2 immunoreactivity did not change with
drug treatment. These data show that at concentrations, which
block neuropeptide-stimulated calcium release, substance-P ana¬
logues are agonists for ERK activation in GRP and V1A expressing
CHO cells.
Mechanisms of ERK phosphorylation
The mechanisms of GRP- and V1Areceptor-mediated ERK activa¬
tion are not fully understood, although it has been shown in some
cell types that activation is mediated by Gq-induced PKC activation
and subsequent activation of raf. Other GPCRs have been shown to
activate ERK in a G; and ras-dependent mechanism, which may or
may not involve activation of PI3K (Delia Rocca et al, 1999). To
examine the possible recruitment of G,, CHO cells were incubated
overnight in quiescent media containing lOOngml-1 pertussis
toxin. Figure 7 shows that in GRP receptor expressing cells, PTX
produced a small but nonsignificant inhibition of bombesin-
stimulated ERK activation whereas the response to 10 /im SP-D was
completely abolished (P<0.01, ANOVA). In V[A-expressing cells,
the response to AVP was not inhibited by PTX pretreatment but
the response to SP-G (20 pM) was completely inhibited (P<0.01,
ANOVA). In both cell types, ERK activation by 1 /im LPA was
completely inhibited by PTX treatment (data not shown). This
differential sensitivity to pertussis toxin indicates that dual G;/Gq-
coupled mechanisms activate the ERK 1/2 cascade via GRP and
V1A receptors expressed in CHO cells.
DISCUSSION
This study utilised a model CHO cell system for neuropeptide
receptor expression as these cells have an acceptable null
background for these receptors. The results from this work shows
that (1) GRP and V1A receptor expression leads to the development
of a transformed phenotype in CHO-K1 cells. (2) Receptor
expressing cells showed some increased resistance to the
chemotherapeutic agent etoposide and increased sensitivity to
the substance-P analogues, SP-D and SP-G. (3) SP-D and SP-G act
as biased agonists at GRP and V1A receptors. This is the first
demonstration of biased agonism at vasopressin receptors. (4)
This pharmacological activity is crucial for the antiproliferative
effect of these agents, which may be of particular benefit in more
differentiated cancers that have developed resistance to che¬
motherapy.
Introduction of the neuropeptide receptors into CHO cells lead
to an increase in proliferation and an increase in the ability of cells
to grow as colonies in semisolid medium. The cells also showed a
greater propensity to grow as nonadherent clusters. Colony growth
was also evident in low serum suggesting that expression of these
receptors allows for anchorage- and serum-independent growth
consistent with transformation. Moreover, it suggests that these
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Figure 6 (A) ERK phosphorylation by neuropeptides. Quiescent GRP (left) or V|A (right) receptor expressing CHO cells were stimulated for 5 min with
neuropeptide at the indicated concentrations. Aliquots of cell lysate were resolved by SDS-PAGE and Western blots probed with monoclonal anti-pERKI/
2 antibody (upper panel) or polyclonal anti-ERK2 antibody (lower panel). Representative Western blots are shown. Bar graphs represent the mean optical
density (mean + s.e.m.) of four separate experiments. (B) ERK phosphorylation by substance-P analogues. Quiescent GRP (left) or V|A (right) receptor
expressing CHO cells were stimulated for 5 min with SP-D (filled bars) or SP-G (open bars) at the indicated concentrations. Aliquots of cell lysate were
resolved by SDS-PAGE and Western blots probed with monoclonal anti-pERKI/2 antibody (upper panel) or polyclonal anti-ERK2 antibody (lower panel).
Representative Western blots are shown. Bar graphs represent the mean optical density (mean + s.e.m.) of four separate experiments.
receptors show some constitutive activity, as wild-type receptor
expression alone was sufficient to increase transformation in the
absence of exogenously added neuropeptide. The ability to observe
constitutive GPCR activity is not only determined by the intrinsic
molecular properties of the GPCR studied but also by the specific
cellular background. Apparent constitutive activity of a wild-type
GPCR may vary substantially in various systems. Differences in
GPCR expression level, GPCR desensitisation, G-protein comple¬
ment and GPCR/G-protein stochiometry can all contribute to such
differences (Seifert and Wenzel-Seifert, 2002) This could explain
why GRP receptors expressed in NCM460 cells, a nonmalignant
human colon epithelial cell line, are constitutively active (Ferris
et al, 1997) but are not in other cell types (Benya et al, 1994). Our
findings are unlikely to be due to an overexpression artefact as the
receptors in this study were expressed at levels not greater than
those measured from a variety of other cancers (100-50 000 sites/
cell, Jensen et al, 2001) So at these moderate levels, wild-type
receptor was sufficient to activate downstream signals that
promote cell survival under anchorage-independent conditions.
The cells were, however, still able to respond to agonist, which
resulted in a small but significant increase in resistance to the
cytotoxic effects of etoposide. It is unclear how significant this
change in sensitivity relates to the development of chemoresistance
in vivo, but highlights an important area for future investigation.
Our previous work shows that sensitivity to AVP and GRP
increases during the progression to chemoresistance in a set of
SCLC cell lines (Waters et al, 2003). This would be analogous to the
development of autocrine and paracrine growth loops in tumour
development in vivo, with tumour cells becoming more dependent
on neuropeptide growth factors for survival and subsequently
developing chemoresistance. The mechanisms governing the
survival advantage gained in neuropeptide receptor expressing
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:igure 7 Effect of pertussis toxin (PTX) on ERK phosphorylation. Confluent cultures of GRP (left) or Via (right) receptor expressing CHO cells were
luiesced overnight in the presence or absence of lOOngmr1 pertussis toxin. Cells were stimulated for 5min with 30 /tm SP-D or SP-G or I nM
leuropeptide as indicated. Aliquots of cell lysate were resolved by SDS-PAGE and Western blots probed with monoclonal anti-pERKI/2 antibody (upper
ianel) or polyclonal anti-ERK2 antibody (lower panel). Representative Western blots are shown. Bar graphs represent the mean optical density
mean+ s.e.m.) of four separate experiments (*significantly different from untreated control, P<0.05 ANOVA).
:ells are poorly understood. During colon cancer progression,
ncreased expression of GRP receptors leads to tumour cell
lifferentiation, increased motility and adhesion to extracellular
natrix via an increased activation of focal adhesion kinase (FAK)
Glover et al, 2004). Previous reports have shown that GRP
eceptors can activate insulin-like growth factor-1 receptors (IGF-
R) leading to Akt activation in prostate cancer cells (Sumitomo
•t al, 2001), a mechanism which may underlie bombesin-mediated
sell survival. In another study, human chorionic gonadotrophin
|hCG) increased ovarian cell survival by up-regulating IGF-1
IKuroda et al, 1998). Conversely, specific bombesin antagonists
lave been shown to inhibit growth and decrease EGF receptor
expression in SCLC cells (Koppan et al, 1998) and breast cancer
sells (Bajo et al, 2002). Bombesin antagonists in combination with
3HRH antagonists have also been shown to down-regulate IGF-1,
IGF-I1, IGF receptors, GRP and EGF receptors in SCLC xenografts
(Kanashiro et al, 2003). There is therefore potential for neuropep¬
tides to regulate growth factor signalling pathways that control
survival.
The present study shows that expression of GRP and V1A
receptors in CHO cells also leads to an increased sensitivity to
substance-P analogues. This was demonstrated by an inhibition of
clonal growth by substance-P analogues only in receptor-
transfected cells. We previously showed that substance-P analo¬
gues are more effective at inhibiting growth of chemoresistant
tumour cells expressing high GRP receptor levels and can sensitise
cells to etoposide-mediated cell death (Waters et al, 2003).
Moreover, diverse tumour types expressing GRP receptors have a
greater sensitivity to SP-D (Waters et al, 2003). Together, these
data suggest that the increase in neuropeptide receptor expression
that occurs as cells become more differentiated may contribute to
the development of chemoresistance and may be exploited as a
target for drug therapy. The potential role of neuropeptide
receptors in the development of chemoresistance is an interesting
finding that requires further study.
The mechanism of action of substance-P analogues was studied
in receptor-transfected cells. Upon neuropeptide receptor transfec-
tion, the cells responded to the appropriate neuropeptide as
expected for these predominately Gq-coupled receptors. The
substance-P analogues behaved as antagonists for Ca2+ release
with potencies that reflected their affinities in receptor binding
experiments, with SP-G showing some selectivity for V1A
receptors. This may be useful in tailoring therapy to a specific
tumour phenotype in as much as SP-G may be more beneficial in
V1A receptor expressing tumours while SP-D may be better for
tumours, which express both GRP and V1A receptors. Both
neuropeptides and the substance-P analogues activated ERK in
CHO cells expressing the GRP receptor and the V1A receptor. No
ERK activation was observed in untransfected CHO cells suggest¬
ing that the activation is receptor mediated. These observations
suggest that substance-P analogues act as dual efficacy receptor
agonists directing receptor signalling via the GRP and the Via
receptor towards ERK activation while blocking liberation of
intracellular calcium. Moreover, the substance-P analogues acti¬
vate ERK via G| as the response is pertussis toxin sensitive and
more prolonged than that observed with neuropeptide (data not
shown). These data support a multitrack signalling complex
leading from neuropeptide receptor to ERK activation; where one
track is mediated by Gq and most likely involves PKC, whereas
another feeds into a Gj-mediated pathway (Wetzker and Bohmer,
2003). Although by far the majority of evidence suggests a
preference for interacting with Gq, some previous work has shown
V1A receptors coupling to Gia3 in quiescent fibroblasts and in
hepatocytes (Strakova et al, 1997; Abel et al, 2000) There is also
evidence that GRP receptors couple to G, in pancreatic acinar cells
(Profrock et al, 1992), and that G, mediates bombesin-stimulated
chemotaxis in monocytes (Djanani et al, 2003). Our data suggest
that in the presence of substance-P analogues, the neuropeptide
receptors exist in a conformation that is unable to activate Gq but
which is able to interact with G; and activate ERK. These analogues
may act at a common region of the GPCRs perhaps at the receptor/
G-protein interface, which favours coupling to G,. Although
activation of ERK is normally associated with a mitogenic response
as is seen with the neuropeptides, deregulated ERK activation has
also been shown to cause disruption of the cell cycle, growth arrest
and apoptosis. In SCLC-activated raf-1, the upstream regulator of
ERK causes growth arrest (Ravi et al, 1998). It is our hypothesis
that deregulated ERK coupled with a decrease in intracellular Ca2 +
are important factors in the growth inhibitory/apoptosis inducing
activity of substance-P analogues.
In summary, the results presented here show that neuropeptide
receptor expression leads to the development of a transformed
phenotype in CHO epithelial cells. These cells display increased
sensitivity to substance-P analogues that parallels the situation
observed in SCLC cells, which develop chemoresistance in vivo.
These analogues activate GRP and V1A receptors in such a way as
© 2005 Cancer Research UK British Journal of Cancer (2005) 92(3), 522-531
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to cause activation of only a subset of possible downstream signals.
They are competitive antagonists for PI hydrolysis mediated via Gq
but have agonist activity that results in activation of ERK via Gj.
This presents a novel pharmacological mechanism whereby
substance-P analogues utilise the normally mitogenic neuropep¬
tide receptors to transduce an antiproliferative and apoptogenic
cell signal. Moreover, the concentration of SPG used in this study
was detected in patient plasma following administration with no
noticeable toxicity (Clive et al, 2001), suggesting therapeutic doses
can be achieved clinically. Development of these agents may
provide a unique opportunity to treat SCLC and may be of
particular benefit for tumours that have developed resistance to
chemotherapy.
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Increased gastrin-re I easing peptide (GRP) receptor expression
in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-
substance P (6-1 l)-induced growth inhibition
CM Waters', AC MacKinnon1, J Cummings2, U Tufail-Hanif1, D Jodrell2, C Haslett1 and T Sethi*'1
'Lung Inflammatory Group, Centre for Inflammation Research, University of Edinburgh Medical School, Hugh Robson Building, George Square, Edinburgh
EH8 9XD, UK; 2Cancer Research UK Medical Oncology Unit Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK
[Arg6,D-Trp7,9,NmePhe8]-substance P (6-1 I) (SP-G) is a novel anticancer agent that has recently completed phase I clinical trials.
SP-G inhibits mitogenic neuropeptide signal transduction and small cell lung cancer (SCLC) cell growth in vitro and in vivo. Using the
SCLC cell line series GLC14, 16 and 19, derived from a single patient during the clinical course of their disease and the development
of chemoresistance, it is shown that there was an increase in responsiveness to neuropeptides. This was paralleled by an increased
sensitivity to SP-G. In a selected panel of tumour cell lines (SCLC, non-SCLC, ovarian, colorectal and pancreatic), the expression of
the mitogenic neuropeptide receptors for vasopressin, gastrin-releasing peptide (GRP), bradykinin and gastrin was examined, and
their sensitivity to SP-G tested in vitro and in vivo. The tumour cell lines displayed a range of sensitivity to SP-G (IC50 values from 10.5
to I 19^). The expression of the GRP receptor measured by reverse transcriptase-polymerase chain reaction, correlated
significantly with growth inhibition by SP-G. Moreover, introduction of the GRP receptor into rat-1A fibroblasts markedly increased
their sensitivity to SP-G. The measurement of receptor expression from biopsy samples by polymerase chain reaction could provide a
suitable diagnostic test to predict efficacy to SP-G clinically. This strategy would be of potential benefit in neuropeptide receptor-
expressing tumours in addition to SCLC, and in tumours that are relatively resistant to conventional chemotherapy.
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Despite recent advances in cytotoxic drug development, it is a
universal goal to develop novel cancer therapies that are more
specific to cancer cells and produce minimal damage to
nonmalignant cells. One approach to realising this goal is the
development of drugs that are able to block the growth-promoting
effects of cancer cell mitogens.
Neuropeptides are important growth factors in a number of
cancers including breast, colon, pancreatic, prostate, renal, gastric
carcinoma and small-cell lung cancer (SCLC). SCLC cells
proliferate in response to a range of neuropeptide growth factors,
and in many cases these neuropeptides are involved in autocrine
and paracrine growth loops that fuel unrestrained proliferation
(Moody et al, 1985; Sethi and Rozengurt, 1991; Sethi et al, 1992,
1993; North et al, 1997). Drugs that target specific mitogenic
neuropeptides have shown little promise. Monoclonal antibodies
have been developed against circulating bombesin and one such
antibody, 2A11, has been shown to inhibit the growth of SCLC in
vitro and also as xenografts in nude mice (Chaudry et al, 1999);
however, it has limited efficacy in human trials. Thus, 'broad-
spectrum' neuropeptide receptor antagonists have been the main
focus of research in this drug development strategy. Synthetic
analogues of substance P, for example, [Arg6,D-Trp7,9,NmePhe8]-
substance P (6-11) (SP-G), were initially identified as antagonists
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of substance P-mediated cellular effects and were subsequently
found to also antagonise the cellular effects of bombesin (Jensen
et al, 1984). When tested in SCLC cell lines, it was found that
several substance P analogues inhibited calcium mobilisation
stimulated by the neuropeptides; bombesin, bradykinin, gastrin,
galanin, vasopressin, cholecystokinin and neurotensin (Woll and
Rozengurt, 1988; Langdon et al, 1992; Sethi et al, 1992). They were
also found to inhibit mitogenesis by the same range of
neuropeptides in both Swiss 3T3 cells and SCLC cells (Woll and
Rozengurt, 1988; Bepler et al, 1989; Sethi et al, 1992).
In addition to the in vitro growth-inhibitory effects of substance
P analogues, these compounds inhibit the growth of tumours in
xenograft models in nude mice (Langdon et al, 1992; Jones et al,
1997). SP-G has recently completed a phase I clinical trial and will
be entering a phase II clinical trial in SCLC in the near future (Clive
et al, 2001). The exact mechanism by which these compounds exert
their antitumour effects are unknown, but we have previously
shown that they act as 'biased' agonists inhibiting neuropeptide-
stimulated growth while directly stimulating apoptosis (Tallett
et al, 1996; MacKinnon et al, 1999, 2001). Understanding the exact
manner in which substance P analogues modulate neuropeptide
receptor signalling will allow for the rational design ofmore potent
analogues. Identification of biological features in tumours that
confer sensitivity to SP-G will elucidate the most effective use of
this group of compounds in clinical practice.
In this study, we measured the expression of the mitogenic
neuropeptide receptors for vasopressin (V1A), gastrin-releasing
peptide (GRP), bradykinin (BK2) and gastrin by reverse
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transcriptase-polymerase chain reaction (RT-PCR), and show
that GRP-receptor expression predicts sensitivity to SP-G in a
variety of tumours (SCLC, non-small-cell lung cancer (NSCLC),
colorectal, ovarian and pancreatic) in vitro and in vivo. Our results
suggest that an antineuropeptide growth factor strategy may be
effective in a wider range of tumours and may also be of benefit in
these neuropeptide-expressing tumours, which have acquired
relative resistance to conventional chemotherapeutic agents.
MATERIALS AND METHODS
Materials
Rat-la cells and rat-la cells stably expressing the mouse bombesin/
GRP receptor (GRPR) (BOR-15) were established by the Imperial
Cancer Research Fund (ICRF, London, UK). RPMI-1640,
Dulbecco's essential Eagle's medium (DMEM), bombesin and
vasopressin were from Sigma (Poole, UK). SP-G was a kind gift
from Peptec (Copenhagen, Denmark). All other reagents were of
the purest grade available.
Cell culture
Stocks were maintained in RPMI-1640 (tumour cell lines) or
DMEM (nontumour cell lines) supplemented with 10% (vv_1) fetal
bovine serum (heat-inactivated at 57°C for 1 h) 50 Uml-1
penicillin, 50^gml_1 streptomycin and 5/rgml-1 L-glutamine in
a humidified atmosphere of 5% C02:95% air at 37°C. For
experimental purposes, cells were either grown in SITA medium
(RPMI-1640 medium supplemented with 30 nM selenium, 5/tgmI-1
insulin, lOpgml-1 transferrin media supplement and 0.25%
bovine serum albumin (tumour cell lines)) or with 0.1% (vv_l)
fetal bovine serum in DMEM (nontumour cell lines). Rat-IA
fibroblasts stably transfected with the mammalian bombesin
receptor (BOR-15 cells) were cultured in the presence of
400^gml-1 G418-sulphate.
1809
by i.p. injection in a volume of 0.1 ml per 20 g of body weight to
yield a dose of 50mgkg_1. The dose schedule employed was twice
daily injections with an 8 h gap for a total of five injections. This
schedule was chosen based largely on the pharmacokinetics of
SP-G in nu/nu mice (Cummings et al, 1995). Controls received the
same dose schedule of vehicle. Xenografts were measured either
two or three times a week by means of calipers and tumour volume
(V) was then calculated by the formula V= n/6LW2, where L is the
longest diameter and W the diameter perpendicular to L. Results
were expressed as a relative tumour volume (RTV) which is defi¬
ned simply as: V on day x/V on day 0, with RTV = 1 on day 0. Xeno¬
graft experiments were repeated on two or three separate occasions.
Semiquantitative RT - PCR
RNA was extracted using Tri-Reagent (Sigma, Poole, UK) from
exponentially growing cells, which had been in SITA medium for
3-5 days and was subsequently treated with DNasel to remove
any DNA contamination. cDNA was produced from this RNA
using a first-strand synthesis kit (Boehringer Mannheim, Roche,
UK). PCR primers used were: GRPR sense 5'-ATCTTCTGTA-
CAGTCAAGTCC-3', antisense 5'-GCTTTCCTCATGGAAGGGATA-
3'; V1AR sense 5'-TACCTGCTACGGCTTCATCTGC-3', antisense
5'-ACACAGTCTTGAAGGAGATGGC-3'; BK2R sense 5'-
CCTGAGTGTCATCACCTTCTGC-3', antisense 5'-TTGATGA-
CACGGCAGAGG-3'; receptor for gastrin (gastrinR) sense 5'-
CCTATCTCCTTCATTCACTTGC-3', antisense 5'-AGTGTGCT-
GATGGTGGTGTAGC-3'; y-actin sense 5'-ATGGCATCGTCAC-
CAACTGG-3', antisense 5'-ATGACAATGCCAGTG-GTGGC-3'.
Polymerase chain reaction products were run on a 1.5% agarose
gel containing 1 /vgml-1 ethidium bromide. Stored images of the
gels were analysed by densitometry using Gel Base/Gel Blot
software. y-Actin levels were measured as an internal control. Each
product was expressed relative to the levels of y-actin for the same
cDNA batch and for each PCR reaction.
Growth assays
Liquid growth was determined in SITA medium in the presence or
absence of mediators. Cell number was determined using a Coulter
Counter (model Zl, Beckman Coulter, Bucks, UK). Colony growth
was determined in 0.3% agarose in SITA medium for 21 days as
described by Sethi and Rozengurt (1991).
Determination of intracellular Ca2 + concentration
Intracellular Ca2 + concentration was determined using the fluor¬
escent indicator Fura-2-tetraacetoxymethylester AME (FURA-2-
AM 1 ixm) as described (Sethi et al, 1993) Ratiometric fluorescence
was monitored in a Perkin-Elmer Fluorometric Spectrophotometer
with dual excitation wavelengths of 340 and 380 nm and emission
wavelength of 510nm.
Xenograft activity
Female nu/nu mice (6 weeks old) (ICRF, London, UK) were
maintained in negative pressure isolators (Moredun Animal
Research Unit, Edinburgh, UK). All xenografts used throughout
were initially established by subcutaneous injection of 107 cells
from their respective cell lines and then maintained by serial
passage of fragments of viable tumour as described previously
(Langdon et al, 1992).
Mice were allocated into control and treatment groups contain¬
ing six to eight mice. Treatment started when the xenografts
reached a diameter of 3-10 mm with the first day of peptide
administration designated as day 0. SP-G was dissolved in sterile
distilled water at a concentration of lOmgml-1 and administered
RESULTS
Neuropeptide sensitivity in the longitudinal cell lines
GLC14, 16 and 19
The GLC14, 16 and 19 cell lines are SCLC cell lines established
from one patient during longitudinal follow-up (Berendsen et al,
1988). During this period, the tumour changed from sensitive
to resistant to chemotherapy, and the in vitro sensitivity to
chemotherapeutic agents reflected the clinical resistance to
treatment (de Vries et al, 1989 and T.S. observations (results not
shown)). Initially, neuropeptides (at a concentration of 100nM) in
each of the three cell lines were screened for their ability to
increase [Ca2 + h. Table 1 and Figure 1A show that the GLC14 cell
line responded to bradykinin and serum resulting in a large
increase in [Ca2 + h and smaller responses were seen in case of
neuropeptides CCK, GRP and neuromedin B. No Ca2+ mobilisa¬
tion was observed in response to neurotensin, substance P or
vasopressin. However, in the GLC19 line, addition of neuropep¬
tides bradykinin, CCK, GRP, neuromedin B and substance P
caused large increases in [Ca2 + ];. Vasopressin and neurotensin
caused smaller but consistent increases in [Ca2 + ], The GLC19 was
the only cell line in which neurotensin caused a measurable
increase in [Ca2 + ];.
One percent serum caused a rapid increase in [Ca2 + h in all
three cell lines of 100-150 nM, suggesting that the mobilisable
Ca2+ pools were equivalent in each line; however bombesin,
neuromedin B and CCK showed an increased responsiveness in the
GLC19 cells. Typical concentration response curves in GLC16 and
19 cells are shown in Figure IB. Thus, during the tumour
progression from GLC14, 16 to 19 cell lines, there is an increase in
i 2003 Cancer Research UK British Journal of Cancer (2003) 88( II), 1808 - 1816
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Table I Neuropeptide Ca2+ mobilisation in the SCLC GLC longitudinal cell line series
Ca2* mobilising
neuropeptides GLCI4 GLC 16 GLC 19
Bombesin 6±3 (n = 7) 25±59 (n = 7) 100 ± 15 (n = 7)
Bradykinin 66±8 (n = 8) 105 ±7 (n = 8) 98 ± 12 (n = 10)
Carbamylcholine 83 ± I I (n = 3) 104+ 18 (n = 5) 113 + 25 (n = 7)
Cholecystokinin 31 ±9 (n = 4) 32+4 (n = 3) 56+5 (n =4)
Neuromedin B 7 + 4 (n = 4) 25 + 3 (n = 3) 150 + 20 (n = 4)
Neurotensin -(n = 3) -(n = 3) 43+12 (n = 5)
Substance P -(n = 3) 39 ±6 (n = 3) 72± 10 (n= 3)
Vasopressin -(n = 3) 28 + 8 (n= 7) 42 ±9 (n = 7)
Serum 105±8 (n = 8) 109 ± 15 (n = 8) 119+19 (n= 10)
The GLC 19, 16 and 14 SCLC cell lines were loaded with I pM Fura2AME washed and resuspended in 2 ml electrolyte
solution and the cell suspension placed in a quartz cuvette and stirred continuously. Neuropeptides were added at 100 nM
concentration and fluorescence was recorded continuously as described in Materials and Methods. Results are expressed as
change in intracellular calcium (nM). The following peptides were also tested at 100 nM - I pM concentrations and no
increase in [Ca2+]j was ever observed: adrenocorticotrophin hormone, angiotensin I, atrial natriuretic peptide, calcitonin,
chorionic gonadotropin, dynorphin, /J-endorphin, endothelin, epinephrine, galanin, growth hormone-releasing hormone,
gastric-inhibitory peptide, glucagons 5-hydroxytryptamine, Leu-enkephalin, neuropeptide-Y, parathyroid hormone,
substance K, thyrotrophin-releasing hormone.
GLC19 GLC16 GLC14
Figure I Effects of bombesin, neuromedin B, bradykinin, cholecystokinin and serum on [Ca2+]j in SCLC cell lines GLCI4, GLCI6 and GLCI9. Cells
loaded with FURA-2-AME were resuspended in electrolyte solution and placed in a quartz cuvette. Fluorescence was monitored and basal and peak [Ca2+]j
calculated as described in Materials and Methods. Panel A: All peptides were added at a final concentration of lOOnM. Abbreviations used: BN, bombesin;
NmB, neuromedin B; BK, bradykinin; CCK, cholecystokinin. Serum was added at a final concentration of \% vv"'. Panel B: Dose-dependent effects of
bombesin, neuromedin B, bradykinin and CCK in SCLC cell lines GLC 16 and GLC 19, open and closed circles, respectively. Peptides were added at the
concentrations indicated. Representative concentration-response relations of three to five experiments are shown. Panel C: mRNA encoding the GRP
receptor was detected by semiquantitative RT-PCR. y-Actin mRNA levels were measured as an internal control for each PCR reaction. The results show a
representative PCR reaction for the GLC 14,16 and 19 cell lines. A bar chart showing relative receptor expression, calculated as density of PCR product/actin
is shown for each cell line. The results represent the mean of two independent experiments.
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■Figure 2 Dose-dependent effects of bombesin, BK, CCK and neuromedin B on colony formation in GLCI6 and GLCI9 SCLC cells. GLCI6 (hatched
bars) and GLCI9 (filled bars) cells, 3-5 days postpassage, were washed and I04 viable cells per ml were plated in SITA medium containing 0.3% agarose on
top of a base of 0.5% agarose in culture medium as described in Materials and Methods. Both layers contained additions at the nanomolar concentrations
indicated. Cultures were incubated at 37°C in a humidified atmosphere at 5% CC>2:95% air for 21 days and then stained with nitro-tetrazolium blue.
Spontaneous colony formation, that is, in the absence of any exogenously added peptide was 140+ 15 (n = 75) and 160+ 20 (n = 85), in the cell lines
GLCI6 and 19, respectively, and normalised to 100%. Each point represents the mean + s.e.m. of two to four experiments each of five replicates.
*Statistically different from neuropeptide concentration matched GLCI6 cells (ANOVA, P<0.05).
the number of neuropeptides able to induce a measurable increase
in [Ca2 + ]i and also an increase in the potency of individual
neuropeptides. The expression of the GRP receptor was examined
in the GLC cell lines by RT-PCR (Figure 1C). GRP receptor
expression increased by six-fold in the GLC16 compared to the
GLC14 cell line and by 11-fold in the GLC19 cell line, paralleling
the increased responsiveness to GRP-induced Ca2+ release.
CCK, bradykinin, neuromedin B and bradykinin stimulated a
concentration-dependent increase in clonal growth in the GLC16
and 19 cell lines. There was a significant increase in the ability of
bombesin, neuromedin B and CCK to stimulate clonal growth in
the GLC19 SCLC cell line compared to the GLC16 cell line
(Figure 2). Bradykinin was equally effective in stimulating clonal
growth in both GLC16 and 19 cell lines. The ability of these
neuropeptides to stimulate clonal growth in the GLC14 cell line
was consistently less than that seen in the GLC16 cell line. Serum
stimulated a 405-370% increase in clonal growth in the GLC19, 16
and 14 cell lines, and the cloning efficiency of all three SCLC cell
lines was approximately 1.5%. Hence, the GLC19 cell line develops
increased Ca2+ responsiveness to the neuropeptides CCK,
bombesin and neuromedin B, and this correlates with an increase
in the ability of these neuropeptides to stimulate clonal growth.
SP-G inhibited Ca2+ mobilisation induced by CCK, bombesin,
neuromedin B and bradykinin in the GLC19 SCLC cell line
(Figure 3A). SP-G also inhibited the growth and cloning efficiency
of the GLC14 (not shown) 16 and 19 cells, but was most potent in
the GLC19 cell line (IC50 for the GLC14, 16 and 19 SCLC cells was
25, 25 and 15 /i.w, respectively, for liquid culture, and 25, 25 and
5 fiM, respectively, for cloning efficiency, Figure 3B). Interestingly,
SP-G was still effective in inhibiting the growth of the GLC19 SCLC
line despite the development of resistance to conventional
chemotherapeutic agents (de Vries et al, 1989). These findings
suggest that increased neuropeptide receptor expression results in
increased sensitivity to SP-G.
Sensitivity to SP-G in a panel of tumour cell lines
A panel of tumour cell lines was selected that represents a
spectrum of tumour types, NSCLC, ovarian, pancreatic and colon
cancer, which express neuropeptide receptors in addition to SCLC.
The characteristics of these cell lines and their sensitivity to SP-G
are shown in Table 2. Growth inhibition by SP-G was not confined
to tumour type. The two most sensitive cells were the H69 SCLC
cell line (IC50 = 10.5 /im) and the HT29 colorectal cell line
(IC50 = 18/im). Four out of five SCLC cell lines had IC50 values
below the mean IC50 value of 44 /<M. Both the ovarian carcinoma
and the non-small-cell carcinoma were sensitive to growth
inhibition by SP-G, with IC50 values of 31 and 33.5 /(M, respectively.
During the phase 1 clinical trial of SP-G, plasma levels of up to
40 /tM were achievable with no dose-limiting toxicity (Clive et al,
2001). A total of 72% of the cancer cell lines tested had IC50 values
below or near this concentration. This suggests that 'broad-
spectrum' neuropeptide antagonists such as SP-G may be effective
antitumour agents in a variety of cancers other than SCLC.
In vivo sensitivity to SP-G in a panel of tumour cell lines
Four members from the original panel of tumour cell lines were
established as xenografts from their respective cell lines: H69
SCLC, HT29 colon carcinoma, PE04 ovarian cancer and PANC-1
pancreatic cancer. Typical growth inhibition curves (Figure 4) are
shown for each xenograft after i.p. treatment with 50mg/kg SP-G.
The HT29 xenograft showed a growth inhibition of 70.4%, 7 days
after the commencement of treatment. In addition, this growth
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Figure 3 (A) Effect of SP-G on neuropeptide-induced Ca + mobilisa¬
tion in GLCI9 SCLC cells. Cells loaded with FURA-2-AME were
resuspended in electrolyte solution and placed in a quartz cuvette.
Fluorescence was monitored and basal and peak [Ca2 + ]i calculated as
described in Materials and Methods. Peptides were added at a final
concentration of 30 nM and SP-G at a final concentration of 30 /tm. (B)
Effect of SP-G on GLCI6 and GLCI9 cell growth. Liquid growth (upper
panel): GLCI6 (triangles) and GLCI9 (squares) SCLC cells were
resuspended at a density of 5 x I04 cells in I ml SITA in the presence or
absence of SP-G in triplicate. The controls (cells in absence of antagonist)
after an initial lag period grew exponentially and then reached a plateau
after 10 days (GLCI9: 4.8 ±0.5 x I05 (n = 6) and GLCI6: 5.7 + 0.5 x I05
(n = 6)). Each point represents the mean cell number after 10 days+ s.e.m.
of two experiments each of three replicates. Colony growth (lower panel):
GLCI6 (triangles) and GLCI9 (squares) SCLC cultures were washed, and
104 viable cells/ml were plated in SITA medium containing 0.3% agarose on
top of a base of 0.5% agarose in culture medium as described in Materials
and Methods. Both layers contained additions as indicated. Cultures were
incubated at 37°C in a humidified atmosphere at 5% C02:95% air for 21
days and then stained with nitro-tetrazolium blue. Each point represents
the mean + s.e.m. of two experiments each of five replicates.
inhibition was maintained over 17 days after the final injection
(Figure 4). The PE04 ovarian xenograft showed a maximum
growth inhibition of 69.3% at day 7, and in common with HT29,
growth inhibition was also maintained over 17 days beyond the
final injection. The H69 xenograft showed a maximum growth
inhibition of 39.9% to SP-G that was sustained for 10 days after
treatment. The PANC-1 pancreatic tumour cell line was one of the
least-sensitive cells lines to SP-G in vitro and proved to be the
least-sensitive xenograft, with statistically significant growth
inhibition recorded at only two time points, day 7 and day 10
(Figure 4). Overall, these data report, for the first time, that SP-G
has marked in vivo xenograft activity in a variety of tumours
including lung, colon, ovarian and pancreatic cancer, and in
cancers such as ovarian cancer (with in vitro derived chemoresis-
tance), NSCLC and colon cancer, which are relatively insensitive to
standard conventional chemotherapy.
Correlation of neuropeptide receptor expression with
sensitivity to SP-G in a panel of tumour cell lines
The expression of GRP, gastrin, BK2 and V1A receptors were
examined by RT-PCR, in nine cell lines from the original panel
representing a spectrum of sensitivity to SP-G. The results are
shown in Table 2 and Figure 5 (n = 4-5 independent experiments).
Receptors for vasopressin (V1AR) were detected in four out of four
lung cancer cell lines (three SCLC and one NSCLC). The WX330
SCLC cell line was the highest expresser of V1AR. The pancreatic
and ovarian cancer lines expressed low levels of the V1AR and in
the colorectal cancer cell lines only HT29 cells expressed V1AR.
GRPRs were detected in three out of four lung cancer cell lines
(two SCLC and one NSCLC). In the colorectal cell lines, the HT29
cell line showed high levels of GRPR expression and HCT116 cell
line showed no detectable GRPR expression with intermediate
expression in the HT18 cell line. The pancreatic cell line PANC1
had very low levels of GRPR expression. The PE04 ovarian cancer
cell line and H69 SCLC cell lines showed high expression of the
GRPR (Table 2). Receptors for bradykinin were detected in all cells
of the cell panel. Other studies have found an almost ubiquitous
expression of bradykinin receptors in human lung cancers (Bunn
et al, 1992). Gastrin receptors were detected in three out of four
lung lines (two SCLC and one NSCLC) and low expression was
detected in the ovarian line PE04. The highest expression was in
the SCLC cell line H510. Interestingly, none of the colorectal cell
lines expressed gastrin receptors (Table 2). This finding confirms
other studies, which show that the gastrin receptor is rarely
expressed in colorectal cancer cell lines (Reubi et al, 1997). These
results show that sensitivity to SP-G in a variety of tumours
appears to correlate with the level of expression of neuropeptide
receptors. In particular, of all the neuropeptide receptors
examined, the correlation between relative GRP receptor expres¬
sion (receptor/y-actin) and sensitivity to SP-G was the most
apparent (Spearmans correlation R = —0.75; P= 0.026, Figure 5).
Effect of GRP receptor expression on SP-G sensitivity
in fibroblasts
The importance of neuropeptide receptor status for cell sensitivity
to SP-G was further tested in a rat-1 fibroblast system in which
only one neuropeptide receptor (the mouse GRPR) was expressed
at high levels (ffd = lnM, Bmax=105 receptors per cell) (Charles-
worth et al, 1996). In native rat-la fibroblasts, bombesin and other
Ca2 +-mobilising neuropeptides, vasopressin, neurotensin, brady¬
kinin and gastrin, failed to mobilise intracellular Ca2 +, suggesting
absence of receptors in the parent cell line (Figure 6A). Rat-la
fibroblast cells stably expressing the mammalian bombesin
receptor (BOR15) respond normally to bombesin stimulation in
terms of signal transduction and stimulation of DNA synthesis
(Charlesworth et al, 1996; MacKinnon et al, 2001). Bombesin
stimulated a marked and rapid increase in [Ca2 + ]j in BOR15 cells,
which was blocked by Sp-G (Figure 6B). The effect of SP-G on the
growth of rat-la fibroblasts and BOR15 cells was therefore
determined. The parent rat-la cells were comparatively resistant
to SP-G-mediated growth inhibition with only partial inhibition
observed at the highest concentration of SP-G (41 + 12% inhibition
at 100/iM, 1C50> 100 j<m), whereas BOR15 cell growth was
completely inhibited by 80 SP-G (IC50 44 /xm, Figure 6). These
results show that the presence of the bombesin receptor leads to
increased sensitivity to growth inhibition by SP-G in fibroblasts.
DISCUSSION
The GLC14, 16 and 19 are classic type SCLC cell lines derived from
a 55-year-old female with SCLC. The GLC14 cell line was
established from a supraclavicular lymph node before treatment.
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Relative NP receptor expression
Cell line IC50 (pit) GRPR* VUR BKjR Gastrin R
H69 (SCLC, Moody et al, 1985) 10.5 0.91 ±0.15 0.8 ±0.18 0.65 ±0.31
0.56±0.49
HT29 (colorectal, Brattain et al, 1981) 18 0.55 ±0.12 0.02 ±0.01 0.35 ±0.04
—
H5I0 (SCLC, Moody et al, 1985) 29 0.3 ±0.11 1.10± 0.21 0.51 ±0.17
1.51 ±40.61
PE04 (ovarian, Lieber et al, 1975) 31 1.31 ±0.25 1.10 ± 0.02 0.24 ±0.10
0.2±0.05
NX002 (NSCLC, Stark et al, 2001) 33.5 1.01 ±0.21
— 0.65 ±0.23 0.56±0.28
HRT18 (colorectal, Fogh et al, 1977) 37 0.18 ±0.04
— 0.80 ±0.21 0.03 ±0.01
W X330 (SCLC, Hay et al, 1991) 42 0.09 ±0.01 3.71 ±0.91 0.22 ±0.12
0.27±0.18
PANC 1 (pancreatic, O'Hara et al, 1986) 58 0.09 ±0.01 0.10 ±0.02 0.38 ±0.11
—
HCTI 16 (colorectal, Langdon et al, 1988) 129 —
— 0.65 ±0.25 —
RT- PCR products were analysed by densitometry and the relative expression level of four neuropeptide receptors are
summarised. These values have been expressed as a ratio of the level of y-actin expression for each cDNA batch and PCR
run. Numbers represent the mean of four to six experiments. Spearman's rank correlation between IC50 value and receptor
expression level was performed. A significant correlation between sensitivity to SP-G and GRPR expression was confirmed
(Spearman's R value = —0.75, P = 0.026*).
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Table 2 Growth inhibition by SP-G (1C50) and neuropeptide receptor expression in a panel of tumour cell
lines
Time (days)
Figure 4 Effect ofSP-G on the growth of H69, HT29, PE04 and PANC-1 xenografts. Four cell lines from the original panel were established as xenografts
from their respective cell lines: H69 SCLC, HT29 colon carcinoma, PE04 ovarian cancer and PANC-1 pancreatic cancer. Typical growth curves are shown
for each xenograft after i.p. treatment with 50mgkg_l SP-G (•) or vehicle control (□) as five separate injections administered over 3 days as two
injections on day I and 2 separated by a 6-h gap with the final injection given on day 3. The results represent the mean tumour volumes from a single study
(n = 6-8). *Statistically significant from vehicle control (Students' t-test, P< 0.05).
After chemotherapy, the patient was in complete remission, 4
months later she relapsed. Further chemotherapy resulted in a
partial response and the GLC16 line was established from a
recurrence in the lung. After radiotherapy, the lung appeared
tumour free; however, 3 months later tumour recurred in the lung
from which the GLC19 cell line was derived. This was resistant to
any further treatment and the patient died 2 months later
(Berendsen et al, 1988; de Vries et al, 1989). In vitro sensitivity
to chemotherapeutic agents reflected the clinically observed
development of resistance to treatment (de Vries et al, 1989). We
were also able to confirm these findings in the GLC cells used in
this study (results not shown). One percent serum caused a rapid
and equivalent increase in [Ca2 + ]; in all three GLC SCLC cell lines
suggesting that the mobilisable Ca2 + pools were equivalent in each
of the three cell lines. However, we show that in the progression to
chemoresistance the GLC cells are able to respond to a greater
PE04
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Figure 5 Upper panel: Correlation between neuropeptide receptor expression and sensitivity to SP-G in tumour cell lines. mRNA encoding the GRP,
VtA, BK2 and gastrin receptors was detected by semiquantitative RT-PCR. y-Actin mRNA levels were measured as an internal control for each PCR
reaction. The results show a representative PCR reaction for each of nine tumour cell lines, which represent a spectrum of sensitivity to SP-G. A bar chart
showing relative receptor expression, calculated as density of PCR product/actin is shown for each receptor. The results represent the mean + s.e.m. of four
independent experiments. Lower panel: Correlation graph between GRPR expression and inhibition of cell growth (IC50) for each of nine tumour cell lines
as indicated (Spearman's R value = —0.75, P= 0.026*).
range of neuropeptides with increased potency, and are conse¬
quently more sensitive to growth inhibition by SP-G. The GLC19
cell line was more sensitive to SP-G both in liquid culture and in
semisolid medium than the GLC16 and 14 cell lines. The Ca2 + -
mobilisation and the clonal growth results suggest that this cell line
may have greater neuropeptide dependence and this is reflected in
its greater sensitivity to neuropeptide growth factor blocking
agents such as SP-G. This led to the hypothesis that other
neuropeptide-expressing tumours may also be sensitive to the
growth-inhibitory effect of SP-G.
It is well known that neuropeptides can stimulate the growth of
many types of cancers including pancreatic, colorectal, prostate,
ovarian, breast and NSCLC (Bologna et al, 1989; Halmos et al,
1995; Aprikian et al, 1996; Ferris et al, 1997). A panel of 11 tumour
cell lines, which represented a spectrum of tumour types, showed
that sensitivity to SP-G differed across the panel with a range of
>1 log order (10 to >100/iM). The sensitive cell lines (four
SCLC, two colorectal carcinoma, one NSCLC and 1 ovarian) had
IC50 values that were in the range of physiologically obtainable
plasma concentrations. Moreover, in the cell lines tested in vitro
sensitivity correlated with sensitivity to SP-G in vivo. The results of
this screen suggest that SP-G could be used therapeutically against
several tumour types in addition to SCLC.
We have previously shown that SP-G augments etoposide-
induced growth inhibition and apoptosis in SCLC cells and
suggested that SP-G may be of increased benefit in patients
following relapse or in conjunction with conventional chemother¬
apy (MacKinnon et al, 1999). It is of interest to note that the cell
lines SCLC GLC19, ovarian cancer PE04 and NSCLC NX022, which
in vitro (and in vivo) are resistant to standard chemotherapeutic
agents such as etoposide, are sensitive to the growth-inhibitory
effects of SP-G. This raises the possibility that SP-G may be an
effective anticancer agent in patients with neuropeptide-expressing
tumours which are intrinsically resistant or have acquired
resistance to conventional chemotherapy. A plausible extension
of this hypothesis is that clinically aggressive drug-resistant SCLC
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Figure 6 Expression of the bombesin/GRP receptor in Rat-1 fibroblasts increases sensitivity to growth inhibition by SP-G. Rat-1 a fibroblasts (A) or rat-1 a
fibroblasts expressing the bombesin receptor (B) were loaded with FURA-2-AME and resuspended in electrolyte solution. Fluorescence was monitored and
basal and peak [Ca2+]j calculated as described in Materials and Methods. (A) Rat-1 a cells were stimulated with IOnM each of bombesin (Bn), vasopressin
(Vp), neurotensin (NT) and bradykinin (Bk), IO^m SP-G or \% FCS. The results are representative of three experiments. (B) (left) Response to IOnM
bombesin in BOR-15 cells and (right) effect of 10 pM SP-G on bombesin-stimulated Ca2 + release in BOR-15 cells. (C) Rat-1 fibroblasts (closed squares) or
Rat-1 fibroblasts expressing the bombesin receptor (BOR 15, open squares) were grown in SITA media in the presence or absence of the indicated
concentrations of SP-G. The cell number was determined and IC50 values calculated following 7 days of growth.
cells that emerge after chemotherapy might have a more extensive
network of neuropeptide regulation and therefore display in¬
creased sensitivity to neuropeptide antagonists. Further studies in
longitudinal cell lines are required to investigate this hypothesis in
further detail.
Although our data cannot indicate the expression of fully
functional receptors, the RT-PCR approach was taken as it could
be used as a possible diagnostic test in cancer patients to
determine the potential tumour sensitivity to neuropeptide growth
factor antagonist therapy. Of the four neuropeptide receptors
tested, the most apparent correlation was between high expression
of the GRP receptor and increased sensitivity to SP-G. This is in
some ways surprising given that SP-G is more selective for the
V1AR (Seckl et al, 1995) which is expressed on many lung cancer
cells. However, GRP secretion and GRPR expression are the
hallmarks of the neuroendocrine phenotype. The presence of the
GRPR in particular may be a reflection of the general neuroendo¬
crine phenotype of the cancer cells indicating greater neuropeptide
dependence for growth. It would be interesting to look at the
expression of other bombesin-like peptide receptors such as the
neuromedin B receptor to assess its role in substance P-analogue-
induced growth inhibition.
The GRPR has been shown to be oncogenic when transfected
into the nonmalignant NCM460 colon epithelial cell line (Ferris
et al, 1997). The increased proliferation was shown to be because
of constitutive activation of the GRPR in that the receptors
tonically coupled to Gq in the absence of ligand. This gives a
potential mechanism whereby the GRPR may act as an oncogene.
In addition, many tumour types such as breast cancer (Halmos
et al, 1995) and prostate cancer (Bologna et al, 1989; Aprikian et al,
1996) have also been shown to aberrently express GRPRs. We and
others have previously shown that the expression of GRPRs in
fibroblasts increases the ability of SP-G and other substance P
analogues to activate the extracellular-signal-regulated kinase
(ERK) and c-;wn-N-terminal kinase (JNK) pathways leading to
growth arrest and apoptosis (Jarpe et al, 1998; MacKinnon et al,
2001). Together, these data demonstrate that not only can GRPR
expression transform cells, but these cells then become more
sensitive to substance P-analogue-induced cell death.
These findings have important implications for the design of
more advanced phase human clinical trials using substance P
analogues. SP-G is currently entering a phase II clinical trial where
its effectiveness will be tested in SCLC patients, but ultimately,
compounds of this type may also be suitable for the treatment of a
wide range of other tumour types and neuropeptide-expressing
tumours that have become resistant to standard conventional
chemotherapeutic agents. Screening tumour biopsy samples for
neuropeptide receptor expression may provide insight into the
likelihood of patients responding to treatment with substance P
analogues, analogous to oestrogen receptor expression conferring
efficacy to tamoxifen in breast cancer. It is suggested that tumours
should be biopsied to select patients for substance P-analogue trials
based on the expression of the GRPR and another neuropeptide
receptor. Our results suggest that these tumours should show
growth inhibition regardless of intrinsic or acquired resistance to
standard chemotherapeutic agents. It is therefore proposed that in
the first instance, patients with tumours that express the GRPR and
another neuropeptide receptor who have failed conventional
treatment should be randomised into two groups - best supportive
care and treatment with substance P analogues.
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